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Abstract 
Major depressive disorder (MDD) is a substantial healthcare concern. Conventionally 
conducted meta-analyses support the efficacy of both psychological and pharmacological 
interventions for MDD, but methodological limitations of  meta-analyses may obfuscate 
rather than clarify the clinical efficacy of available interventions. 
 
The thesis begins with a systematic review of meta-analyses of high quality psychological 
treatment studies for MDD. The results of  the systematic review indicated that 48% of 
patients achieved remission after a course of psychological treatment. However, 
approximately 70% of remitted patients  relapsed within 3 years after the discontinuation of 
psychological therapy. Consistent methodological limitations were identified in the primary 
outcome studies contributing to the meta-analyses.  The primary studies  typically published 
insufficient evidence on treatment fidelity.  There was  considerable variability in the overall 
treatment duration, the mean severity of samples and the definition of clinical significance. 
These factors pose a risk to the validity of meta-analytic results of psychological 
interventions for MDD. 
 
The next component of the thesis investigated the impact of idiosyncratic clinical 
significance definitions on the published conclusions of studies that used the Beck 
Depression Inventory (BDI) or Hamilton Rating Scale for Depression (HRSD) to assess 
outcome. The availability of individual patient data (IPD) for 7 published studies enabled the 
empirically-based Jacobson Method of clinical significance to be used as a standard 
definition of recovery across IPD studies. Comparisons of published and Jacobson method 
clinical significance rates for each IPD study showed that idiosyncratic outcome definitions 
typically overestimated treatment efficacy. Moreover,  treatment efficacy was confounded 
with the definition of clinical significance employed.  This indicates that to  reduce the risk 
of bias in meta-analysis, a standard and empirically-based definition of clinical significance 
should be used across primary MDD treatment studies. Subsequently, the moderating role of 
pre-treatment severity on clinical significance rates was investigated via individual patient 
data meta-analysis. It was found that being male and having higher pre-treatment severity 
both predicted a significantly reduced likelihood of achieving clinical recovery. 
 
It is evident that between-study methodological differences means that even high quality 
conventional meta-analyses of psychological treatments for MDD remain at risk of bias. The 
novel finding that gender significantly moderated treatment outcome indicates that IPD 
meta-analyses are both more powerful and flexible than conventional meta-analyses based 
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on summary data. Ideally, future meta-analyses of primary MDD treatment studies should be 
based on individual patient data.  
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Chapter One 
 
Overview of Thesis 
1.1  
As depression places many burdens on individuals and the wider economy it is imperative 
that highly efficacious treatments are available. Consequently, identifying those treatments 
which best promote remission of depressive symptoms is of great value to stakeholders, 
clinicians and individuals. However, this is no simple task, as remission rates for the same 
treatment type often differ markedly between treatment studies. The variability in treatment 
outcomes makes it difficult to assess the relative and absolute efficacy of psychological 
treatments for major depression. Synthesising outcome data across multiple outcome studies 
has become the preserve of meta analytic reviews. However, although meta-analyses can 
accommodate variability between the results of primary studies and are thus widely used in 
healthcare research, their application within reviews concerned with the efficacy of 
psychological treatments for depression has not led to consistent conclusions. The lack of 
consistency between the results of meta-analytic reviews has arisen for a variety of 
methodological reasons. For example, reviews have differed concerning which treatment 
studies should be included, as well as the specific statistical methods employed to perform 
meta- analysis. 
 
This thesis uses the findings of meta-analyses of psychological treatment studies for major 
depression as a starting point to examine several methodological issues which contribute to 
between-study variability in treatment outcome. In addition, this thesis examines whether 
these factors reduce the validity of meta-analyses of psychological treatment studies for 
major depression. The research presented here is based on examinations of the methods and 
results of published meta-analyses as well as original analyses of patient outcome data 
obtained from the authors of published treatment studies.  
 
The first part of this thesis presents a description of major depression in terms of its 
diagnosis, epidemiology and burden. Following this a historical review and methodological 
critique of meta-analysis in the context of psychological treatment studies for depression is 
presented. Here, methodological factors that potentially bias meta-analyses of depression 
treatment studies are described. Subsequently, study 1 examines the findings and 
methodological limitations of seven meta-analytic reviews of psychological treatment 
studies for major depression that obviated previously identified sources of bias. The most 
BLANK 
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reliable available evidence from meta-analytic reviews suggested that less than 50% of 
patients starting individual psychotherapy achieved remission. Whilst there was no evidence 
that medication was superior to psychological treatment in general, the results indicate that 
the efficacy of both treatment types may be considerably improved. However, study 1 
revealed four methodological factors which reduced confidence in the validity of the 
conclusions reached in all meta-analytic reviews. First, it was possible that psychological 
treatments were poorly implemented in some of the studies included in reviews. Second, 
there was considerable variability between the included studies in reviews concerning (i) the 
duration and intensity of psychotherapy, (ii) the mean pre-treatment severity of samples and 
(iii) the methods used to define remission. Moreover, the employment of idiosyncratic 
remission definitions across included studies meant that it was unclear to what degree 
overall review findings represented the proportion of patients who genuinely achieved 
remission. 
 
Quantifying the proportion of patients who achieve a clinically significant outcome  across 
treatment studies requires the use of empirically-based and standardised definition. The 
Jacobson Method of clinical significance (Jacobson et al., 1984; Jacobson and Revenstorf, 
1988; Jacobson and Truax, 1991) is ideally suited for this purpose. However, application of 
the Jacobson Method requires that individual patient data (IPD) be made available by the 
authors of primary studies. Following a review and critique of the Jacobson Method,  it was 
employed in the two studies which comprise the second part of the thesis. 
 
In study 2, the proportion of patients who recovered according to the Jacobson Method 
following psychotherapy for major depression was quantified. Individual patient data (IPD) 
was obtained from seven primary studies where treatment outcome was assessed using either 
the Beck Depression Inventory (BDI, Beck et al., 1961) or Hamilton Rating Scale for 
Depression (HRSD, Hamilton, 1960). The results showed that less than 50% of patients 
across IPD studies achieved recovery according to the Jacobson Method and that published 
rates for the treatments in individual IPD studies could differ considerably from their 
corresponding Jacobson Method recovery rate. The use of idiosyncratic published outcome 
definitions also meant that the rank-ordering of treatment efficacy in IPD studies could differ 
according to published or Jacobson Method definitions of clinical significance. Finally, 
when recovery according to the Jacobson Method was used to compare measures, poor 
agreement was found between the BDI and HRSD in samples assessed on both. Overall, the 
results of study 2 indicated that conclusions concerning the relative efficacy of treatments 
within individual studies may be confounded with the definition of clinical significance 
employed. Consequently, the failure by primary researchers to employ a standard definition 
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of clinical significance risks that meta-analyses investigating the absolute or relative efficacy 
of depression treatments will be biased.  
 
In study 3, the availability of individual patient data (IPD) meant that it was possible to 
investigate whether pre-treatment severity was predictive of recovery as defined by the 
Jacobson Method. Consequently, IPD meta-analyses employing hierarchical binary logistic 
regression with recovery status as the dependent and pre-treatment severity as the 
independent variable were undertaken. Separate analyses for the BDI and HRSD both 
controlled for study, treatment type (psychotherapy or medication) and gender. The results 
of the HRSD analysis showed that increasing pre-treatment severity predicted a reduced 
probability of recovery. However, the results of the BDI analysis showed that increasing pre-
treatment severity predicted a reduced probability of recovery in females only. Pre-treatment 
severity on the BDI was not a significant predictor of outcome in males. Overall, the results 
of study 3 revealed that at lower severities, females were significantly more likely to recover 
than males of an equivalent pre-treatment severity on either measure. Only in severe cases 
was the probability of recovery no different between genders. The identification of a 
significant gender difference using this novel approach contrasts with previous research that 
identified no gender difference in response to psychotherapy (Parker et al., 2011). 
Consequently, the IPD meta-analytic approach may be a more powerful method by which to 
investigate factors that moderate outcome across depression treatment studies. 
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Chapter Two   
 
The Nature of Major Depression 
 
2.1 Introduction  
It has been recognised for centuries that sadness and despair are a common experience for 
many people.  Historical accounts indicate that the cause of severe mood disturbance was 
typically ascribed to physical illness for which the sufferer bore no responsibility. Symptoms 
of historical melancholia included extreme sadness, an inability to function and the frequent 
presence of delusions (Daly, 2007). Thus, historical melancholia may be a description of 
modern bipolar disorder or severe unipolar depression (Akiskal and Akiskal, 2007). The 
extreme nature of melancholia meant that its cause was attributed to an imbalance of the 
‘bodily humours’ (Daly, 2007; Akiskal and Akiskal, 2007). However, historical accounts 
also describe less severe mood problems for which the sufferer was believed ultimately 
responsible. The ‘sin’ of acedia (Daly, 2007) originated in early Christian monastic settings 
and referred to a constellation of undesirable feelings and behaviours which interfered with 
devotional duties (Jackson, 1981). These were attributed to laziness or a ‘lack of care’ and 
included apathy, loss of hope, drowsiness and a desire to flee the monastery (LaMotte, 
2007). However, acedia was not considered equivalent to normal sadness as the 4th century 
monk John Cassian described it as a ‘dangerous foe’ that was ‘akin to sadness’ (Daly, 2007; 
p34). These historical descriptions of the ‘symptoms’ of melancholia and acedia loosely 
correspond to those of major depression as defined by modern diagnostic systems.   
 
This chapter describes major depression in terms of its diagnosis, epidemiology and the 
considerable burden it places on both the individual and wider economy. It will become 
apparent that major depression is a common but clinically heterogeneous disorder that is 
frequently comorbid with other disorders. Moreover, whilst many individuals with major 
depression will experience a single episode, a substantial minority will experience recurrent 
episodes. The heavy personal, social and economic burdens associated with major 
depression demand that effective treatments are available. 
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2.2 Diagnosing Major Depression 
As there are no reliable physiological markers to denote the presence of major depression, 
current diagnostic methods rely on identifying psychological and behavioural symptoms 
(APA, 2000). The two major classificatory schemes by which major depression is diagnosed 
are the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental 
Disorders (DSM IV; APA, 1994) and the World Health Organisation’s International 
Classification of Diseases (ICD-10; WHO, 1993). Because major depression is a highly 
recurrent disorder (Boland and Keller, 2008), both systems operationalise it in terms of the 
occurrence of a single ‘depressive episode’ (WHO, 1992) or ‘major depressive episode’ 
(MDE, APA, 2000). The diagnostic criteria for a depressive episode are similar in both 
systems. The DSM IV and ICD-10 both define recurrent depression as the occurrence of two 
or more episodes which are separated by at least 2 months where the criteria for a depressive 
episode are not met (APA, 2000; WHO, 1993).  In DSM IV, the term Major Depressive 
Disorder (MDD) is used to denote the occurrence of one or more major depressive episodes 
and is thus synonymous with major depression.  
 
In addition to being highly recurrent, major depression is also a clinically heterogeneous 
disorder (Rush, 2007). The diagnostic criteria of both the DSM IV and ICD-10 systems were 
designed to account for such heterogeneity. However, this means that depressed individuals 
with markedly divergent symptoms are assigned to the same diagnostic category (APA, 
2000; Krueger et al., 2005). For example, two individuals diagnosed with a major depressive 
episode may both experience depressed mood and concentration difficulties. However, one 
individual may have accompanying symptoms of significant weight loss and insomnia, 
whilst the other experiences significant weight gain and hypersomnia. Because such 
differences may be important for the selection of appropriate treatment and thus prognosis 
(APA, 2000; WHO, 1992; Rush, 2007), both the DSM IV and ICD-10 systems enable the 
specification of depressive sub-type and episode severity (APA, 2000; WHO, 1992).   
 
Whilst the DSM IV and ICD-10 diagnostic systems are very similar, sufficient differences 
exist which can make direct comparisons between them problematic. To illustrate, the 
degree of functional disability associated with the presenting problem cannot be used to 
support a diagnosis within the ICD-10 framework (WHO, 1992). In contrast, diagnosis 
within the DSM IV system explicitly requires that the disorder is sufficiently severe to cause 
clinically significant distress or impairment in social, occupational, or other important areas 
of functioning (APA, 2000). It is theoretically possible that individuals will meet the 
diagnostic criteria for a depressive episode according to ICD-10 but not DSM IV criteria as 
6 
 
they are not sufficiently distressed or impaired according to the latter system. However, 
Spitzer & Wakefield (1999) have argued that the DSM IV requirement of clinical distress is 
redundant for a diagnosis of MDD because it is highly unlikely that those meeting the DSM 
IV symptom criteria alone would not be distressed. This suggests that the ICD-10 and DSM 
IV systems will show high levels of agreement concerning individual diagnoses because 
their symptom criteria are very similar. However, because the focus of this thesis concerns 
the findings of psychological treatment studies that typically employ the DSM system, the 
DSM IV criteria for MDD will be presented in detail. Important differences between DSM 
IV and ICD-10 diagnostic criteria will be described where appropriate. 
 
2.2.1 Diagnostic Criteria for Major Depressive Disorder 
The current DSM IV (APA, 2000) is based on successive revisions of the DSM III (APA, 
1980). The DSM III marked a radical departure from previous versions by providing explicit 
criteria by which to reach a diagnosis (Decker, 2007). By organising mental disorder in 
terms of prototypical symptom-based categories (Krueger et al., 2005) and avoiding 
theoretical issues concerning the aetiology of disorders, the DSM III led to both improved 
diagnostic reliability and a restoration of the scientific status of American psychiatry 
(Decker, 2007). Table 1 presents the current DSM IV diagnostic criteria for a major 
depressive episode.  
 
According to DSM IV, the diagnosis of a major depressive episode requires that all criteria 
from A to E in Table 1 are met. An inspection of criterion ‘A’ shows that at least 5 of the 9 
symptoms must be present nearly every day for at least two weeks and that one of these must 
be either depressed mood or a marked loss of interest or pleasure in most activities. The 
ICD-10 also requires that symptomatic criteria for a depressive episode are met for at least 
two weeks. However, the two systems use markedly different criteria to establish the 
presence of a depressive episode. The DSM IV requires that at least 5 of the criterion 
symptoms in Table 1 are present irrespective of episode severity. In contrast, the minimum 
number of symptoms required to meet diagnostic criteria in the ICD system varies according 
to episode severity. For example, a mild episode according to ICD criteria requires the 
presence of only four criterion symptoms, two of which must be typical in depression, i.e. 
depressed mood, loss of interest or increased fatigue (WHO, 1992).  
 
However, a severe episode according to ICD criteria requires the presence of all 3 typical 
symptoms and at least four of seven additional symptoms. These are reduced 
concentration/attention, lowered self esteem/confidence, guilt, pessimism concerning  the 
future, suicidality, sleep difficulties and diminished appetite (WHO, 1992). Thus, whilst 
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both systems use very similar symptomatic criteria
1
, only the ICD system incorporates 
symptom count in defining the severity of depressive episodes. However, ICD-10 
descriptions concerning the functional impact of mild, moderate and severe episodes 
correspond closely to those of DSM IV. 
 
 
Table 1. DSM IV-TR Diagnostic Criteria For A Major Depressive Episode 
A Five (or more) of the following symptoms have been present during the same 2-week period and represent 
a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss 
of interest or pleasure.1 
 1. Depressed mood most of the day, nearly every day, as indicated by either subjective report (e.g., 
feels sad or empty) or observation made by others (e.g., appears tearful).2     
 2. Markedly diminished interest or pleasure in all, or almost all, activities most of the day, nearly every 
day (as indicated by either subjective account or observation made by others) 
 3. Significant weight loss when not dieting or weight gain (e.g., a change of more than 5% of body 
weight in a month), or decrease or increase in appetite nearly every day.3    
 4. Insomnia or hypersomnia nearly every day 
 5. Psychomotor agitation or retardation nearly every day (observable by others, not merely subjective 
feelings of restlessness or being slowed down) 
 6. Fatigue or loss of energy nearly every day 
 7. Feelings of worthlessness or excessive or inappropriate guilt (which may be delusional) nearly every 
day (not merely self-reproach or guilt about being sick) 
 8. Diminished ability to think or concentrate, or indecisiveness, nearly every day (either by subjective 
account or as observed by others) 
 9. Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a specific 
plan, or a suicide attempt or a specific plan for committing suicide 
B The symptoms do not meet criteria for a Mixed Episode 
C The symptoms cause clinically significant distress or impairment in social, occupational,  
or other important areas of functioning. 
D The symptoms are not due to the direct physiological effects of a substance (e.g., a drug of abuse, a 
medication) or a general medical condition (e.g., hypothyroidism). 
E The symptoms are not better accounted for by Bereavement, i.e., after the loss of a loved one, the 
symptoms persist for longer than 2 months or are characterized by marked functional impairment, morbid 
preoccupation with worthlessness, suicidal ideation, psychotic symptoms, or psychomotor retardation. 
Notes: 
1. Do not include symptoms that are clearly due to a general medical condition, or mood-incongruent 
delusions or hallucinations. 
2. In children and adolescents, can be irritable mood. 
3. In children, consider failure to make expected weight gains. 
Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text 
Revision, (Copyright ©2000).  American Psychiatric Association. 
 
 
 
 
                                                 
1
 In strict terms, ICD-10 excludes weight changes and increased appetite whereas DSM IV excludes pessimism. 
8 
 
Returning to DSM IV, a closer inspection of criterion ‘A’ in Table 1 reveals that individuals 
meeting diagnostic criteria for a depressive episode need not share any symptoms in 
common. In theory, two individuals may share none of the 9 symptoms in Table 1 because 
items 3 to 5 allow for increases or decreases in weight, sleep and psychomotor activity 
respectively. Nevertheless, researchers and clinicians have observed what appear to be 
relatively consistent constellations of depressive symptoms which may respond differently 
to treatment (Rush, 2007).  Consequently, successive revisions of the DSM since version III 
have included specifiers that enable potentially important clinical characteristics of episodes 
to be recorded (APA, 2000). These episode specifiers are described below and concern 
symptom severity, remission status, chronicity and symptomatic features that may denote 
depressive sub-types. 
 
2.2.2 DSM IV Episode Specifiers 
Severity 
The DSM IV categorises severity as mild, moderate or severe across three different domains. 
These are the number of criterion symptoms, their severity, and the degree of associated 
disability and distress.  A mild episode has sufficient but perhaps no more symptoms than 
required for diagnosis. However, it must be associated with mild disability or reduced 
functionality that takes a substantial effort to overcome. A severe episode without psychotic 
features is characterised by the presence of a majority of criterion symptoms and evident 
occupational or social disability (e.g. inability to work). A severe episode with psychotic 
features is characterised by mood-congruent delusions or hallucinations. A moderate 
depressive episode is characterised as falling between mild and severe.  
 
The utility of the three DSM IV severity domains in predicting a range of clinically 
important phenomena was investigated by Lux et al. (2010). They found that the three 
severity domains were not equally effective in predicting individual clinical phenomena 
(Lux et al., 2010). For example, symptom count was the strongest predictor of concurrent 
anxiety, whereas symptom severity was the strongest predictor of episode duration, and 
disability the strongest predictor of lifetime comorbid anxiety (Lux et al., 2010). Lux et al. 
(2010) concluded that depressive severity is a multifaceted and heterogeneous construct that 
cannot be fully captured according to any single domain described in the DSM IV. However, 
treatment studies that quantify depressive severity using symptom measures have shown that 
more severe patients typically require longer treatment (Shapiro et al., 1994), are less likely 
to benefit from non-specific treatment effects (Schatzberg and Kraemer, 2000) and make 
relatively poorer symptomatic improvements compared to less severe cases (Jarrett et al., 
1991; Frank et al., 2011).  
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Remission status & chronicity  
Remission is a vital concept in the assessment of treatment outcome, as it implies that an 
individual’s functioning is no longer impaired (Keller, 2003; Boland and Keller, 2008). 
Remission refers to a level of symptomatic improvements sufficient to no longer meet 
diagnostic criteria (Romera et al., 2011; Keller, 2003). Remission according to the DSM IV 
(APA, 2000) may be full or partial. Full remission denotes a period of at least 2 months 
where significant symptoms of depression are absent. Partial remission refers to either (i) the 
absence of significant criterion symptoms for a period less than 2 months, or (ii) the 
presence of some criterion symptoms but the full criteria for a major depressive episode are 
no longer met (APA, 2000; p 412). Thus, irrespective of whether it is full or partial, the 
DSM IV defines remission as not meeting diagnostic criteria for an MDE for at least 2 
months. DSM IV defines chronic depression as the failure to achieve remission over a period 
of  2 years or more (APA, 2000). 
 
Depressive features 
In order to increase diagnostic specificity within the clinically heterogeneous diagnostic 
category of major depressive disorder (Fink et al., 2007), the DSM IV includes depressive 
feature specifiers that identify potentially important symptom constellations (APA, 2000).  
Depressive features specifiers include melancholic features and atypical features, which for 
ease of presentation are described here as depressive sub-types. According to DSM criteria, 
the major feature of the melancholic sub-type is that the depressed mood is qualitatively 
different from that seen in non-melancholic depression; there is virtually no ability to 
experience pleasure and the depressed mood is not reactive to pleasurable stimuli (APA, 
2000). The melancholic specifier also requires that three of the following five symptoms are 
present; mood worse in the morning, early awakening, weight changes, psychomotor 
changes, and excessive guilt.  In contrast, the major feature of the atypical sub-type is that 
the depressed mood is reactive to pleasurable stimuli (APA, 2000). The atypical specifier 
also requires that two of the following four symptoms are present; increased appetite/weight, 
increased need to sleep (hypersomnia), feeling heavy or weighed down (leaden paralysis), 
and a long-standing pattern of pathological sensitivity to perceived rejection (APA, 2000).  It 
must be noted that atypical features are not uncommon as they are estimated to occur in 
between 15 to 36 percent of depressed individuals (Cristancho et al., 2011). The term 
‘atypical’ was originally used to differentiate between patients who responded significantly 
more favourably to monoamine oxidase inhibitors than imipramine (Thase, 2009). 
 
The DSM IV specifications of melancholic and atypical features have been criticised as 
having limited utility. Firstly, where symptomatically distinct sub-groups are valid, they 
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ought to enable the identification of between group differences in either the course or 
treatment of depression (Rush, 2007). However, the stability of both DSM IV sub-types 
across separate episodes is poor (Melartin et al., 2004) and melancholic features are 
frequently concurrent with atypical features within the same individual (Angst et al., 2007).  
Moreover, after controlling for pre-treatment severity, Melartin et al. (2004) found no 
significant group differences between DSM IV melancholic and non-melancholic sub-types 
in treatment outcome.    
 
However, a second criticism of both of these specifiers is that their respective DSM IV 
criteria do not adequately capture the symptomatology of melancholia or atypical depression 
on which they were originally based. This shortcoming may be responsible for study 
findings that have failed to support their clinical utility as the misclassification of non-
melancholic (or non-atypical) patients will serve to confound results. For example, Taylor & 
Fink (2008) assert that melancholia is a well defined clinical syndrome that can be reliably 
diagnosed according to the following criteria: significantly reduced functioning due to an 
unremitting depressed mood, the presence of marked psychomotor disturbance and at least 
two vegetative symptoms from impaired sleep, appetite, libido or cognition (Taylor and 
Fink, 2008). Moreover, melancholic patients should demonstrate abnormally high cortisol 
levels or disturbed sleep patterns (Taylor and Fink, 2008). Consequently, Taylor & Fink 
(2008) argue that the current DSM IV melancholic features specifier is insufficiently 
stringent. Similarly, there is strong evidence for the existence of MDD with atypical features 
(Stewart et al., 2009). However, it has been proposed that the atypical features criteria of the 
DSM IV need revising, as they fail to reliably identify atypical cases (Thase, 2009). The 
most important shortcoming of the DSM criteria is that the presence of mood reactivity, 
which is the only obligatory feature for DSM atypical depression, is both redundant and does 
not discriminate between atypical and non-atypical cases (Thase, 2009).  
 
In summary, the DSM IV melancholic and atypical depressive features specifiers were 
intended to enable clinicians to discriminate between patient sub-groups who might benefit 
from different treatment approaches. However, evidence has shown that they are of little 
prognostic value, possibly because the current DSM specifiers do not adequately reflect the 
criteria by which these sub-types were originally formulated. Consequently, until the 
controversy surrounding what constitute valid  criteria for both are resolved, the melancholic 
and atypical sub-types may be better viewed as merely descriptive. 
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2.3 Course  
Depression was once thought to be an acute and self-limiting disorder. However, it is now 
recognised that many remitted individuals will experience more than one episode and that 
the course of symptoms over time is highly variable. Early research into the course of MDD 
was characterised by the use of inconsistent terminology which hindered the identification of 
potentially important clinical information (Boland and Keller, 2008). In 1991 the MacArthur 
Foundation (Frank et al., 1991) recommended the use of standardised operational definitions 
of change points to describe the course of MDD within clinical trials. Their standardised 
definitions of remission, recovery, relapse and recurrence were summarised and updated in 
2006 by the ACNP Task Force on Response and Remission in Major Depressive Disorder 
(Rush et al., 2006). The ACNP Task Force recommended that response should not be used 
in group comparison trials due to difficulties in its operationalisation (Rush et al., 2006). For 
example, whilst response is often defined as a minimum reduction of 50% on symptom 
measures in treatment trials, its clinical meaningfulness concerning individual patients is 
highly dependent on their pre-treatment severity score (Rush et al., 2006).  
 
The ACNP Task Force defined remission as no longer meeting the criteria for an MDE 
according to DSM IV. However, in contrast to the DSM IV definition which requires 2 
months, the ACNP definition requires only a 3 week period where no significant DSM IV 
criterion symptoms are present. Also, the ACNP criteria concerning what constitutes 
significant depressive symptomatology are more explicit than DSM IV descriptions. 
According to the ACNP Task Force remission requires that 3 or less DSM IV criterion 
symptoms are present over 3 weeks,  none of which may be depressed mood or diminished 
interest. The ACNP Task Force provided definitions of recovery and relapse which are not 
used in DSM IV. Recovery is conceptualised as the point in time where an MDE is unlikely 
to occur in the near future (Rush et al., 2006; p1847) and is defined as a period of remission 
lasting more than 4 months. Thus, the ACNP definitions of remission and recovery differ 
only in terms of the length of time that a patient no longer meets DSM IV diagnostic criteria 
for an MDE. However, because biomarkers that reliably differentiate remission from 
recovery have not been identified, it is possible that the ACNP’s proposed distinction 
between remission and recovery is not valid (Rush et al., 2006). Finally, the terms relapse 
and recurrence both refer to symptomatic worsening which means that an individual again 
meets the criteria for an MDE (Rush et al., 2006). However, the ACNP Task Force 
recommended that relapse be used to denote that diagnostic criteria are again met prior to 
recovery (i.e. during remission but before recovery), whereas recurrence be used to denote 
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the occurrence of a new major depressive episode after recovery has been established (Rush 
et al., 2006).  
 
Prior to the  publication of the ACNP Task Force recommendations in 2006 (Rush et al., 
2006), individual studies typically employed idiosyncratic criteria to define what are 
nominally the same clinical outcomes (Keller, 2003). Consequently, remission, recovery, 
relapse and recurrence rates from such studies are likely to only approximate those that 
would be obtained according to ACNP definitions. This must be borne in mind for the 
majority of the research findings presented in the remainder of this chapter.  
 
2.3.1 Duration of Untreated Episodes 
There have been few naturalistic studies of the duration of untreated major depressive 
episodes for ethical reasons. However, prospective data suggest that the majority of cases 
will remit within one year and that the duration of episodes is higher in more severe cases. 
However, at 2 years it is likely that a substantial minority will meet criteria for chronic 
depression. 
 
Prospective population based estimates for the duration of depressive episodes were 
obtained in the Netherlands Mental Health Survey and Incidence Study (NEMESIS, Spijker 
et al., 2002). Of 250 respondents who experienced a new episode according to DSM III-R 
criteria, the proportions recovered
2
 were 50% at 3 months, 76% at 12 months and 80% at 21 
months. Spijker et al. (2002) reported that higher severity or comorbid dysthymia predicted 
longer episodes, whilst recurrent depression predicted shorter episodes (Spijker et al., 2002). 
Posternak et al. (2006) found similar result for a sample of 130 non-chronically depressed 
patients who experienced a new episode over 15 years within the National Institute of 
Mental Health’s Collaborative Program on the Psychobiology of Depression study (CDS, 
Katz et al., 1979). Of 84 individuals who did not receive any form of somatic treatment for a 
new MDE diagnosed according to the Research Diagnostic Criteria (RDC, Spitzer et al., 
1978), the proportions recovered
3
 were 38% at 3 months, 70% at 12 months and 75% at 2 
years (Posternak et al., 2006). However, the CDS results failed to show that recurrent 
depression predicted shorter episodes (Solomon et al., 1997). 
 
The NEMESIS results presented above do not account for treatment status. However, 
Spijker et al. (2002) found no significant difference in mean episode duration between those 
who did (67%) or did not receive treatment (33%). To explain this finding, Spijker et al. 
                                                 
2
 Defined as no or minimal symptoms over 3 months. 
3
 Defined as no or minimal symptoms over 8 consecutive weeks. 
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(2002) suggested that treatment seekers were more likely to be severely depressed and 
would thus have experienced longer episodes had they not received treatment. The results of 
both the CDS and NCS-R studies appear to support this explanation. Firstly, non-treatment 
seekers
4
  in the CDS achieved remission more rapidly than the sample as a whole which 
implies they had a better prognosis (Posternak et al., 2006). Secondly, higher severity in the 
NCS-R was predictive of longer episode duration (mild duration = 13.8 weeks; very severe 
duration = 23.1 weeks; Kessler et al., 2003).  
 
Whilst it is possible that more severely depressed individuals were more likely to seek 
treatment and thus bias the results of the studies presented here, the overall results suggest 
that between a third to a half of cases will remit according to DSM IV criteria after 3 months 
and the majority by 12 months. However, approximately one fifth of cases will continue to 
be depressed at 12 months.   
 
2.3.2 Recurrence  
The onset of a first major depressive episode typically follows distressing life events such as 
bereavement, or divorce (APA, 2000). However, the onset of subsequent episodes are less 
likely to be preceded by an obvious cause (APA, 2000). The prospective CDS study (Katz et 
al., 1979) has provided important information concerning the naturalistic course of 
depression over 2 decades. The results indicate that recurrence is very common in patients 
who seek treatment for MDD and that the time between episodes typically decreases with 
increasing number of episodes. An important factor that may serve to both reduce the time to 
recurrence and increase the frequency of episodes is the persistence of residual depressive 
symptomatology during recovery. The experience of 3 or more major depressive episodes 
significantly increases the risk of recurrence.  
 
The CDS results (Katz et al., 1979) showed that 22% of a sample of 141 non-dysthymic 
patients experienced a recurrence within the first year following recovery
5
 (Keller et al., 
1983). The risk of recurrence was highest immediately after the establishment of recovery 
but reduced consistently during follow-up (Keller et al., 1983). Over the longer term, 
recurrence rates at 5, 10, 15 and 20 years in the CDS were 60%, 75%,  87% and 91% 
respectively (Boland and Keller, 2008). However, an important finding was that the 
occurrence of 3 or more previous episodes predicted a significantly increased risk of 
recurrence which was estimated to increase by 16% following each episode (Solomon et al., 
2000). In addition, whilst individuals did not demonstrate consistent time patterns between 
                                                 
4 i.e. those who did not receive somatic treatments 
5
 Defined as no or minimal symptoms over 8 consecutive weeks. 
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episodes, the overall results showed that the time between episodes decreased as the number 
of episodes increased. For example, the median time to recurrence following a first episode 
was 150 weeks, whereas it was 57 weeks following a fifth episode (Solomon et al., 2000).  A 
consistent finding was that the rate and timing of new episodes was associated with the level 
of residual symptoms in recovered patients. Full recovery led to fewer recurrent episodes 
that were less frequent than recovery with residual symptoms. For example, recurrence rates 
in asymptomatic and symptomatic but recovered patients were 66% and 87% respectively; 
the mean time to recurrence for these groups were 180 and 33 weeks respectively (Boland 
and Keller, 2008). 
 
 
2.4 Epidemiology of Major Depression 
Surveys of the prevalence of psychiatric disorders have been undertaken since the Second 
World War. However, estimates of prevalence varied widely due to differences in 
methodology. Following the Second World War, the prevalence of MDD was typically 
assessed using screening instruments (Kessler et al., 2007). This method was severely 
limited as (i) screening instruments were prone to poor specificity or sensitivity leading to 
inaccuracy (ii) the use of different instruments between surveys makes comparing their 
results problematic. This has become less of an issue since the World Health Organisation 
commissioned the Composite International Diagnostic Instrument in the 1980s (CIDI, 
Kessler and Ustun, 2004) to compare psychiatric prevalence rates between countries 
according to standardised criteria (Kessler et al., 2007). The CIDI was based on the 
Diagnostic Interview Schedule (Robins et al., 1981) and was designed to be administered by 
lay interviewers. The CIDI was also designed to support psychiatric diagnoses according to 
both ICD and DSM criteria (Kessler and Ustun, 2004). However, the original version of the 
CIDI was not designed to capture detailed demographic and clinical data. This meant that 
countries could only be broadly compared in terms of overall prevalence rates (Kessler and 
Ustun, 2004).  
 
The latest CIDI (version 3) was designed for the World Mental Health Survey Initiative 
(WMHS, Kessler, 1999) to facilitate the acquisition and comparison of psychiatric 
epidemiological data within participating countries (Kessler and Ustun, 2004).  In addition 
to enabling the quantification of lifetime and 12 month diagnoses according to both DSM-IV 
and ICD–10 criteria, the CIDI-3 also includes items that assess severity, demographic, 
quality of life and disability data (Kessler and Ustun, 2004). Unlike previous versions, the 
CIDI-3 includes interview probe questions that increase the reliability of autobiographical 
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recall. These were designed to produce less biased estimates of prevalence and age of first 
onset data than previous versions (Kessler et al., 2010). However, any method that employs 
a retrospective approach remains likely to underestimate lifetime prevalence rates. For 
example, Wells & Horwood (2004) reported that only 44% of 25 year olds with a previous 
diagnosis of MDD recalled either of the key DSM IV symptoms of depression (items 1 & 2 
in Table 1). Despite this potential limitation, the methodological rigour used to produce 
different translations of the CIDI-3 has led to it being described as ‘state of the art’ for 
comparing epidemiological findings across participating WMHS countries (Alonso and 
Lepine, 2007). Two large scale surveys within the WMHS framework have specifically 
examined the epidemiology of MDD. These are the European Study of the Epidemiology of 
Mental Disorders (ESEMeD, Alonso et al., 2002) and the American National Comorbidity 
Survey Replication Study (NCS-R, Kessler et al., 2003).  
 
2.4.1 Prevalence 
The NCS-R and ESEMeD surveys estimated that the 12 month prevalence of MDD 
according to DSM IV criteria is 6.6% in American and 4.1% in European adults (Alonso et 
al., 2004; Kessler et al., 2003). In terms of lifetime rates, 16.2% of Americans and 13.4% of 
Europeans will experience at least one depressive episode. The difference between these 
surveys may reflect that rates are genuinely higher in the American population. However, it 
is also possible that between-country difference concerning the stigma associated with 
mental disorder led to under-reporting across European countries as a whole (Bernert et al., 
2009).  However, both the ESEMeD and NCS-R lifetime prevalence rates are likely to be 
underestimates due to recall biases (Wells and Horwood, 2004) and the proportion of never-
depressed individuals surveyed who will meet MDE diagnostic criteria in the future (Kessler 
and Wang, 2008).   
 
The NCS-R results revealed that at least 13.1 million US adults met DSM IV criteria for a 
major depressive episode in the preceding year (Kessler et al., 2003). In terms of DSM IV 
symptomatology, the NCS-R results estimated that 10.4% of 12 month cases were mild, 
38.6% moderate, 38% severe and 12.9% very severe according to the Quick Inventory of 
Depressive Symptomatology Self Report (QUIDS-SR; Rush et al., 2003; Kessler et al., 
2003).  Thus, a substantial proportion of 12 month cases demonstrated severe or very severe 
clinical symptoms in the NCS-R sample. Given that current demands for treatment exceed 
available resources, it would appear that the most efficient use of resources is to target only 
those who experience severe and persistent depression (Kessler, 2007). However, providing 
effective treatment for the large population of less severe cases could be an effective 
preventative strategy (Kessler, 2007).   
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2.4.2 Age Differences  
Results from the ESEMeD study showed that the 12 month prevalence for any mental 
disorder is highest in the 18 to 24 year age group and lowest for individuals over 65 (Alonso 
and Lepine, 2007). Comparable results for the prevalence of MDE were found in the NCS-R 
where 12 month and lifetime rates in the youngest cohort (18 to 29 years) were significantly 
higher than those over 60 years (Kessler et al., 2003). However, the DSM IV employs 
hierarchical exclusion rules that typically prohibit a diagnosis of MDE in the presence of 
significant physical comorbidity (APA, 2000). The lower 12 month prevalence rate for older 
cohorts in the NCS-R may be artefactual, as higher levels of physical comorbidity in older 
adults may have precluded the diagnosis of a depressive episode (Kessler et al., 2010). To 
investigate this possibility, Kessler et al. (2010) re-analysed the WMHS data by omitting the 
hierarchical and organic exclusion rules normally employed.  This meant that depression 
comorbid with a physical disorder was included in analyses. 
 
The WMHS comorbidity study (Kessler et al., 2010) showed that the pattern of MDE 
prevalence by age reported in the NCS-R (Kessler et al., 2003) was similar to that seen in 
most developed countries. In Belgium, France, Germany, Israel, Italy, Japan, the 
Netherlands, New Zealand, Spain and the USA, the 12 month MDE prevalence rate was 
significantly lower in the oldest cohort compared to the youngest. Only Israel, Italy and 
Spain did not demonstrate significant age related differences in the 12 month prevalence of 
MDE. It appears that higher rates of physical comorbidity were not responsible for the lower 
rates of depression typically observed for older cohorts in developed countries (Kessler et 
al., 2010). An analysis across all WMHS developed countries showed that 12 month MDE 
prevalence for the oldest cohort was significantly lower than for the youngest cohort 
(Kessler et al., 2010). The WMHS 12 month  MDE prevalence rate for each age cohort 
across developed countries was 7% (18 to 34 years), 6% (35 to 49 years),  5.1% (50 to 64 
years) and 2.6% (65+ years).  However, only Brazil reproduced the overall pattern observed 
across developed countries. A pooled analysis across Brazil, Colombia, India, Lebanon, 
Mexico, South Africa and Ukraine failed to demonstrate the existence of a 12 month MDE 
cohort effect across developing countries (Kessler et al., 2010). 
 
In addition to providing data concerning age differences in the prevalence of MDE, the 
WMHS comorbidity study also enabled overall 12 month prevalence rates to be compared 
across countries. The results showed that overall estimated 12 month MDE prevalence rates 
across developed and developing countries were similar at 5.5% and 5.9% respectively 
(Kessler et al., 2010). However, individual countries showed marked variability in 
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prevalence rates which ranged from 2.2% (Japan) to 8.3% (USA) in developed countries, 
and from 4% (Mexico) to 10.4% (Brazil) in developing countries (Kessler et al., 2010).  
 
The results of the WMHS comorbidity study suggest that the mean age of onset in younger 
cohorts is decreasing across both developed and developing countries (Kessler et al., 2010). 
Kessler et al (2010) proposed that these findings were plausible as the time interval between 
respondents’ mean age and reported lifetime onset also increased with age.  This result 
contrasted with previous findings showing that the mean age of onset across all age cohorts 
typically cluster in the ten years prior to interview due to retrospective reporting bias (Simon 
and Vonkorff, 1992). The WMHS comorbidity study results also revealed that the 
prevalence of severe episodes, as assessed using the QUIDS-SR, demonstrate an inverse 
relationship with age in developed countries as severe episodes were significantly less 
prevalent in the 65+ age group (19.6%) compared to younger cohorts (range 29.6% to 
39.7%). This relationship was not seen for developing countries (Kessler et al., 2010). 
Finally, the WMHS comorbidity study results suggest that episode duration increases with 
age (Kessler et al., 2010).  Mean episode duration in the 12 months prior to interview to 
significantly increased with age across both developed and developing countries. In 
developed countries, the mean episode for the youngest cohort lasted 25 weeks compared to 
31 weeks for the oldest cohort (Kessler et al., 2010). However, these results may be 
confounded by treatment seeking differences between cohorts, as approximately 59% of 
respondents reported receiving some form of treatment.   
 
2.4.3 Gender Differences 
One of the most consistent epidemiological findings concerning MDD is that female 
prevalence rates  are typically twice those seen in males (Boughton and Street, 2007). Both 
the ESEMeD and NCS-R studies found 12 month and lifetime MDD prevalence rates for 
females were approximately twice those for males.  
 
Higher female prevalence is known to emerge in adolescence and continue into adulthood 
(Boughton and Street, 2007) although no significant gender differences have been found in 
terms of recurrence or chronicity (Kessler et al., 1993; APA, 2000).  However, the results of 
the U.K.’s National Survey of Psychiatric Morbidity (NSPB; Bebbington et al., 2003) have 
shown that the preponderance of female depression disappears after the age of 55 due to a 
reduction in the prevalence of female depression. Boughton & Street (2007)  reviewed 
numerous non-biological theories proposed to explain the higher rates of depression seen in 
females. Some theories propose, that higher levels of neuroticism or dependency in females 
increase the risk for depression, whilst others attribute differences to social restrictions 
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imposed by the female role. Alternatively, the construct of major depression may itself be 
biased towards identifying disorder in females (Boughton and Street, 2007). Irrespective of 
whether the latter proposal is true, it has been shown that the choice of measure used to 
quantify depression severity determines whether females are rated as more severely 
depressed than males (Salokangas et al., 2002; Sigmon et al., 2005).  
 
However, whilst many factors are likely to contribute to gender differences in the prevalence 
of depression, there is increasing evidence that gender differences concerning emotional 
regulation are a key factor (Nolen-Hoeksema, 2012). Emotional regulation refers to 
activities that enable the individual to modify the nature of an emotional response (e.g. 
distraction, Nolen-Hoeksema, 2012). However, whilst females have been shown to employ a 
wider range of emotional regulatory behaviours than men (Tamres et al., 2002), it has been 
proposed that their greater tendency to ruminate on the causes and meaning of negative 
emotions places a higher proportion of them at risk of developing depression (Nolen-
Hoeksema, 2012). Evidence that greater rumination in females may explain their higher risk 
for MDD has been provided in studies that show rumination to be predictive of higher 
depression scores (Nolen-Hoeksema, 2000; Nolen-Hoeksema and Aldao, 2011; Nolen-
Hoeksema et al., 1997). Moreover, because it is associated with an increased risk for social 
phobia, generalised anxiety disorder and post-traumatic stress disorder (Nolen-Hoeksema, 
2012), rumination is likely to be a key transdiagnostic risk factor for the development of 
several psychological disorders (Rachman, 1971; Nolen-Hoeksema, 1987; Morrow and 
Nolen-Hoeksema, 1990; Nolen-Hoeksema et al., 1993). 
 
2.4.4 Comorbidity 
Major depressive disorder is highly comorbid with psychological (Rush et al., 2005) and 
somatic disorders (Schmitz et al., 2007). In the NCS-R study  64% of 12 month MDD cases 
also met diagnostic criteria for another DSM IV 12 month disorder (Kessler et al., 2003). 
However, whilst MDD was highly comorbid with other psychological disorders, it only 
preceded other 12 month disorders in 12.6% of cases (Kessler et al., 2003). Estimates for the 
prevalence of major depression comorbid with physical disorders range from  5% to 10% in 
primary care settings, and from 8% to 15% in medical inpatient settings (Schmitz et al., 
2007). Comorbid depression is associated with greater levels of disability and poorer 
prognosis for both psychological and physical disorders (Rush et al., 2005; Schmitz et al., 
2007).  
 
Where depression is comorbid with a physical disorder, the greatest impairments are seen in 
those who experience chronic physical problems. The Canadian Community & Health 
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Survey (Schmitz et al., 2007) revealed that the prevalence of functional disability in the 2 
weeks prior to interview was significantly higher in respondents with chronic physical 
disorders and comorbid MDD (46%) compared to those with only chronic physical disorders 
(21%) or only MDD (27.8%). One of the most striking findings concerning the effect of 
comorbid depression and physical illness concerns cardiac mortality. In patients hospitalised 
for myocardial infarction, Lesperance et al. (2002) found a direct dose-response relationship 
between depressive symptomatology on the Beck Depression Inventory (BDI, Beck et al., 
1996) and the risk of cardiac mortality during 5 year follow-up. Notably, the mortality rate 
in patients who scored 19 or more on the BDI was significantly higher than those scored less 
than 19 on the BDI after controlling for cardiac disease severity (Lesperance et al., 2002). 
These results suggest that comorbid depression is associated with increased mortality during 
recovery from myocardial infarction.  
 
Where another psychological disorder is comorbid with MDD, episodes are typically more 
severe and last longer (Rush et al., 2005). As described earlier, there is evidence comorbid 
dysthymia increases the duration of depressive episodes (Spijker et al., 2002). However 
results from the naturalistic CDS study also indicated that comorbid panic (Coryell et al., 
1988) or alcohol abuse (Mueller et al., 1994) reduce the likelihood of recovery from an 
MDE. Coryell et al. (1988) found that comorbid panic and MDD predicted significantly 
lower levels of recovery compared to non-comorbid cases (75% versus 86% respectively) 
over 2 years, whilst Mueller et al. (1994) found that comorbid alcoholism reduced the 
likelihood of recovery by 50% over an observation period of 10 years. However, neither of 
these studies controlled for treatment differences in their analyses.  Nevertheless,  they 
provide strong evidence that comorbidity serves to increase episode duration and suggests 
treatment efficacy will be lower in patients with comorbid conditions.  
 
The moderating effect of comorbidity on treatment outcome has received relatively little 
attention (Carter et al., 2012; Hamilton and Dobson, 2002). However, there is consistent 
evidence that elevated anxiety symptomatology during an episode predicts poorer response 
to medication (Carter et al., 2012) and a lower probability of successful outcome following 
psychotherapy (Hamilton and Dobson, 2002).  Given than anxiety disorders are highly 
comorbid with MDD, e.g. 57% of 12 month MDD cases met diagnostic criteria for at least 
one comorbid DSM IV anxiety disorder (Kessler et al., 2003), they are likely to be an 
important moderator of treatment outcome in MDD. 
 
Finally, many previously remitted axis 1 disorders have not been identified as a risk factor 
for the development of a major depressive episode with the exception of early-onset simple 
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phobia and panic (Kessler & Wang 2008). However, Generalised Anxiety Disorder (GAD) 
has been identified as having the highest risk for the development of subsequent comorbid 
depression (Kessler & Wang 2008).  The high levels of comorbidity between depression and 
anxiety disorders has been argued to be an artefact of changes in the diagnostic criteria for 
successive versions of the DSM which have allowed an increasing number of diagnoses to 
be made for the same individual (Kessler & Wang 2008). There have been suggestions that 
cases of comorbid anxiety and depression may stem from a common pathological process, 
and that the separation of the disorders in DSM III onwards has produced an artificial 
distinction for these patients (Frances, Manning et al., 1991).  However, future research on 
the validity of differentiating between the two disorders is still required (Kessler & Wang 
2008). 
 
2.4.5 The Burden of Major Depressive Disorder 
One of the most distressing aspects of mood disorders is the strong association with suicidal 
behaviour. Beautrais et al. (1996) reported that whilst 90% of patients hospitalised for 
attempted suicide met DSM III-R criteria for a psychiatric disorder, mood disorders 
specifically accounted for 80% of the attributable risk for serious suicide attempts (Beautrais 
et al., 1996) which themselves strongly predict completed suicide (Yoshimasu et al., 2008).  
Whilst it has been recommended that suicide prevention strategies should not focus solely on 
depression (Fleischmann et al., 2005), MDD itself is likely to be a major predictor of suicide 
as it accounted for approximately 28% of the attributable risk for suicide within the 
ESEMeD study (Bernal et al., 2007). It is estimated that up to 15% of severe MDD cases 
will die by suicide (APA, 2000).  In addition to suicide, MDD is known to increase the risk 
of physical morbidity. For example, MDD has been shown to predict higher pain and 
mortality in medical inpatients (Herrmann et al., 1998; APA, 2000) and an increased 
likelihood of both admission to, and mortality in nursing homes (Onder et al., 2007; APA, 
2000). In addition to poorer prognoses for cardiac patients with comorbid depression, MDD 
is itself a risk factor for the development of cardiac problems (Frasure-Smith and 
Lesperance, 2005).   
 
Major depressive disorder is also a risk factor for a range of maladaptive behaviours.  NCS-
R data revealed that 45% of American respondents meeting DSM IV diagnostic criteria for 
substance use disorders in the previous 12 months also reported antecedent symptoms 
meeting criteria for an MDE (Kessler et al., 2003). This implies that depressive symptoms 
led to substance abuse in such cases. However, it cannot be ruled out that common factors 
lead to both disorders as the association between depression and substance abuse is 
complicated by the interaction between multiple factors (Swendsen and Merikangas, 2000). 
21 
 
When the onset of MDD occurs in adolescence it is associated with an increased risk of poor 
educational attainment, teenage pregnancy and impaired future marital relationships (Kessler 
and Wang, 2008). Within marital relationships, MDD is significantly associated with an 
increased risk of divorce due to impaired problem solving and communication (Davila et al., 
2008). Moreover, where one partner has recovered from a depressive episode, the marital 
relationship may remain at risk as spousal negativity towards MDD has been shown to 
predict future episodes (Davila et al., 2008).   
 
In addition to physical and behavioural burdens, MDD is costly to the wider economy. 
Major depression impairs work performance to a greater degree than arthritis, asthma, 
migraine, irritable bowel syndrome and hypertension (Kessler et al., 2008).  Unsurprisingly,  
the economic impact of depression increases with increasing severity which leads to poorer 
work performance, increased risk of unemployment and the greater need for treatment 
(Birnbaum et al., 2010). The 1991 cost of treating MDD within the UK’s National Health 
Service was estimated to be £417 million. However, the overall economic cost due to 
absence from work and premature mortality was  far higher at nearly £3 billion (Churchill et 
al., 2001).    
 
The importance of depression as a personal and economic burden is reflected in the World 
Health Organisation’s projection that its contribution to the Global Burden of Disease 
(GBD) will rise from fourth place in 2001 to second place by 2020. In 2020 it is projected 
that the GBD associated with MDD will rank only behind that of ischemic heart disease.  In 
developed countries it is projected to be the major burden of disease by 2020 (WHO, 2001).  
Thus, the identification and effective treatment of major depressive disorder is an 
increasingly pressing public health concern (WHO, 2001; WHO, 2008). 
 
2.4.6 Treatment  
Despite the high personal and economic costs associated with MDD, research indicates that  
depressed individuals show considerable delays in seeking treatment, that the recognition of 
depression is poor in treatment settings and that treatment is often inadequate. 
 
The NCS-R provided data concerning the proportion of individuals with lifetime MDD who 
sought professional treatment (Wang et al., 2005). Treatment was defined in the NCS-R as 
any form of professional healing contact meaning that psychologists, counsellors, spiritual 
advisors and herbalists were included with conventional medical professionals (Wang et al., 
2005). The NCS-R results showed that the vast majority (88%) of those with lifetime MDD 
sought some form of treatment for depressive symptoms. Several factors consistently 
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predicted the probability of initial treatment contact. Females and younger cohorts were 
more likely to seek treatment than males and older cohorts respectively. However, those 
with younger age at first onset were less likely to seek treatment than those with older age at 
first onset. Whilst 37% reported seeking initial treatment in the year following their first 
depressive episode, treatment seeking was typically delayed as the median delay was 8 years 
(Wang et al., 2005). Older cohort age and younger age at first onset predicted the longest 
delays in seeking initial treatment contact. Wang & Kessler (2005) suggested that the delays 
and lower treatment seeking rates associated with early age of first onset cases may have 
been due to poorer recognition of MDD symptoms in minors.   
 
The results reported by Wang et al. (2005) were limited in that their analyses were unable to 
identify the proportions who actually received treatment. The World Health Organisation’s 
Collaborative Study on Psychological Problems in General Health Care (CSPP, Sartorius et 
al., 1993) was specifically designed to investigate the detection and treatment of 
psychological disorders in primary care settings. The longitudinal CSPP study employed 
ICD-10 criteria to diagnose psychiatric disorders in a total sample of 26,422 adult patients 
across 15 sites worldwide. The CSPP results suggest that the identification of MDD is 
typically low in primary care settings as only 15% of those meeting ICD-10 criteria for 
major depression were correctly diagnosed. Of the remaining depressed individuals, 54% 
were identified as being psychiatric cases whilst 31% received no diagnosis (Lecrubier, 
2007). The CSPP results also showed that patients in the youngest cohort were significantly 
less likely to be diagnosed with major depression than those in older cohorts. For example, 
only 43% of 18 to 24 year olds were correctly diagnosed with MDD compared to 59% of 25 
to 44 year olds (p < .05; Lecrubier, 2007). The lower rate for the youngest cohort may have 
arisen because physicians are sometimes unwilling to diagnose a chronic mental disorder 
such as MDD in younger patients (Lecrubier, 2007). Finally, the CSPP results suggested 
that, even where correctly diagnosed, patients typically received inadequate treatment for 
depression from primary care physicians. However, treatment adequacy in the CSPP was 
assessed only in terms of whether patients received psychotropic medication (Lecrubier, 
2007).  
 
Data from the NCS-R (Kessler et al., 2003) enabled an assessment of the adequacy of both 
pharmacological and psychological treatments for MDD.  Minimal treatment adequacy for 
MDD in the NCS-R was defined as receiving either, (i) 4 or more outpatient visits with a 
physician for pharmacological treatment over 30 days or more, (ii) 8 or more outpatient 
visits with any specialist provider of psychotherapy each lasting for 30 minutes or more 
(Kessler et al., 2003). The NCS-R results showed that 57% of 12 month MDD cases sought 
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help for emotional problems in the 12-months prior to interview. Of these, 90% were treated 
in healthcare settings and 55% of this sample were treated in specialist mental health settings 
(Kessler et al., 2003). The highest rate of minimally adequate treatment (64%) was seen in 
specialist mental health settings, where interventions were provided by psychiatrists, 
psychologists, counsellors or social workers (Kessler et al., 2003). The rate of minimally 
adequate treatment in general medical settings was 41% where treatments were provided by 
primary care physicians, other medical specialists, or non-specialist nurses (Kessler et al., 
2003).  Increasing severity according to the QUIDS-SR (Rush et al., 2003) and increasing 
number of comorbid DSM IV disorders both significantly predicted treatment seeking and 
treatment adequacy (Kessler et al., 2003). Finally, the NCS-R results revealed that of the 
entire sample meeting DSM IV diagnostic criteria for MDD only 21.7% received adequate 
treatment (Kessler et al., 2003).   
 
 
2.5 Summary & Concluding Remarks 
Major depressive disorder is a highly comorbid and recurrent disorder that affects twice as 
many females as males. Approximately 5% of adults in developed countries will meet 
diagnostic criteria for major depression each year and at least 10% will experience at least 
one episode in their lifetime. MDD is a major risk factor for suicide and a range of physical 
and behavioural sequelae that place a great burden on individuals and the wider economy.  
The burdens associated with MDD appear to be increasing in developed countries as 
younger cohorts demonstrate both the highest 12 month prevalence rates and most severe 
episodes. That the effective treatment of MDD is a pressing public health concern is 
highlighted by the World Health Organisation’s prediction that it will form the major disease 
burden in developed countries by 2020. However, it appears that the majority of depressed 
individuals do not receive adequate treatment.  
 
The apparently low rate of adequate treatment provision does not reflect attempts to improve 
the efficacy of depression treatments over recent decades. Indeed, a large body of primary 
research has been accumulated concerning the efficacy of specific psychological and 
pharmacological treatments. Recent attempts to summarise the results of numerous 
psychological treatment studies, and thus determine which treatments are the most effective, 
have relied on meta-analytic approaches. The next chapter will present an overview and 
critique of meta-analyses that have investigated the efficacy of psychological treatments for 
MDD. 
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Chapter Three 
 
Meta-Analyses of Depression Studies: Overview and Critique 
 
3.1 Introduction 
Meta-analyses are increasingly used to summarise the results of primary treatment studies. 
However, whilst meta-analysis is capable of providing highly reliable empirical evidence 
concerning treatment efficacy, there are  a range of methodological factors that can bias the 
results and in turn the conclusions drawn. To reduce the risk of bias within meta-analysis, 
the systematic review method has been developed. Adherence to the systematic review 
method ensures that potential methodological risk factors are minimised thus increasing 
confidence in meta-analytic results. The systematic review method is briefly described, 
along with an illustrative example of a major systematic review and meta-analysis of 
controlled trials on the efficacy of psychological treatments for depression (Churchill et al., 
2001). However, the results of Churchill et al. (2001) demonstrate that the results of meta-
analyses concerning the efficacy of psychological treatments are still at considerable risk of 
bias despite the employment of systematic review methods. 
 
 
3.2 Evidence Based Movement in Healthcare 
Since the 1980s, healthcare funding agencies have made increasing demands that the 
efficacy of treatments be demonstrated in empirical research (Niessen et al., 2000). The 
randomised controlled trial (RCT) is widely seen as the “Gold Standard” method to 
determine treatment efficacy (Pilling, 2008; Staines, 2007). The RCT is a trial in which 
subjects are assigned to one of two groups. One group is the experimental group and the 
other the control or comparison group.  Both groups are assessed at pre and post-treatment 
and often followed up beyond the end of the treatment phase. The groups are compared to 
see if there are differences in outcome to determine which intervention was the most 
efficacious. Conducting an RCT requires the researcher to pay careful attention to the design 
and implementation of the trial to minimise potential confounds. By selecting patients 
according to pre-specified inclusion criteria and subsequent randomisation to treatment 
group, the RCT affords the best protection against threats to internal validity and increases 
confidence that interventions were responsible for any observed group differences in 
outcome (Howard et al., 1996; Chambless and Hollon, 1998). Despite their methodological 
rigour, the generalisability of RCT findings concerning psychological treatments have been 
criticised on the basis that included patients are not representative of those encountered in 
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applied clinical settings (Howard et al., 1996; Westen et al., 2004). However, where patients 
and treatments in research and applied settings are similar, RCT evidence will generalise to 
clinical settings (Wilson, 1998). In general, results of RCTs are considered to be the most 
reliable source of evidence concerning treatment efficacy and form a major component in 
the development of health policy and treatment guidelines (Oxman, 2004; NICE, 2009). 
 
However, methodologically similar RCTs can produce conflicting findings (Chambless and 
Hollon, 1998). Studies may disagree on the relative efficacy of a specific treatment or 
whether a treatment is more efficacious than treatment as usual controls. Moreover, even 
where studies support the efficacy of a treatment, quantitative estimates of treatment effect 
can vary between studies which makes it difficult to estimate the average effect of treatment. 
This variability may arise for many reasons that include between-study differences in patient 
demographics, treatment implementation or the measures used to quantify symptomatic 
change. Consequently, valid methods of summarising the results of primary studies are 
required.  
 
 
3.3 Methods for Summarising Research 
Smith & Glass (1977) first used meta-analysis to summarise psychotherapy research 
findings in order to overcome the limitations of previous approaches. Previously, the expert 
literature review formed the basis by which the evidence base for treatment efficacy was 
synthesised. However, this method was criticised for two reasons: (i) subjective biases could 
lead to the exclusion of potentially important studies, (ii) the methods used to summarise the 
evidence lacked scientific rigour (Mullen and Ramirez, 2006). The ‘vote counting’ method 
was typically used to summarise the evidence concerning the efficacy of specific treatment 
approaches. In the vote counting method, the superior efficacy of treatment A over treatment 
B is confirmed when the majority of comparison studies find treatment A superior to 
treatment B (Andrews and Harvey, 1981; Mullen and Ramirez, 2006; Smith and Glass, 
1977). However, the vote counting method cannot provide an estimate of the average effect 
of treatment across studies and actually suffers from reduced statistical power as the number 
of included studies is increased (Hedges and Olkin, 1980; Andrews and Harvey, 1981). 
These limitations led to the adoption of meta-analysis to summarise the evidence base for 
psychotherapy research (Andrews and Harvey, 1981; Smith and Glass, 1977). In contrast to 
vote counting methods, the statistical power to detect treatment differences in meta-analysis 
increases with the number of included studies (Mullen and Ramirez, 2006). The meta-
analytic method is now briefly described, followed by a description of the history and 
methodological issues surrounding its use in the field of depression research.  
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3.3.1 Meta Analysis 
Meta-analysis is a statistical method used to summarise either continuous or categorical 
outcome data from primary treatment studies. As currently practiced, the Centre for Reviews 
and Dissemination (CRD, 2009) state that it is necessary for primary studies to be 
methodologically similar and to compare the same types of treatment. Where primary 
studies include an untreated control group, the overall result of meta-analysis is an estimate 
of the mean efficacy of the active treatment. Where primary studies compare two active 
treatments, the overall results of meta-analysis is an estimate of their relative efficacy, that 
is, how much better on average one treatment is than the other. A fundamental assumption 
underlying the application of the majority of meta-analyses is that the variable treatment 
effect observed across primary studies are individual samples of the mean treatment effect in 
the clinical population of interest (Field, 2003). Such analyses are described as fixed-effects 
meta-analyses. An alternative approach is to assume that the results of included studies are 
sampled from differing clinical populations. Analyses that account for this latter assumption 
are used to find the mean treatment effect across populations and are termed random-effects 
meta-analyses (Field, 2003; CRD, 2009). However, for simplicity the following discussion 
will refer only to fixed-effects meta-analyses. 
 
In order to calculate the mean effect of treatment across primary studies, it is necessary to 
combine their results in meta-analysis. However, individual studies often employ different 
outcome measures to compare treatment groups (e.g. treatment A & treatment B). Where 
categorical outcomes are employed in primary studies, the definition of what constitutes a 
clinically desirable outcome may vary. These studywise differences make pooling their 
results problematic. For example, for continuous outcomes it is unlikely that identical scores 
on different measures denote equivalent symptom severity (CRD, 2009). Consequently, the 
magnitude of the mean difference between treatments A and B will not be directly 
comparable between studies. This problem is overcome within meta-analysis by using a 
standardised dimensionless measure, or effect size, to compare treatment outcomes between 
the groups in individual studies (CRD, 2009).  
 
The most commonly used effect size for continuous measures is the standardised mean 
difference (SMD, Nugent, 2006), a typical example of which is Cohen’s d. This is calculated 
as the difference between the post-treatment mean scores between treatment groups A and B 
divided by their pooled pre-treatment standard deviation (Cohen, 1988). For example, where 
the mean of treatment type B is subtracted from the mean of treatment A, a Cohen’s d of +1 
indicates that the post-treatment mean for group A is one pooled standard deviation higher 
than that for group B. Where d = 0, there is no difference in the mean symptomatic change 
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between treatment groups A and B. It is generally assumed that such dimensionless SMD 
effect sizes are independent of the measure used to derive them (CRD, 2009; Smith and 
Glass, 1977). However, this assumption has recently been challenged as unjustified where 
there is a non-linear relationship across the range of possible scores between different 
outcome measures used across studies (Nugent, 2006). In such cases, failure to adjust 
individual effect sizes to account for the imperfect reliability of measures may lead to biased 
conclusions (Nugent, 2006; Nugent, 2009). Furthermore, as SMD effect sizes are 
dimensionless it may be difficult to interpret the clinical importance of any overall 
difference between treatments (CRD, 2009). Where primary studies have compared 
treatments using categorical outcomes, the odds (or risk) of achieving a clinically desirable 
outcome in each group is used to calculate an odds (or risk) ratio between treatment groups.  
 
After effect sizes have been calculated for the treatments in each included study, they are 
combined to produce an overall effect size which reflects the average effect of treatment in 
the population (CRD, 2009). Weighting techniques are frequently used to ensure that effect 
sizes from smaller, and thus less precise studies, do not bias overall results (CRD, 2009). 
The overall effect size is then tested to determine whether its magnitude differs significantly 
from the predicted value according to the null hypothesis, i.e. treatments are equally 
effective. Where a significant overall effect size favours treatment over controls, the efficacy 
of treatment is supported. Where a significant overall effect size favours treatment A over 
treatment B, the relative efficacy of treatment A is superior to that of treatment B. In both 
cases, the overall effect size resulting from meta-analysis is a measure of how much better, 
on average, one treatment is relative to the other. 
 
3.3.2 Meta-Analyses of Psychotherapy Studies 
Smith & Glass (1977) performed an early meta-analysis to answer previous criticisms that 
psychotherapy was no more effective than the usual care received by patients (Eysenck, 
1952). They avoided selection bias by including the results of nearly 400 studies that 
investigated the efficacy of individual and group based psychological treatments across a 
range of disorders (Andrews and Harvey, 1981). By pooling the results of studies that 
compared psychotherapy with untreated controls, Smith & Glass (1977) derived a significant 
SMD of 0.68 in favour of psychotherapy. They concluded that the average psychotherapy 
client was better off than 75% of those not receiving treatment.  An additional analysis failed 
to demonstrate any difference between behavioural and non-behaviourally based therapies 
(Smith and Glass, 1977).   
However, their methodology was criticised because Smith & Glass (1977) included studies 
that used non-clinical samples such as prisoners and college students. For such groups it was 
argued that the observed reductions in symptomatology may not be representative of actual 
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clinical outcomes (Andrews and Harvey, 1981). Thus, Smith & Glass’s results may have 
overestimated the efficacy of psychological treatments in clinical patients (Andrews and 
Harvey, 1981). Andrews & Harvey (1981) re-analysed the dataset used by Smith & Glass 
but excluded non-clinical studies. Whilst their results confirmed that psychotherapy was 
more effective than no treatment, they were of limited utility to clinicians as  they were 
based on studies varying widely in terms of diagnosis, therapy type and treatment duration 
(Andrews and Harvey, 1981). Consequently, Andrews & Harvey (1981) proposed that meta-
analysis would be better suited to answering more specific questions concerning which 
treatments work best for specific psychological disorders. More recently, researchers have 
increasingly used meta-analysis to assess the efficacy of treatments for specific clinical 
populations. 
 
3.3.3 Meta-Analyses of Psychotherapy Studies for Depression 
Several well-known meta-analyses investigating the efficacy of psychological treatments for 
depression have been published. However, they have frequently reported conflicting results 
concerning the efficacy of specific psychological treatments for depression. Dobson (1989) 
reported that Cognitive Therapy (Beck et al., 1979) was superior to other psychological 
treatment approaches following a meta-analysis of 28 primary studies. However, Robinson 
et al. (1990) criticised Dobson’s methodology on the basis that Dobson (1989) failed to use 
all available studies, had employed only one outcome measure - the Beck Depression 
Inventory (BDI, Beck et al., 1961), and failed to account for researcher allegiance biases 
(Berman et al., 1985).   
 
In order to conduct the most comprehensive to-date assessment of psychotherapy treatment 
outcomes for depression, Robinson et al. (1990) included 58 studies in their meta-analysis.  
They found that psychotherapy in general was more effective than control conditions (wait-
list, attentional control and pill-placebo) and that cognitive, behavioural and cognitive-
behavioural approaches were superior to a broad category of ‘general verbal therapy’ which 
included psychodynamic, client-centred and interpersonal approaches (Robinson et al., 
1990). However, once effect sizes were adjusted to control for researcher allegiance there 
were no significant differences between any type of psychotherapy (Robinson et al., 1990).  
Furthermore Robinson et al. found that studies using treatment manuals, therapist 
monitoring or a formal diagnosis of depression produced effect sizes that were no different 
from those that did not. Effect sizes were also found to be unaffected by the length or format 
of treatment, the type of outcome measure employed, initial symptom severity or the level of 
training of therapists (Robinson et al., 1990). However, in contrast to Dobson (1989), the 
individual study effect sizes included in meta-analysis by Robinson et al. (1990) were an 
average of all those reported by individual studies.  This method was of questionable validity 
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and likely to be biased, as the mean effect size will have been based on some measures that 
were not correlated with symptomatic change (Nugent, 2009; Matt and Navarro, 1997).   
 
The meta-analyses by Dobson (1989) and Robinson et al. (1990) were both at risk of 
producing biased results due to the inclusion of non-randomised studies (Gloaguen et al., 
1998).  However, the contrasting methods used to derive effect sizes from primary studies 
by these authors highlights that an agreed methodological approach to meta-analysis was 
lacking. The increasing influence of meta-analysis in healthcare research led to calls for the  
development and publication of recommended methodological approaches (Boissel et al., 
1989). This was due to concerns that the widespread use of inappropriate methods and 
statistical techniques could lead to misleading conclusions within clinical research (Boissel 
et al., 1989). In addition, it was recognised that agreed methods were needed for the 
assessment of the methodological quality of studies, and, to deal with situations where the 
results of one or more included studies led to statistical heterogeneity (Boissel et al., 1989). 
Statistical heterogeneity refers to significant variation between the effect sizes of individual 
studies that cannot be ascribed to sampling error (CRD, 2009). Where identified, it may 
indicate that there are important clinical differences between patients’ response to treatment 
across individual studies which raises the possibility that the overall results do not derive 
from a single population (CRD, 2009). However, statistical heterogeneity may also arise in 
analyses of the same clinical population due to methodological differences between included 
studies and suggests that the results of one or more studies are biased (CRD, 2009).  
 
Gloaguen et al. (1998) published a meta-analysis which was “distinguished by its 
sophistication” (Wampold et al., 2002; p160). Gloaguen et al. included 48 randomised 
studies that had compared cognitive therapy (CT) with controls, antidepressant medication 
(ADM), behaviour therapy, or a combination of other psychotherapeutic approaches. 
Treatment outcomes following CT were superior to wait list/pill-placebo controls, ADM and 
all psychological approaches other than behaviour therapy.  However, significant statistical 
heterogeneity was identified in  the comparisons of CT with  non-behavioural therapies. This 
suggested that outcomes for non-behavioural therapies were not equivalent between studies. 
According to Wampold et al. (2002), the superiority of CT to non-behavioural therapies in 
the presence of significant heterogeneity occurred because non-behavioural approaches in 
some studies were either not intended to be effective, or lacked common factors known to be 
therapeutic (Wampold et al., 2002). Wampold et al. (2002) referred to these as ‘non-bona 
fide’ treatments and defined as ‘bona fide’ those therapies that were tailored to the needs of 
individuals and provided in face-to-face situations by suitably qualified therapists.  
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Wampold et al. (2002) re-performed Gloaguen et al.’s (1998) meta-analysis but excluded 
studies that employed non-bona fide treatments. Wampold et al. (2002) required that bona 
fide therapies were either (i) previously known, (ii) described in sufficient detail to establish 
that psychologically ‘active ingredients’ were employed to modify specific psychological 
processes (Wampold et al., 2002). Their re-analysis confirmed Wampold et al.’s hypothesis 
that the superiority of CT to non-behavioural therapies would disappear following the 
removal of non-bona fide treatments. However, their additional hypothesis, that comparisons 
of CT with bona fide treatments would not be heterogeneous was not supported. Wampold et 
al. (2002) traced the source of statistical heterogeneity in their results to a single study that 
provided an extreme effect size favouring CT (McLean and Hakstian, 1979). This extreme 
effect size occurred because significantly fewer CT patients dropped out of treatment than in 
the comparison group, leading to a loss of randomisation between groups (Wampold et al., 
2002). Wampold et al. (2002) justified removing the McLean & Hakstian study from their 
analysis on this basis and no longer found statistical heterogeneity for their results. However, 
this example reveals that the use of completer sample data has the potential to bias the 
results of individual studies, and thus meta-analysis, which has led to recommendations that  
only intention to treat (ITT) samples be used (CRD, 2009). 
 
The examples presented thus far show that meta-analysis has increasingly been used to 
answer specific clinical questions.  However, they also show that the results of meta-
analyses may be unreliable due to biases arising from methodological factors such as the 
internal validity, definition of treatment type and the choice of outcome measures used in 
primary studies as well as the type of samples analysed. Because policy makers and 
practitioners demand the best available evidence concerning treatment efficacy, the 
systematic review methodology has been developed and disseminated in order to enable 
researchers to reliably identify, evaluate and summarise the results from all relevant studies 
that answer a specific review question (CRD, 2009; Higgins and Green, 2006).  Indeed, 
whilst the U.K.’s National Institute for Health and Clinical Excellence (NICE) uses a range 
of methods to determine the efficacy  of treatments, systematic reviews including meta-
analysis of RCT data have been described as standing at the apex of the evidence hierarchy 
(Goldberg, 2006).   
 
3.3.4 The Systematic Review Method 
Systematic review refers to a method that attempts to identify all relevant empirical evidence 
in order to answer a specific research question (Liberati et al., 2009). By following explicit, 
pre-defined and reproducible methods, the systematic review has the potential to provide 
unbiased conclusions concerning treatment efficacy when combined with meta-analysis 
(Mullen and Ramirez, 2006; CRD, 2009). The key elements of systematic review that reduce 
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the risk of bias are the clear specification of the review’s objectives and methods, a 
comprehensive search for eligible studies, the use of independent reviewers to assess the 
validity of included evidence and the systematic presentation of results (Liberati et al., 2009; 
CRD, 2009). The specification of a review’s objectives includes the clinical population of 
interest, the interventions under comparison, the outcomes of interest and the design of 
studies to be included (CRD, 2009). Ideally, the search process should include both 
published and unpublished study evidence, as the inclusion of unpublished results can lead 
to significantly different conclusions to those based on published results alone (CRD, 2009; 
Pilling, 2008). Following search, reviewers independently determine the eligibility of 
potential studies according to pre-specified inclusion criteria. Where reviewers disagree 
concerning study eligibility, the methods used to resolve the issue of eligibility should be 
transparent. The use of independent reviewers reduces the risk that inappropriate studies are 
included or that appropriate studies are excluded. Following inclusion, the independent 
extraction of data from individual studies enables an unbiased assessment of whether their 
results are valid and thus suitable for inclusion in subsequent meta-analysis (CRD, 2009).   
 
In comparison to earlier approaches, conducting a systematic review prior to meta-analysis 
has the potential to reduce the risk that estimates of treatment efficacy are biased. This is in 
part due to the use of pre-specified aims and methods which reduce the chance that 
individual subjectivity will influence the selection of studies for inclusion. Of equal 
importance is that adherence to published recommendations concerning the statistical 
process of meta-analysis will help identify results that are methodologically robust.  
However, adherence to systematic methods is no guarantee that meta-analysis can provide 
unbiased evidence concerning the absolute or relative efficacy of psychological treatments.  
This will be illustrated by presenting the post-treatment findings for Churchill et al.’s (2001) 
systematic review and meta-analysis that sought to determine the efficacy of brief 
psychological treatments in depressed adults.   
 
3.3.5 Churchill et al.’s Systematic Review & Meta-Analysis  
Churchill et al. (2001) conducted a systematic review that included a series of meta-analyses 
of results from controlled studies investigating the efficacy of psychological treatments in 
depressed adults. They included only studies where an explicit psychological model was 
employed in treatments lasting 20 sessions or less. Depression was operationalised in studies 
as an elevated symptom score on validated symptom measures (e.g. the BDI), an elevated 
symptom score in addition to clinical interview, or following diagnosis according to 
standardised diagnostic criteria (e.g. DSM IV). Where included studies operationalised 
depression as an elevated score on symptom measures there was considerable between-study 
variation in the minimum criterion score required for entry. For example, the minimum 
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criterion BDI score in four studies was less than 10 points, whilst six required that patients 
score between 10 and 17 points. According to Beck et al. (1988), scores of less than 10 
represent minimal or no depression, whilst those between 10 and 18 represent mild to 
moderate depression.  However, Beck et al.’s score criteria for the BDI were based on the 
symptoms observed in patients formally diagnosed with an affective disorder (Beck et al., 
1988). Consequently, where studies used only elevated symptom scores to identify 
depression, it is inevitable that a substantial proportion would not have met a formal 
diagnosis of MDD (Coyne, 1994).  
 
Sixty three studies were included in Churchill et al.’s meta-analysis following a search of 
both published and unpublished work. They tested four main hypotheses: (i) all variants of 
psychotherapy were superior to treatment as usual or wait-list controls (controls), (ii) 
cognitive and behavioural approaches (CBT) were superior to Interpersonal, Psychodynamic 
or Supportive therapies combined (non-CBT), (iii) individual therapy was superior to group 
therapy,  (iv) CBT was superior to controls.  The hypotheses were tested separately in ITT 
analyses for both continuous and categorical post-treatment outcomes (symptom severity 
and remission
6
 respectively). In addition, Churchill et al. conducted post-hoc sensitivity 
analyses to determine whether the results were robust to changes in several study-level 
factors that they considered important a priori. Firstly, sensitivity analyses were conducted 
concerning the methodological quality of studies as assessed by the Quality Rating Scale 
(QRS, Moncrieff et al., 2001). The QRS enabled included studies to be rated on the 
descriptive adequacy concerning patient samples and the treatments employed, in addition to 
enabling an assessment of  their internal validity. In brief, randomised studies employing 
blinded assessment on valid measures and comparing treatments via intention to treat 
analyses were deemed to possess high internal validity. Sensitivity analyses were also 
conducted to examine the effects of the mean depressive severity of patients in studies, the 
number of available therapy sessions in studies and the recruitment source of patients (i.e. 
whether patients came from clinical settings or were volunteers/responders to 
advertisements).  
 
The results of Churchill et al.’s (2001) meta-analyses supported all four of their main 
hypotheses. However, their sub-analysis concerning study quality also revealed that the 
inclusion of low quality studies in meta-analysis had an unpredictable effect on conclusions.  
Whilst overall results based on all studies showed that psychotherapy in general was 
superior to controls, the mean symptomatic reduction between treated patients and controls 
                                                 
6 Churchill et al. (2001) used the term recovery to denote the absence of clinically significant levels of depression 
at post-treatment.  Remission is the more appropriate term according to ACNP recommendations (Rush et al., 
2006). 
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demonstrated only a ‘borderline difference’ when analysis was restricted to the poorest 
quality studies (Churchill et al., 2001). Moreover, remission rates in poorer quality studies 
were the lowest in comparison to higher quality studies and the superiority of psychotherapy 
to controls became more pronounced as study quality increased (Churchill et al., 2001). In 
contrast, their overall finding that CBT was superior to controls revealed an opposite trend. 
Here, lower quality studies contributed higher remission rates and estimates of symptomatic 
reduction than those of higher quality (Churchill et al., 2001). This latter trend was evident 
in their comparison of remission rates for CBT versus non-CBT approaches, as the 
superiority of CBT to non-CBT approaches was lost in analyses that excluded poor quality 
studies (Churchill et al., 2001).  
 
Churchill et al. (2001) concluded that the overall findings for their four main hypotheses 
were likely to be biased because the majority of studies demonstrated both low quality and 
low internal validity. In particular, the  generally poor reporting of randomisation methods, 
the frequent use of antidepressants in psychotherapy arms, and potential researcher biases 
leading to the poor implementation of non-CBT approaches led them to conclude that the 
potential influence of bias on their results ‘cannot be under-estimated’ (Churchill et al., 
2001, p94). However, based on the results of the remaining sub-analyses, they cautiously 
suggested that several study characteristics served to alter estimates of treatment efficacy. 
Studies that had included higher severity patients, clinical samples, or patients with a formal 
diagnosis of depression had consistently contributed lower estimates of treatment efficacy 
than those that had not. In addition their analysis suggested that overall treatment outcomes 
improved as the number of available therapy sessions increased (Churchill et al., 2001). 
 
 
3.4 Summary & Concluding Remarks 
Increasing demands for empirical evidence concerning the efficacy of psychological 
treatments have seen an increase in both the sophistication and employment of meta-analytic 
methods. In recent decades, meta-analysis has been increasingly focused on determining the 
efficacy of specific psychological treatment approaches for specific disorders. However, 
whilst the introduction and widespread adoption of the systematic review method has 
reduced the likelihood that meta-analytic results are unreliable due to the employment of 
sub-optimal methods, the risk of bias remains considerable. Churchill et al.’s (2001) results 
revealed that several methodological factors continue to undermine confidence that meta-
analyses of psychological treatment studies are reliable. Foremost amongst these is the 
failure to either properly implement or report the methods by which patients are randomised 
to treatment condition in primary studies. In addition to the risk of bias posed by the 
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inclusion of non-randomised studies in meta-analysis, Churchill et al. (2001) showed that the 
inclusion of studies which included undiagnosed patients led to higher estimates of treatment 
efficacy than studies employing formal diagnostic procedures. Consequently, the inclusion 
of such studies in meta-analysis may serve to increase estimates of treatment efficacy thus 
reducing the generalisability of results as a substantial minority of included patients may not 
actually be depressed. 
 
Given these caveats and the current importance of systematic review including meta-analysis 
to healthcare research, the first study of this thesis is itself a systematic review. Study 1 is a 
systematic review of published meta-analytic reviews that have investigated the efficacy of 
psychological treatments for adult MDD. However, to overcome the methodological 
difficulties identified by Churchill et al. (2001), all included studies in reviews were required 
to be RCTs where patients met formal diagnostic criteria for MDD. In addition, all 
treatments were required to be provided individually in order to increase the specificity of 
results. This approach allowed an assessment of what the best meta-analytic evidence tells 
us about the efficacy of psychological treatments for major depression. 
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Chapter Four  
 
Study 1  
 
A Systematic Review of Meta-Analyses Investigating Psychological 
Treatments for Major Depression 
 
4.1 Introduction 
The previous chapter presented an overview and critique of meta-analysis when used to 
synthesise the results of psychological treatment studies for MDD. Whilst some of the 
earlier methodological difficulties associated with this approach have been overcome by the 
adoption of the systematic review method prior to meta-analysis, there are still 
methodological factors which may undermine the reliability of review findings. The 
systematic review by Churchill et al. (2001) served as an example which revealed that the 
inclusion of non-randomised studies poses a major risk to the validity of meta-analyses 
within systematic reviews. Also, Churchill et al.’s (2001) results indicated that the inclusion 
of undiagnosed individuals may threaten the generalisability of results across clinical 
populations. Given that the results of meta-analysis are now a key element in the creation of 
clinical guidance, it is of vital importance to assess the quality of potentially influential 
reviews that have investigated treatments for depression. 
 
The purpose of the present systematic review was to identify and examine published reviews 
where the efficacy of psychological treatments for MDD has been investigated via meta-
analysis. Reviews were considered methodologically rigorous where included studies were 
randomised controlled trials (RCTs) that had investigated the efficacy of individual 
psychological treatments in patients who met standardised diagnostic criteria for MDD. In 
addition, psychological treatments were required to have been based on theoretical models 
of psychopathology. Consequently, approaches such as non-directive counselling were 
excluded. The identification of such meta-analytic reviews enabled an assessment of how 
effective current psychological treatments are for MDD. Furthermore, assessments of the 
methodological quality of included reviews enabled a determination of whether they were at 
risk of providing biased results both individually and across all reviews. 
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4.2 Method 
4.2.1 Search Strategy 
Meta-analytic reviews were searched for using the following databases: Cochrane DARE, 
Cochrane Database of Controlled Trials, Cochrane Database of Economic Evaluations, 
Cochrane Database of Systematic Reviews, Cochrane Database of Technology Assessments, 
PsychINFO (1967-2009), EMBASE (1980-2009), Ovid MEDLINE(R) In-Process & Other 
Non-Indexed Citations (6/03/2009), Ovid MEDLINE(R) (1950-2009), SCOPUS 
(12/03/2009) and Web of Knowledge (SCI-EXPANDED 1945 to 11/03/2009; SSCI 1956 to 
11/03/2009).  An experienced reviewer (YD) designed the search filter template.  Search 
terms included: depression, depressive, major depressive disorder, depressive disorder, 
dysthymia, psychotherapy meta-analysis, systematic review and possible variants for each 
database.  The full search strategy is illustrated appendix A.   References of the included 
reviews were searched to identify any additional eligible articles.  No attempt was made to 
find eligible ‘in press’ articles.   All databases were searched in the first two weeks of March 
2009.   
 
4.2.2 Eligibility Criteria 
The eligibility criteria for reviews are shown in Table 2. No limitations were imposed on 
publication date, length of treatment or follow-up, outcome measures used to determine 
depressive symptom severity or numerical methods used for meta-analysis.  
 
4.2.3 Selection of Meta-analytic Reviews 
All identified articles were combined in a single database and duplicates removed.  A single 
reviewer (MC) then excluded references which clearly did not meet the eligibility criteria 
based on title alone.  If there was any doubt concerning an article’s eligibility at this stage of 
the selection process the reference was retained and included in the abstract screening stage.   
Two independent reviewers (MC/RD) then screened the abstracts of remaining articles to 
exclude ineligible articles.  Articles which could not be excluded on the basis of title or 
abstract were obtained and assessed by two independent reviewers (MC/CH) using a 
purpose made screening tool (see appendix B).  This tool operationalised the eligibility 
criteria and permitted each eligibility criterion to be recorded as present, absent or 
questionable for each meta-analytic review. The tool also included space to make comments, 
where it was not possible to fully assess a criterion from the manuscript alone, or where a 
minority of studies included in the review could result in the review’s exclusion.  Where 
reviewers failed to agree concerning the eligibility of reviews a third reviewer was consulted 
(PF).  
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Table 2. Eligibility Criteria for Included Meta-analytic Reviews 
 
 Inclusion Criteria Exclusion Criteria 
Review Type Systematic review, meta-analysis or review  
of randomised controlled trials 
Published in peer reviewed source 
No English translation available 
Unpublished 
Patient Type Adults diagnosed with major depression 
according to a classificatory diagnostic 
scheme 
Diagnosis based solely on screening 
instruments or where consistent methods were 
not described when using published criteria 
Depression treated specifically in the context 
of substance abuse, personality, psychotic or 
medical disorders 
Sub syndromal depression not meeting criteria 
for major depression 
Treatment Individual psychotherapy in at least one 
treatment condition based on theoretical 
model of psychopathology 
Group therapy 
Computer administered therapy 
Self help interventions 
Comparison 
Conditions 
Treatment as usual, waiting list control, 
attentional control, psychotherapy, 
pharmacotherapy 
 
Outcomes Meta-analytic estimates of therapeutic 
efficacy based on group-level data   
Narrative review 
Reviews not using group as the unit of analysis 
 
 
 
4.2.4 Data Extraction 
Substantive data from included meta-analytic reviews were extracted using a modified 
version of the University of York’s Centre for Reviews and Dissemination’s abstract 
reporting format (CRD, 2009a). One reviewer (MC) extracted data which was checked and 
revised if necessary by another (CH) concerning: 
 
 the authors’ objectives 
 search methods and included designs 
 patient type, severity and duration of depression 
 comparison conditions 
 therapy types and diagnostic techniques used in studies 
 setting and duration of therapy  
 assessment points in time 
 results from meta-analysis 
 findings of any heterogeneity of results between included studies and whether they 
were accounted for 
 authors conclusions & statements concerning implications for practice or research 
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The risk that any single review provided biased meta-analytic results was assessed using an 
instrument based on the University of Sheffield’s School of Health & Related Research 
(ScHARR) Systematic Review Quality Appraisal guidance (University of Sheffield, 2009).  
Risk of bias data (formerly called, ‘quality data’ Liberati et al., 2009) were extracted by two 
independent reviewers (MC/YD). The quality of reviews was assessed in terms of the 
following questions: 
 
 was the search process adequate? 
 were eligibility criteria reported? 
 included studies valid? 
 was there an assessment of study quality? 
 appropriate outcome measures used? 
 methods of data extraction reported? 
 appropriateness of any numerical synthesis and any sub-group analyses? 
 presented numerical results appropriate? 
 issues of generalisability addressed? 
 
Answers to these questions were independently categorised as yes/no or partially with 
disagreements being resolved by discussion.  Appendix C contains the composite instrument 
used to extract both types of data. 
 
The risk that the results of reviews were biased was assessed in terms of within and across 
review risk of bias.  Within review risk refers to the risk that an individual review provided 
biased results by virtue of its methodology.  In contrast, across review bias refers to the risk 
that all reviews provided biased results as a consequence of shared methodological 
shortcomings. This approach to review bias was analogous to current recommendations for 
the reporting of risk of bias in single systematic reviews and meta-analyses of primary 
studies (Liberati et al., 2009). Within review risk of bias was assessed using the quality 
appraisal instrument for systematic reviews described above. Across review risk of bias was 
assessed within an iterative analysis of substantive and quality data. Important 
methodological issues that potentially affected all reviews were raised by some individual 
review authors. Where individual reviews provided insufficient information to assess across 
review risk of bias, the manuscripts of their included studies were consulted where possible.  
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4.3 Results 
4.3.1 Review Selection & Objectives 
Figure 1 presents an overview of the selection procedure.  The independent assessment of 
substantive data from 107 full manuscripts identified 12 potentially eligible articles with a 
reviewer agreement rate of 94% (101 of 107 articles).  It was found that some meta-analytic 
reviews contained results which were based on studies meeting our eligibility criteria whilst 
other results within the same review were not.  In this case only the eligible results were 
extracted.  Ten meta-analytic reviews were borderline cases for inclusion, five of which 
were included following further investigation and referral to the third reviewer PF 
(Casacalenda et al., 2002; Friedman et al., 2004; Leichsenring, 2001; Parker et al., 2008; 
Vittengl et al., 2007).  The reasons for their inclusion are presented in appendix E. A search 
of the references of the seven included meta-analytic reviews failed to identify any further 
eligible reviews.   
 
The objectives of included meta-analytic reviews are presented in Table 3. All compared the 
efficacy of psychotherapy with an alternative condition at post-treatment, with four 
providing results for follow-up outcomes (de Maat et al., 2006; Friedman et al., 2004; 
Leichsenring, 2001; Vittengl et al., 2007). Acute phase psychotherapy was compared in six 
reviews, whilst Vittengl et al. (2007) included comparisons of continuation phase 
psychotherapy (C-CT) with an alternative condition.  
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Figure 1. Selection of Eligible Meta-analytic Reviews 
 
 
  
References identified from Cochrane 
Library, EMBASE, PsychINFO, Medline & 
Medline in Process, Scopus and Web of 
Knowledge. 
Total = 3791 
Excluded n = 1459 
Excluded n = 872  
Excluded n = 1353 
Excluded n = 95 
Excluded n = 5 
Excluded n = 6 
Relevant review not meeting 
inclusion criteria    
n = 45 
 
Not relevant or not a quantitative 
review specific to depression   
n = 61 
Final number of included reviews = 7 
References following duplicate removal 
2332 
References following title screening 
1460 
References following abstract screening 
107 
References following independent 
manuscript review & application of 
eligibility criteria = 12 
Reviews explicitly meeting all criteria = 2 
Reviews requiring manuscript retrieval for 
constituent studies and/or discussion with 
third reviewer concerning eligibility = 10 
Included reviews = 7 Reviews identified from 
bibliographies = 6   
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Table 3. Objectives of Included Meta-analytic Reviews. 
 
 
 
 
Review Objectives of the Review 
Casacalenda et al. (2002) To determine the percentages of patients achieving remission from depressive symptoms 
within randomised controlled trials that had directly compared psychotherapy, 
pharmacotherapy and control conditions. 
de Maat et al. (2006) To determine the relative efficacy of pharmacotherapy & psychotherapy assessed at 
treatment termination and at follow-up for clinically homogeneous patients.  A 
secondary objective was to investigate the impact of dropout and the severity or 
chronicity of depression on outcomes. 
de Maat et al. (2007) To determine the relative efficacy of psychotherapy & psychotherapy combined with 
pharmacotherapy in the acute treatment of depression for clinically homogeneous 
patients. A secondary objective was to investigate possible differences in dropout rates 
between conditions and whether differences existed in prognosis for patients suffering 
differing severities or durations of depression. 
Friedman et al. (2004) To determine whether combined therapy was more efficacious than pharmacotherapy or 
psychotherapy alone as part of a broader review of the literature on combined treatment 
for major depressive disorder.  Only studies which compared the same type of 
psychotherapy across treatment conditions were included. 
Leichsenring (2001) To directly compare the efficacies of Short Term Psychodynamic Therapy and CBT at 
post treatment and at follow-up for treatments lasting at least 13 sessions.  The analysis 
used a range of psychosocial and psychiatric measures in addition to depression 
symptom measures. 
Parker et al. (2008) To challenge the findings of a previous meta-analysis by Gloaguen et.al (1998) where it 
was concluded that CBT for depression demonstrated superior post-treatment outcomes 
than pharmacotherapy. Only a sub-set of the original studies using the BDI and meeting 
stricter inclusion criteria than in the original meta analysis were used. 
Vittengl et al. (2007) To determine (i) the rate of relapse-recurrence amongst responders to acute phase 
cognitive therapy (A-CT) and (ii) whether A-CT reduced relapse-recurrence better than 
other acute phase treatments during follow-up. 
 
To determine whether continuation phase cognitive therapy (C-CT) reduced relapse-
recurrence more than non-active control conditions or other active continuation phase 
treatments at the end of C-CT and during follow-up. 
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Table 4. Characteristics of Meta-analytic Reviews: Post-treatment Comparisons. 
Review Primary Comparison  Therapy  
Models 
Setting Diagnostic  
Criteria 
Pre-treatment Severity Ns Np Maximum 
Therapy 
Sessions  
Treatment  
Duration  
(weeks) 
Primary  Outcome  
Casacalenda et al. (2002) Psychotherapy  vs   
ADM or  controls 
CBT 
IPT 
PST  
SWC  
Outpatient DSMIII  
DSMIII-R 
RDC 
Min BD  14 to 20 
Min HRSD 13 to 14 
6 883 6 to 20 10 to 34 Patients remitted 
de Maat al. (2006) Psychotherapy vs  
ADM 
CT/CBT 
CBASP  
IPT 
Outpatient DSMIII-R 
DSMIV 
RDC 
Min BDI  14 to 20 
Min HRSD 10 to 20 
10 1233 16 to 24 8 to 20 Patients remitted  
 
de Maat et al. (2007) Psychotherapy vs 
combined therapy 
CT/CBT 
CBASP 
STPP  
Outpatient DSMIII-R 
DSMIV 
RDC 
Min BDI  14 to 20 
Min HRSD 12 to 20 
7 903 16 to 24 8 to 20 Patients remitted 
Friedman et al. (2004) Psychotherapy  vs 
combined therapy 
CBASP 
PST  
CT 
Outpatient 
 
RDC 
Feighner  
DSMIV  
Min HRSD 13 to 20 3 530 6 to 20 12 Effect sizes for: 
Symptom reduction 
Recovery  
Leichsenring  (2001) CBT vs STPP CBT 
STPP 
Outpatient RDC  
DSMIII 
Feighner 
Min BDI  10 to 17 
Min HRSD  14 
5 323 13 to 20 n/a Patients remitted or 
improved 
Parker et al. (2008) Cognitive Therapy vs 
ADM 
CBT Outpatient/ 
Inpatient 
RDC 
Feighner  
DSMIII-R 
Min BDI  14 to 23 
Min HRSD  10 to 20 
9 327 12 to 24 8 to 15 Effect sizes for: 
symptom reduction, 
patients responding 
Vittengl et al. (2007a) C-CT vs non-active 
controls 
CT Outpatient DSMIII-R 
DSMIV 
Min HRSD  12 to 16 4 234 6 to 10 35 to 52 Relapse/recurrence 
assessed at  the end of 
C-CT 
Key:  ADM = antidepressant medication;  BDI = Beck Depression Inventory; CBASP = cognitive behavioural analysis system of psychotherapy; CBT = cognitive behavioural therapy; 
C-CT = continuation phase cognitive therapy; CT = cognitive therapy; DSM = Diagnostic & Statistical Manual of Mental Disorders; Feighner = Feighner Diagnostic Criteria for Use in 
Psychiatric Research; HRSD = Hamilton Rating Scale for Depression; ; ITT = Intention to treat analysis; IPT = interpersonal psychotherapy; Min = Minimum; n/a = not available; Np = 
total number of patients included in post-treatment analysis; Ns = maximum number of studies used in any post-treatment meta analysis; PST = problem solving therapy; RDC = research 
diagnostic criteria; STPP = short term psychodynamic psychotherapy; SWC = social work counselling.
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Table 5. Characteristics of Meta-analytic Reviews: Follow-up Comparisons. 
Review  Primary Comparison Therapy  
Models 
Diagnostic  
Criteria 
Pre-treatment Severity at 
Start of Acute Treatment  
Ns Np Maximum 
Therapy 
Sessions  
Treatment  
Duration 
(weeks) 
Follow-up  
Period  
(weeks) 
 Primary  Outcome 
de Maat al.  (2006) Psychotherapy vs ADM CT/CBT 
IPT 
DSMIII-R 
DSMIV 
RDC 
HRSD mild to moderate 6 231 20 to 24 8 to 20 52 to 104 Relapse  
Friedman et al. (2004) Psychotherapy  vs 
combined therapy 
CT RDC  
DSM III  
Min BDI  10 to 17  
Min HRSD 14 
3 78 20 to 23 12 to 20 52 to 104 Relapse 
Leichsenring (2001) CBT vs STPP CBT    
STPP 
RDC  
DSMIII 
Min BDI  10  to 17  
Min HRSD 14 
4 270 16 to 20 n/a 52 to 104 Patients remitted or 
improved 
Vittengl et al. (2007b) C-CT vs non-active 
controls 
CT  RDC 
DSMIII-R 
DSMIV 
Min HRSD 12 to 16 5 232 10 20 to 35 69 to 312  Relapse/recurrence 
Vittengl et al. (2007c) A-CT vs Other  
depression specific 
psychotherapies 
CT RDC  
DSMIII 
DSMIII-R 
Min BDI  20  
Min HRSD 14 
4 194 8 to 20 16 52 to 104  Relapse/recurrence 
Vittengl et al. (2007d) A-CT vs ADM CT RDC  
DSMIII 
DSMIII-R 
DSMIV 
DSMIV-TR 
Min BDI 20 to 21  
Min HRSD 12 to 21 
7 344 20 to 24 8 to 16 52to 104  Relapse/recurrence 
Vittengl et al. (2007e) A-CT vs Combined 
therapy 
CT DSMIII 
DSMIV 
Min BDI 20 to 21  
Min HRSD 14 to 21 
3 136 20 to 24 8 to 12 52 to 104 Relapse/recurrence 
Key: ADM = antidepressant medication;  A-CT = acute phase cognitive therapy; BDI = Beck Depression Inventory; CBT = cognitive behavioural therapy; C-CT = continuation phase 
cognitive therapy; CT = cognitive therapy; DSM = Diagnostic & Statistical Manual of Mental Disorders; HRSD = Hamilton Rating Scale for Depression; IPT = interpersonal 
psychotherapy; Min = Minimum;  n/a = not available;  Np = total number of patients included in follow-up analysis Ns = number of studies used in follow-up  meta analysis; RDC = 
research diagnostic criteria; STPP = short term psychodynamic psychotherapy. 
Note: all session and duration data refer to acute treatment studies providing data for follow-up comparisons except for Vittengl et al. (2007b) which refers to continuation treatments 
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4.3.2  Characteristics of Meta-analytic Reviews 
In order to aid clarity Table 4 and Table 5 present the characteristics of included meta-
analytic reviews for post-treatment and follow-up comparisons respectively. There are four 
references to Vittengl et al. (2007) in Table 5 as Vittengl et al. provided more than one type 
of treatment comparison at follow-up. 
 
Treatment Comparisons 
Post-treatment 
Table 4 shows that three reviews compared psychotherapy with anti-depressant medication 
(ADM; Casacalenda et al., 2002; de Maat et al., 2006; Parker et al., 2008), two with 
psychotherapy plus ADM (combined therapy; de Maat et al., 2007; Friedman et al., 2004), 
and two with controls (Casacalenda et al., 2002; Vittengl et al., 2007). Specific 
psychotherapy models were compared with alternative treatments in three reviews 
(Leichsenring, 2001; Parker et al., 2008; Vittengl et al., 2007), whereas four reviews pooled 
psychotherapy models for their comparisons with alternative treatments (Casacalenda et al., 
2002; de Maat et al., 2006; de Maat et al., 2007; Friedman et al., 2004).  The post-treatment 
comparison for Vittengl et al. (2007a) in Table 4 refers to outcomes at the end of C-CT in 
patients who responded
7
 to acute phase psychological treatments and were subsequently 
assigned to either a C-CT or untreated control group. Table 6 provides references to the 
studies used for post-treatment analyses in reviews. 
 
Follow-up 
Table 5 shows that four reviews made the same treatment comparisons at follow-up as seen 
at post-treatment in Table 4 (de Maat et al., 2006; Friedman et al., 2004; Leichsenring, 2001; 
Vittengl et al., 2007b).  De Maat et al. (2006) and Leichsenring (2001) based their follow-up 
comparisons only on follow-up data that was available for the patients included in their post-
treatment comparisons. However, both Friedman et al. (2004) and Vittengl (2007b) included 
follow-up data from studies that were not included in their post-treatment analyses. Vittengl 
et al. (2007) provided three additional comparisons for which there were no corresponding 
post-treatment results in Table 4. These compared A-CT with ADM (Vittengl et al., 2007d), 
combined therapy (Vittengl et al., 2007e), or other depression specific psychotherapies 
(Vittengl et al., 2007c). This was because the primary focus of Vittengl et al.’s review was to 
compare the efficacy of treatments in the prevention of relapse/recurrence - not the efficacy 
of acute treatments. The studies included for follow-up comparisons in reviews are 
referenced in Table 7. 
 
                                                 
7 The criteria for response employed by original authors are not presented in this review. 
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Table 6 Studies Used for Post-treatment Comparisons in Reviews 
Casacalenda 2002  X        X  X    X  X   X        
de Maat  2006    X
 
 X    X X    X  X  X  X  X     X 
de Maat  2007    X  X X    X      X      X   X   
Friedman 2004      X     X            X X     
Leichsenring  2001     X    X X   X X               
Parker 2008 X  X X  X  X  X X    X  X            
Vittengl 2007 (a)                    X  X   X  X  
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For Vittengl et al (2007):  a = C-CT vs controls 
 
 
 
Table 7. Studies Used for Follow-up Comparisons in Reviews 
 
 
For Vittengl et al (2007):  
 b = C-CT vs non active controls 
 c = A-CT vs other depression specific psychotherapies 
 d = A-CT vs ADM 
 e = A-CT vs combined therapy
de Maat  2006 X X  X X    X       X  
Friedman 2004 X X   X             
Leichsenring  2001   X X   X X          
Vittengl 2007 (b)          X  X X X X   
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Diagnosis & Patient Samples 
Table 4 and Table 5 both show that patients contributing to all meta-analyses in reviews 
were diagnosed with MDD using a variety of clinician rated diagnostic criteria. Post-
treatment comparisons in six reviews were based on outpatients, whilst Parker et al. (2008) 
included a single study (Hautzinger, 1996) that had included inpatient data (Table 4). 
However, this study was used in only in one of four comparisons made by Parker et al. 
(2008) where inpatients contributed approximately 16% to both the sample of 181 CBT and 
166 ADM patients.  De Maat et al. (2006, 2007) also included Hautzinger et al. (1996) but 
extracted data for outpatients only.  
 
Mean pre-treatment severity of patients in included studies 
An examination of the included studies in reviews (Table 6 & Table 7) enabled the mean 
pre-treatment severity of patient samples used in meta-analysis to be compared between 
some reviews.  De Maat et al. (2006, 2007) described the mean pre-treatment severity for 
each of their included studies.  Because included studies used differing versions of the 
HRSD, de Maat et al. (2006, 2007) used a published algorithm to convert scores from 
differing versions to correspond with those of the 17 item HRSD. De Maat et al. (2006, 
2007) concluded that the mean pre-treatment severity of patients across their studies fell 
within the mild to moderately depressed range (12 to 19.9 and 20 to 24.9 points 
respectively). Casacalenda et al. (2002) also reported mean HRSD scores ranging from 15.3 
to 23.4 indicating mean severities in the mild to moderate range.  However, Casacalenda et 
al. (2002) did not report which versions of the HRSD were used, and a mean score of 23.4 
for Schulberg et al. (1996) suggested that approximately 50% of patients in this study may 
have been severely depressed according to de Maat et al.’s (2006, 2007) criteria.   
 
Table 6 indicates that the majority of post-treatment studies in Friedman et al. (2004) and 
Parker et al, (2008) were included in de Maat et al. (2006).  This suggested that the mean pre 
treatment severity of patients in these studies fell within the mild to moderately depressed 
range according to de Maat et al.’s (2006, 2007) criteria.  Similarly, Table 7 indicates that all 
of the follow-up studies included by Friedman et al. (2004) and Vittengl et al. (2007e) were 
included in de Maat et al.’s (2006) follow-up analysis, again suggesting that their mean pre-
treatment severity fell within the mild to moderate range.  Finally, five out of seven studies 
in Vittengl et al. (2007d) were included by de Maat et al. (2006), suggesting that the 
majority of studies in Vittengl et al.’s (2007d) comparison had mean pre-treatment severities 
in the mild to moderate range.   
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Number of patients in meta-analytic comparisons 
Table 4 and Table 5 show that the highest numbers of patients were included in meta-
analytic comparisons of psychotherapy with ADM at both post-treatment (de Maat et al., 
2006) and follow-up (Vittengl et al., 2007d). The lowest number of patients in post-
treatment comparisons were found for comparisons of specific psychotherapy models (Table 
4). However, this was not the case at follow-up where Vittengl et al. (2007d) incorporated 
the highest number of patients in a comparison of A-CT with ADM (Table 5). 
 
Treatment Sessions & Overall Duration of Therapy  
 Post-treatment Analyses (Table 4). 
Review meta-analyses pooled studies that varied considerably in terms of the maximum 
number of psychotherapy sessions available to patients. For example, Casacalenda et al. 
(2002) pooled studies where treatment ranged from 6 to 20 sessions. Acute treatment 
comparisons showed a wider range of maximum available treatment sessions than seen for 
continuation treatment. Original articles for the included studies in reviews were consulted 
which indicated that the median number of maximum available sessions for acute treatments 
was 20 across reviews.  For continuation treatments the median number of maximum 
available sessions was 10.   
 
The time period over which acute treatment sessions were provided also showed 
considerable variability except for Friedman et al. (2004) where all were scheduled for 12 
weeks. The longest acute treatment duration of 34 weeks in Casacalenda et al. (2002) was 
due to the inclusion of Schulberg et al. (1996) where 16 weekly acute sessions were 
followed by four monthly continuation sessions. The highest treatment durations 
contributing to post-treatment analyses were seen for continuation treatments (Vittengl et al., 
2007a) as continuation phase sessions were provided less frequently than for acute 
treatments (Table 5).   
 
Follow-up Analyses  (Table 5). 
With the exception of Vittengl et al. (2007c), follow-up comparisons were based on studies 
that demonstrated a smaller range of available sessions than those used in post-treatment 
comparisons. The median values for available sessions and the duration of acute treatments 
were 20 and 16 weeks respectively.  For C-CT the corresponding values were 10 sessions 
and 27 weeks (Vittengl et al., 2007b).   
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Definitions of Outcome 
All meta-analytic reviews compared treatments in terms of categorical outcomes, the most 
common being remission at post-treatment and relapse
8
 at follow-up (Table 8 & Table 9). 
Only Friedman et al. (2004) and Parker et al. (2008) presented effect sizes based on 
continuous measures i.e. symptom reduction (Table 4). The vast majority of categorical 
outcomes used in post-treatment comparisons were derived from studies that had effectively 
assessed remission in terms of a minimum severity score on either the Hamilton Rating 
Scale for Depression (HRSD, Hamilton, 1960) or Beck Depression Inventory (BDI, Beck et 
al., 1961). For example, most of Parker et al.’s (2008) definitions of ‘response’ were 
operationalised as a BDI score of less than 10 (Table 8). According to  Beck et al. (1988) 
scores below 10 represent minimal or no depression in patients previously diagnosed with an 
affective disorder which indicates that the majority of outcomes in Parker et al. (2008) were 
estimates of remission.  Similarly, the HRSD criteria used to define post-treatment recovery 
according to Friedman et al. (2004) were typically the same as those that de Maat et al. used 
to define remission (Table 8). The majority of categorical outcomes for follow-up 
comparisons were based on the identification of relapse/recurrence following a new MDE or 
retreatment for depression (Table 9).  However, Table 8 and Table 9 reveal that the 
treatment comparisons in all reviews were based on diverse outcome definitions.  For 
example, Table 8 shows that de Maat et al. (2006) included studies which defined remission 
as a criterion score of 6 or less on the HRSD whilst others used 7, 8 or 9. In addition, 
included studies could operationalise outcomes based on more than one criterion. For 
example, relapse was defined in one of Friedman et al.’s (2004) studies as a BDI greater 
than or equal to 16, or retreatment for depression (Table 9). 
 
  
                                                 
8 This is better described as recurrence, however, the term will be retained to correspond with the definitions used 
in primary studies. 
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Table 8. Definitions of  Post- treatment Outcome Used in Review Studies 
 
Comparison Review Outcome Criteria Definitions of Outcome  
Controls Casacalenda  et al. (2002) Remission - ITT  HRSD ≤ 6 or 7 
Raskin Depression Scale ≤ 5 
 Remission - Completer HRSD ≤ 6 or 7 
 Vittengl et al. (2007 a) Relapse/recurrence  MDE or retreatment for depression. 
MDD and HRSD ≥ 16 for ≥ 2 visits 
Psychotherapies 
 
Leichsenring (2001) Remission or 
improvement 
HRSD ≤ 6 
BDI ≤ 8 
BDI & HRSD ≤ 10 
SADS-Change, RDC 
ADM 
 
Casacalenda  et al. (2002) Remission - ITT HRSD ≤ 6 or 7 
Raskin Depression Scale ≤ 5 
Remission - Completer HRSD ≤ 6 or 7 
De Maat et al. (2006) Remission  HRSD ≤ 6, 7, 8 or 9 
HRSD ≤ 9 and BDI ≤ 8 
HRSD ≤ 9 and BDI ≤ 9 
Parker  et al. (2008) Response - ITT BDI ≤ 7 or 9 
BDI ≤ 9 after at least 12 sessions and 
15 weeks of treatment. 
Response - Completer  BDI ≤ 9 
BDI and HRSD ≤ 9 
BDI ≤ 9 after at least  12 sessions and 
15 weeks of treatment. 
50% decrease in BDI (or HRSD) after 
maximum of 12 weeks. 
BDI ≤ 14 following at least 50% 
reduction in score. 
Combined  
Therapy 
 
de Maat et al. (2007) 
 
Remission- ITT HRSD ≤ 6, 7 or 8 
BDI ≤ 10 
BDI ≤ 9 and HRSD ≤ 9 
BDI ≤ 8 and HRSD ≤ 9 
Friedman et al. (2004) Recovery - Completer HRSD ≤ 6, 7 or 8 
Recovery - ITT HRSD ≤ 6 or 7 
Key:  ADM = antidepressant medication; BDI = Beck Depression Inventory; Completer = completer sample; 
HRSD = Hamilton Rating Scale for Depression; ITT = intention to treat sample; MDE = major depressive 
episode; MDD = major depressive disorder; RDC = Research Diagnostic Criteria; SADS = Schedule for 
Affective Disorders;. 
 
See original reviews for references to instruments. 
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Table 9. Definitions of Follow-up Outcome Used in Review Studies 
 
Comparison   Review  Outcome Criteria  Definitions of Outcome  
Controls Vittengl et al. (2007b) Relapse/ recurrence MDE.  
MDE or retreatment for depression 
Psychotherapies    Leichsenring (2001) Remission or 
improvement 
BDI ≤ 8.  
LIFE-II, MDD. 
SADS-Change, RDC 
 Vittengl et al. (2007c) Relapse/ recurrence MDE.  
BDI ≥ 16.  
BDI ≥ 16 or BDI ≥ 9 and retreatment for 
depression. 
ADM De Maat et al. (2006) Relapse BDI >15.  
Physician indicated need for treatment.   
Meeting RDC criteria for MDD for more 
than 2 weeks.  
Two BDI scores > 15 separated by 1 week.  
IDS > 29.  
Meeting criteria for MDD for more than 2 
weeks  or HRSD > 13. 
 Vittengl et al. (2007d) Relapse/ recurrence MDE.  
BDI ≥ 16 for 2 weeks or more.  
IDSC ≥ 21 for  2 months or more.  
MDE or HRSD ≥ 14 for 2 weeks or more.  
MDE or retreatment for depression.  
MDE & BDI ≥ 15 or HRSD ≥ 16.  
Retreatment for depression or BDI ≥ 16. 
Combined  
Therapy 
Friedman et al. (2004) Relapse Retreatment for depression or BDI ≥ 16.  
BDI ≥ 16 for 2 weeks or more. 
Physician indicated need for treatment. 
Vittengl et al. (2007e) Relapse/ recurrence Retreatment for depression or BDI ≥ 16.  
BDI ≥ 16 for 2 weeks or more. 
IDSC ≥ 21 for  2 months or more. 
Key: ADM = antidepressant medication; BDI = Beck Depression Inventory; HRSD = Hamilton Rating Scale for 
Depression; IDS = Inventory of  Depressive Symptomatology; IDSC = Inventory of Depressive Symptomatology 
– Clinician Version; MDE = major depressive episode; MDD = major depressive disorder;  RDC = Research 
Diagnostic Criteria; SADS = Schedule for Affective Disorders;   
 
See original reviews for references to instruments. 
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4.3.3 Results of Meta-Analyses  
Post-treatment Results 
The post-treatment results for reviews’ comparisons of psychotherapy with alternative 
treatments are presented in Table 10. The table shows that the majority of reviews presented 
overall meta-analytic results in terms of the clinical significance of treatments, i.e. rates of 
remission, response or relapse-recurrence (Casacalenda et al., 2002; de Maat et al., 2006; de 
Maat et al., 2007; Parker et al., 2008; Vittengl et al., 2007). Friedman et al. (2004) analysed 
categorical outcomes but presented overall comparisons in terms of Cohen’s d. Significant 
statistical heterogeneity between the results of individual studies contributing to meta-
analysis was found in one of six reviews (Parker et al., 2008).    
 
Psychotherapy vs. Controls  
Two reviews reported significantly better outcomes for psychotherapy in comparison to 
control conditions (Casacalenda et al., 2002; Vittengl et al., 2007). Casacalenda et al. (2002) 
reported that remission for acute psychotherapy was significantly higher than for control 
conditions in both ITT (47.9% vs. 27.7%) and completer analyses (59.5% vs. 24.6%). 
However, the superiority of psychotherapy to controls in their completer analysis was only 
identified following the removal of Herceg-Baron et al. (1979) where patient attrition was 
considered excessive (Casacalenda et al., 2002). Controls in Casacalenda et al. comparisons 
consisted of pill placebo (3 studies), treatment as usual (TAU, 2 studies) or ‘supportive 
therapy’. The latter was intended as a non-treatment comparison condition for 
psychotherapy where patients could request one therapy session per month in addition to a 
scheduled monthly assessment (Herceg-Baron et al., 1979). Casacalenda et al. (2002) 
reported that approximately 45% of patients in the two TAU conditions received ADM.  
Vittengl et al. (2007) reported that the relapse/recurrence rate was significantly lower at the 
end of C-CT than that seen for non-treatment controls (12% vs. 38% respectively).   
 
Psychotherapy vs. Psychotherapy 
A single review (Leichsenring, 2001) reported no significant difference between the 
efficacies of acute STPP and CBT in terms of remission or improvement (Table 10).   
 
Psychotherapy vs. Medication 
Three reviews reported no evidence for the superiority of psychotherapy or ADM in terms of 
remission or symptom reduction (Casacalenda et al., 2002; de Maat et al., 2006; Parker et 
al., 2008). Parker et al. (2008) attributed the single significant result that favoured CBT over 
ADM in Table 10 to bias arising from significantly higher attrition rates in ADM patients. 
However, Parker et al. (2008) identified significant statistical heterogeneity between the 
results of individual studies for all four of their meta-analytic comparisons. Table 10 reveals 
 52 
 
that pooled quantitative estimates of psychotherapeutic efficacy showed considerable 
variation between reviews. For example, the estimated ITT psychotherapy remission rates 
for Casacalenda et al. (2002) and de Maat et al. (2006) were 47.9% and 37.9% respectively, 
whilst the ITT relative risk of remission in Parker et al. (2008) and de Maat et al. (2006) 
were 1.795 and 0.91 respectively.  
 
Psychotherapy vs. Combined therapy 
Two reviews reported an advantage for combined therapy over psychotherapy with no 
evidence of heterogeneity between included studies (de Maat et al., 2007; Friedman et al., 
2004).  However, only de Maat et al. (2007) reported the significance of their results which 
showed significantly higher pooled ITT remission rates for combined therapy (46%) 
compared to psychotherapy alone (34%). However, de Maat et al. (2007) performed 
sensitivity analyses which revealed that combined therapy was superior to psychotherapy 
only for chronically depressed patients who were moderately depressed at pre-treatment. 
This will be further described in the discussion. 
 
Follow-up results 
Follow-up results are presented in Table 11. Two reviews presented categorical results (de 
Maat et al., 2006; Vittengl et al., 2007), and two presented results in terms of symptomatic 
reduction (Friedman et al., 2004; Leichsenring, 2001).  Only the comparison of C-CT with 
non-active controls (Vittengl et al., 2007b), reported on additional treatment during the 
follow-up phase. No review identified statistically significant heterogeneity between the 
results of their included studies.   
 
Psychotherapy vs. Controls  
A single review (Vittengl et al, 2007b) reported that relapse rates were significantly lower in 
C-CT patients than in no-treatment controls  during follow-up (40% versus 73% respectively 
over a mean of 153 weeks).   
 
Psychotherapy vs. Psychotherapy 
Two reviews failed to identify the superiority of CT over STPP (Leichsenring, 2001) or 
other depression specific psychotherapies (Vittengl et al., 2007c) at follow-up.  Relapse rates 
during follow-up (mean =  92 weeks) were 25% and 29% for CT and other depression 
specific psychotherapies respectively (Vittengl et al., 2007c). 
 
Psychotherapy vs. ADM 
Two reviews reported that psychotherapy was superior to ADM in the prevention of relapse 
during follow-up ranging between 52 to 104 weeks (de Maat et al., 2006; Vittengl et al., 
2007d).  Table 11 shows that the relapse rate for psychotherapy patients of 27% in de Maat 
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et al. (2006) was numerically lower than the 39% seen for Vittengl et al. (2007d).  However, 
relapse for ADM patients in both studies was similar at approximately 60%.    
 
Psychotherapy vs. Combined therapy 
One review (Vittengl et al., 2007e) reported no difference in relapse between CT and 
combined therapy during a mean follow-up period of 61 weeks (33% and 39% respectively). 
Friedman et al. (2004) reported a Cohen’s d of 0.12 that favoured combined therapy but 
failed to indicate its significance level.  
 
Summary  
Where reviews made the same treatment comparisons they reached the same conclusions. 
The reviews indicated that psychotherapy is more efficacious than no treatment, but that 
psychotherapies do not differ at post-treatment and follow-up.  Comparisons between 
psychotherapy and ADM indicated equivalent efficacy at post-treatment, but that 
psychotherapy is more effective by follow-up.  The combination of psychotherapy and ADM 
appears to be more efficacious at post-treatment but not at follow-up. 
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Table 10.  Post-treatment Comparisons with Psychotherapy 
 
Comparison Review Outcome  Sample NS Results  C.I (95%) 
Controls  Casacalenda (2002) Remission ITT 6 Psychotherapy 
Controls 
47.9% 
27.7%** 
37.8 – 57.9 
15.7 – 39.7 
  Remission CompleterΩ 2 Psychotherapy 
Controls  
59.5% 
24.6%** 
n/a 
 Vittengl (2007a) Relapse/ 
Recurrence 
over a mean of 
41 weeks 
Unclear 4 C-CT 
Controls  
AUC 
12% 
38% 
0.61* 
n/a  
n/a 
0.53 – 0.68 
        
STPP vs CBT Leichsenring (2001) Remission or  
Improvement 
Unclear 5 Cramer’s Φ   0.08 n/a  
        
ADM Casacalenda (2002) Remission ITT 6 ADM  
Psychotherapy  
46.2%   
47.9%   
37.6 – 54.8 
37.8 – 57.9 
  Remission CompleterΩ 2 ADM  
Psychotherapy  
61.8% 
59.5% 
n/a 
 De Maat (2006) Remission  ITT 10 ADM  
Psychotherapy  
Relative Risk  
34.8%  
37.9%   
0.91     
n/a 
n/a 
0.79 – 1.06 
 Parker (2008) Response ITT 
Completer  
5 
7 
Relative Risk  1.795†*∂ 
1.11† 
n/a 
  Symptom  
reduction 
ITT 
Completer 
5 
5 
Cohen’s d 
for BDI 
-0.353† 
-0.173†   
-0.81 – 0.10 
-0.64 – 0.29 
        
Combined  
Therapy 
De Maat (2007) Remission ITT 7 Psychotherapy  
Combined 
therapy  
Relative Risk 
34% *** 
46% 
1.32 Δ 
 
 
1.12 – 1.56 
 Friedman (2004) Symptom 
reduction 
Completer 2 Cohen’s d  
for BDI 
+0.1¶Δ n/a 
  
Recovery Completer 
ITT 
3 
2 
Cohen’s d  
for HRSD 
+0.69Δ¶ 
+0.24Δ¶ 
n/a 
 
Key: ADM = antidepressant medication; AUC = Area under the curve; BDI = Beck depression inventory;  CBT = 
cognitive behavioural therapy;  Completer = completer analysis;  C-CT = continuation phase cognitive therapy;  C.I. = 95% 
confidence interval;  HRSD = Hamilton rating scale for depression;  ITT = intention to treat analysis;  n/a = not available;  
NS = number of studies used in analysis;  STPP = short term psychodynamic psychotherapy.  Ω = Following removal of 
Herceg-Baron et al (1979).   
 
Δ = favoured combined therapy 
¶ = unknown significance level 
∂ = favoured CBT  
† = significant heterogeneity between included studies 
 
* = p < 0.05; ** = p < 0.01; *** = p < 0.001 
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Table 11.  Follow-up Comparisons with Psychotherapy 
 
Comparison   Review Outcome  NS Follow-up 
(weeks) 
 Results   C.I (95%) 
Controls Vittengl (2007b) Relapse/recurrence 
over a mean of 153 
weeks 
5 69 – 312 
 
 
C-CT   
Controls  
AUC 
40%  
73% 
0.64* 
n/a 
 
0.57 – 0.72 
        
STPP vs CBT Leichsenring (2001) Remission or 
improvement 
4 26 - 104 Cramer’s Φ   0.12 n/a 
 Vittengl (2007c) Relapse/recurrence 
over a mean of 92 
weeks 
4 52 – 104 
 
 
CT  
Other PT 
AUC 
25%  
29% 
0.50 
n/a 
n/a 
0.42 – 0.58 
        
ADM De Maat (2006) Relapse 6 52 - 104 ADM 
Psychotherapy 
Relative Risk 
57%  
27%  
0.46*** 
n/a 
n/a 
0.33 – 0.65 
 Vittengl (2007d) Relapse/recurrence 
over a mean of 68 
weeks 
7 52 - 104 ADM  
CT 
AUC 
61%  
39% 
0.61* 
n/a 
n/a 
0.53 – 0.67 
        
Combined  
Therapy 
Friedman (2004) Symptom  
reduction 
3 26 - 104 Cohen’s d  - 0.12¶Δ n/a 
 Vittengl (2007e) Relapse/recurrence 
over a mean of 61 
weeks 
3 52 - 104 CT   
CT plus ADM 
AUC 
33%  
39% 
0.51 
n/a 
n/a 
0.42 – 0.61 
Key: ADM = antidepressant medication; CT = cognitive therapy; CBT = cognitive behavioural therapy;  C-CT 
= continuation phase cognitive therapy;  C.I. = 95% confidence interval;  NS = number of studies used in analysis;  Other PT 
= other depression specific psychotherapies.  
 
Δ = favours combined therapy  
¶ = unknown significance level 
 
* = p < 0.05; ** = p < 0.01; *** = p < 0.001  
 
For Vittengl et al. (2007):  b = C-CT vs non active controls 
 c = A-CT vs other depression specific psychotherapies  
 d = A-CT vs ADM  
 e = A-CT vs combined therapy 
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Table 12. Within Review Risk of Bias Data 
 
Review
α
 Search Period 
Databases 
Searched  
Reviewers Assessed 
Validity of Studies? 
Sample  
Analysed 
Casacalenda (2002) until 2000 Medline  
PsychINFO 
yes ITT 
Completer 
de Maat (2006) 1980 to 2005 Medline  
EMBASE  
CCTR  
CDRP  
PsychINFO 
yes ITT 
de Maat (2007) 1980 to 2005 Medline 
EMBASE  
CCTR  
CDRP  
PsychINFO 
yes ITT 
Friedman (2004) 1967 to 2002 Medline  
PsychINFO 
no ITT 
Completer 
Leichsenring (2001) 1966 to 1998 Medline  
Psychlit 
yes Unclear 
Parker (2008) 1977 to 1996 β Medline β  
EMBASE  
no ITT 
Completer 
Vittengl (2007) until 2006 Medline  
PsychINFO 
no Unclear 
Key:  CCTR = Cochrane Controlled Trials Register; CDRP = Cochrane Database of Reviews and 
Protocols. 
 
α = first author only  
β: studies originally identified in Gloaguen et al. (1998) 
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4.3.4 Assessments of Review Bias  
 
Within Review Risk of Bias 
The risk that meta-analyses provide unreliable results has been reduced by the introduction 
of systematic methods to identify and assess eligible studies as valid for inclusion.  
Important factors affecting the validity of eligible studies include inadequate randomisation 
methods, and between-group differences in patient attrition or treatment integrity 
(Perepletchikova and Kazdin, 2005).  Where results are combined from studies that differ 
widely for these factors, it is likely that the results of meta-analysis will biased (CRD, 2009).  
It is therefore essential that studies of poorer quality are identified in order that they be 
excluded or investigated concerning their potential influence on meta-analytic results via 
sensitivity analysis (CRD, 2009). An evaluation of substantive and quality data revealed that 
reviews differed on factors known to increase the risk of providing biased results. 
 
No review was identified as a systematic review by its authors and there was considerable 
variation in the reporting of methodological details.  Our quality of review instrument 
showed that only two reviews provided adequate detail concerning their method of data 
extraction (de Maat et al., 2006, 2007).  However, all reviews clearly described their 
eligibility criteria, included appropriate studies and based outcome comparisons on widely 
used symptom rating scales or  a diagnosis of depression. There was no evidence that the 
pooling of included studies in meta-analysis in any review was inappropriate according to 
our quality appraisal instrument. However, it was found that Casacalenda et al. (2002) did 
not adhere to recommended methods for pooling individual study effect sizes.  Only 
Leichsenring (2001) and Friedman et al. (2004) failed to provide confidence intervals for 
their main results, with the latter providing no indication of their statistical significance. All 
reviews addressed relevant issues concerning the generalisability of their results. Additional 
within review risk of bias data is presented in Table 12. 
 
Search  
Six reviews searched electronic databases as their primary source (Table 12). The seventh 
(Parker et al., 2008) was a replication of a previous meta-analysis with only the studies 
identified in the previous work assessed for eligibility (Gloaguen et al., 1998).  De Maat et 
al. (2006, 2007) specified a priori that included studies must be published after 1980, the 
year the DSM III was published.  Friedman et al., (2004) and Leichsenring (2001) gave no 
reason for their earliest search date. Table 12 shows that two reviews had no earliest date 
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limitation for the publication of included studies (Casacalenda et al., 2002; Vittengl et al., 
2007).  Two reviews required that studies be published in English (Casacalenda et al., 2002; 
Friedman et al., 2004).  Four reviews (de Maat et al., 2006; de Maat et al., 2007; Parker et 
al., 2008; Vittengl et al., 2007) included one study not published in English (Hautzinger et 
al., 1996).  No review included unpublished studies nor tested for publication bias.  Whilst 
no review performed a search that corresponded to the methods recommended for a full 
systematic review, the detail of reporting and comprehensive search undertaken by de Maat 
et al. (2006, 2007) suggested that their results were the least likely to be affected by search 
bias. 
 
Eligibility criteria 
All reviews required that included studies were RCTs comparing outcomes for adults 
diagnosed with depression according to a classificatory diagnostic scheme.  Only de Maat et 
al. (2006, 2007) required that independent reviewers agree for study inclusion.  All reviews 
reported additional eligibility criteria which are presented along with their rationale in Table 
13. 
 
Reviews’ assessments of study validity  
Four reviews reported assessments of the validity for their included studies (Table 12). 
However, assessment according to published standards was used in only three (Casacalenda 
et al., 2002; de Maat et al., 2006; de Maat et al., 2007).  De Maat et al. (2006, 2007) required 
that eligible studies meet published quality criteria in terms of randomisation, reporting of 
attrition and the use of blinded outcome assessments.  Also, patients in all included studies 
were required to receive equivalent amounts of treatment contact to minimise performance 
bias (de Maat et al., 2006; 2007).  Only de Maat et al. (2006, 2007) required that eligible 
studies use methods to ensure that medication was administered at a therapeutic dose.  
However, despite providing the clearest descriptions concerning study validity, de Maat et 
al. (2006, 2007) did not report that the validity of studies was assessed beyond this 
requirement. Casacalenda et al. (2002) reported that a post hoc assessment showed that all 
their studies had used blinded assessments, however, they reported that 50% of studies had 
failed to provide an adequate description of the randomisation process.   
 
None of the remaining reviews reported assessments of study quality according to published 
standards.  However, Table 6 shows that six of eight studies in Parker et al. (2008) and  three 
of four in Friedman et al. (2004) were included in Maat et al.’s (2006, 2007) post-treatment 
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comparisons and thus met published standards. Similarly, Table 7 reveals that all follow-up 
studies in Friedman et al. (2004) and Vittengl et al. (2007e) met de Maat et al.’s validity 
criteria, as did the majority of those included in Vittengl et al. (2007d). 
 
 
Table 13.  Additional Eligibility Criteria for Studies Included in Reviews 
 
Review Eligible studies required to:  Rationale: 
Casacalenda et al. (2002) Compare treatment with controls.  
 
 
 
 
Provide remission rates by treatment.  
To answer criticisms that previous meta-
analyses included studies with no 
empirical evidence of treatment efficacy 
(Klein, 2000). 
 
To provide clinically relevant results.  
   
de Maat et al. (2006, 2007) Meet methodological quality criteria 
of the Cochrane Collaboration. 
Include only psychiatric outpatients. 
Ensure adequate medication. 
Use formal psychotherapies lasting 
less than 6 months. 
 
Provide remission rates by treatment. 
To reduce the methodological and 
clinical heterogeneity of studies included 
in previous meta-analyses. 
 
 
 
 
To provide clinically relevant results.  
   
Friedman et al.  (2004) Use same psychotherapy in both 
treatment conditions. 
None given. 
   
Leichsenring (2001) Include 20 or more patients in 
treatments.  
 
Provide 13 or more sessions of 
psychotherapy. 
Increased statistical power. 
 
 
To ensure adequate psychotherapy 
provided. 
   
Parker et al. (2008) Compare CBT as stand-alone 
treatment with ADM.  
 
 
 
Report outcomes for the BDI alone. 
To perform a re-analysis of Gloaguen et. 
al.’s (1998) meta-analysis by excluding 
potentially confounding studies where 
some CBT patients received ADM. 
 
BDI used by Gloaguen et al. (1998).  
   
Vittengl et al. (2007) Provide follow-up data for CBT 
versus other treatments. 
Provide relapse/recurrence rates for 
responders to acute treatment. 
To provide clinically useful follow-up  
data for both acute and continuation 
phase CBT. 
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Synthesis methods 
Estimates of treatment efficacy can be based on those patients who complete a predefined 
adequate course of treatment (completer analysis) or on all patients who commence 
treatment (intention to treat analysis, ITT).  Meta-analysis of individual study ITT data 
provides protection against the possible emergence of non-randomisation bias due to 
differential attrition between treatments groups (CRD, 2009). Table 12 shows that three 
reviews presented post-treatment comparisons based on both completer and ITT data, and 
two for ITT data alone.  It was unclear which types of sample were used by Leichsenring 
(2001) and Vittengl et al. (2007) as well as for all follow-up comparisons. This made it 
impossible to assess the potential impact of patient attrition on these comparisons.   
 
The reviews used differing methods to synthesise study data.  Four used a fixed effects 
model (Casacalenda et al., 2002; de Maat et al., 2006, 2007; Friedman et al., 2004), whilst 
Parker et al. (2008) and Vittengl et al. (2007) used a random effects model.  It was unclear 
which model was used by Leichsenring (2001). Casacalenda et al. (2002) was the only 
review that pooled study effect sizes without first weighting them to account for differences 
in study size. This raised the possibility that their results were biased by large observed 
treatment differences which are more likely in smaller studies (CRD, 2009). All reviews 
except Casacalenda et al. (2002) tested for significant heterogeneity between individual 
study effect sizes.  Appendix D presents further details of the synthesis methods used in 
reviews. 
 
Summary 
De Maat et al. (2006, 2007) adhered to systematic methods and presented the lowest overall 
risk of bias according to our review appraisal instrument.  The lack of information provided 
by the five remaining reviews, and differences in their methods, made it difficult to 
determine their relative risk of providing biased results.  For example, the risk of bias in 
Casacalenda et al. (2002) was reduced by their post hoc appraisal of study validity and the 
inclusion of only blinded assessments. Whilst this was a methodological strength, as 
unblinded assessments are at greater risk of bias than blinded (Jadad et al., 1996; Lynch et 
al., 2010), the risk of bias was increased by the possibility of poor randomisation in 50% of 
studies and their unconventional method of synthesis.  In contrast, Parker et al. (2008) used 
conventional synthesis methods but did not report assessments of study validity, nor sought 
to identify all eligible studies. However, the majority of studies in post-treatment 
comparisons of psychotherapy with ADM in Parker et al. (2008) were valid according to 
criteria used by de Maat et al. (2006).  It was found that follow-up comparisons were at 
greater risk of bias than those for post-treatment due to a lack of information concerning the 
type of samples used for synthesis.  The corresponding lack of information provided by 
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Leichsenring (2001) and Vittengl et al. (2007) for post-treatment outcomes, and Friedman et 
al.’s (2004) failure to report the significance of their findings suggests that these reviews 
provided the highest risk of bias.   
 
 
Across Review Risk of Bias 
It was described earlier that no review searched for unpublished studies nor tested for 
publication bias. In addition, an examination of substantive and quality data indicated that all 
reviews were at a risk of bias due to further common methodological limitations. Individual 
reviews pooled studies that showed considerable variability concerning pre-treatment 
severity, duration of psychotherapy and definition of remission. Of equal importance was the 
finding that the integrity of psychological treatments in all studies in every review could not 
be assured.   
 
Treatment integrity  
In order that valid conclusions be made concerning treatment efficacy, it is essential that 
treatment is provided as intended (Perepletchikova, 2009).  Where the integrity of treatment 
is in doubt, it is not possible to be confident that observed treatment differences are due to 
differences in the treatments themselves. Confidence in the integrity of psychotherapy is 
increased where it can be shown that therapists (i) adhere only to the principles specific to 
the psychotherapy under investigation and, (ii) are competent in the use of these principles 
(Perepletchikova et al., 2007; Westen et al., 2004).  Whilst treatment manuals specify which 
techniques may and may not be used, failure to monitor therapist performance during 
psychotherapy risks that proscribed techniques are used, or that prescribed techniques are 
provided improperly.  The issue of treatment integrity was raised by some review authors 
which led to further scrutiny here. 
 
Concern was expressed by Friedman et al. (2004) and Vittengl et al. (2007) that the integrity 
of psychotherapy was likely to have been inconsistent between the included studies in their 
reviews. In addition, de Maat et al. (2006, 2007) reported that included studies had ensured 
the integrity of ADM treatments but did not report the same for psychological treatments.  
An examination of the original manuscripts of studies included by de Maat et al. (2006, 
2007) revealed that some provided no, or little information concerning the methods used to 
ensure the integrity of psychological treatments.  For example, Murphy et al. (1995) reported 
that psychotherapists were required to demonstrate competence in the provision of CBT 
prior to the study, whereas, Blackburn et al. (1997) described only that therapists were 
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extensively trained.  In contrast, de Rubeis et al. (2005) reported therapists’ experience, that 
the least experienced had received training judged to establish their competence in CBT, and 
that all had followed standard procedures for the provision of CBT.  However, none reported 
that the integrity of psychotherapy was assessed during treatment.  Thus, the risk remained 
across all reviews that their results were biased by the inclusion of studies that had failed to 
ensure the integrity of psychological treatments.   
 
Treatment duration  
In general, reviews pooled results from studies that varied considerably in terms of treatment 
duration, and the number and frequency of psychotherapy sessions (see Table 4). The 
pooling of results for psychotherapies across a range of treatment durations is problematic. 
For example, psychotherapy provided for 16 weeks may produce much higher remission 
rates than if provided for 8 weeks. If so, any pooled estimate of treatment effect based on 
both these durations is not representative of either. This may appear unimportant in 
comparisons of relative efficacy because individual studies compare treatments over the 
same time interval. However, the inclusion of shorter studies that compare psychotherapy 
with ADM in analyses could bias results in favour of the latter treatment, as medication is 
known to produce more rapid symptomatic reduction during early treatment (Watkins et al., 
1993; Elkin et al., 1989). The potentially more rapid onset of ADM efficacy may favour its 
provision over psychotherapy in the shorter term. However, the results of this review suggest 
that acute psychotherapy provides better protection against relapse than acute ADM during 
follow-up. 
 
It was implicit in the examples above that the frequency of psychotherapy sessions was the 
same across different treatment durations. However, the frequency of psychotherapy 
sessions was also highly variable between included studies in individual reviews. For 
example, the study by Hautzinger et al. (1996) provided 3 sessions of CBT per week for 8 
weeks and was included in three reviews (de Maat et al., 2006; de Maat et al., 2007; 
Leichsenring, 2001). This contrasts with Blackburn et al. (1981) where 23 sessions of CBT 
were provided over 20 weeks and was included in three reviews (de Maat et al., 2006; de 
Maat et al., 2007; Parker et al., 2008). The difference in duration of 12 weeks between these 
studies is considerable despite patients receiving over 20 sessions in both. This result shows 
that the intensity of treatment could vary for specific therapy types. If it is the case that the 
intensity of psychotherapy sessions is a determinant of treatment efficacy, then the inclusion 
of studies that vary on this factor may confound the results of meta-analysis.  
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Pre-treatment severity  
In addition to a diagnosis of MDD, the vast majority of included studies required that 
patients meet a minimum criterion score on a symptom severity measure prior to study entry.  
The range of minimum severity scores in review studies was presented in Table 4 and Table 
5. There was considerable variation in the minimum criterion for study entry in all but one 
review comparison (Vittengl et al., 2007c).  For example, Table 4 shows that the minimum 
criterion score for the HRSD ranged from 10 to 20 for the studies in Parker et al. (2008).  
According to the American Psychiatric Association, an HRSD score of 10 is classified as 
mild, whereas, a score of 20 is classified as severe depression (Kriston and von Wolff, 
2011). This indicates that the mean pre-treatment severity of patients varied considerably 
across included studies in the majority of reviews.  
 
This is a matter for concern as decreasing pre-treatment severity is associated with increased 
response to placebo (Schatzberg and Kraemer, 2000; Fournier et al., 2010). Moreover, in the 
absence of untreated control data, it is not possible to estimate the proportion of patients 
whose symptomatic change may actually be attributed to treatment in individual studies 
(Klein, 1996). Consequently, where reviews made direct treatment comparisons, lower 
severity studies would be more likely than higher severity studies to produce results that 
were confounded with placebo response. Thus, there was a risk in reviews that compared the 
relative efficacy of treatments, that a large proportion of patients in low severity studies did 
not remit as a direct result of treatment. If so, this would serve to overestimate the efficacy 
of treatments and likely obscure any treatment differences that may exist in more severely 
depressed samples. 
 
Definitions of treatment outcome  
An inspection of Table 8 reveals that the definitions of remission employed across included 
studies in reviews showed considerable variation. Similarly, Table 9 shows that definitions 
of relapse were also highly variable across studies. The use of differing outcome definitions 
between included studies in reviews is a severe limitation which will be described 
concerning post-treatment outcomes. The same issues affect analyses of follow-up data. 
Table 8 shows that the majority of included studies defined remission in terms of a minimum 
criterion score on the BDI or HRSD (or both). For both measures, lower scores represent a 
more stringent definition of remission than do higher scores. For example, Zimmerman et al. 
(2004b) reported that 6.8% of patients scoring 10 or less on the 17-item HRSD still met 
DSM IV diagnostic criteria for MDD compared to 3.4% for a criterion of 7 or less, and none 
for 3 or less.  However, Table 8 reveals that included studies in individual reviews 
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frequently used different criterion scores to define remission on the HRSD. For example, the 
HRSD criterion for studies included in de Maat et al. (2006) ranged from 6 points or less to 
9 points or less. Thus, studies using less stringent definitions will have contributed higher 
remission rates to de Maat et al.’s overall analysis than those using more stringent 
definitions. Table 8 shows similar results for the BDI, where the minimum BDI criterion 
ranged from 7 to 10 points across studies included in reviews.  
 
The absence of  a consistent definition of what constitutes a clinically significant outcome 
for each of these measures is problematic for several reasons.  Firstly, as definitions become 
less stringent, it becomes less likely that patients have actually remitted from depression. 
Consequently, where studies use a range of idiosyncratic outcome definitions, it is unclear to 
what degree the overall clinical significance rates provided by meta-analysis actually 
represent remission. Furthermore, where categorical outcomes are used in meta-analysis, it 
cannot be assumed that the relative efficacy of depression treatments will be invariant as the 
stringency of definitions change. Thus, it is possible that the results of individual meta-
analyses will be biased by larger studies where the stringency of the criterion score used to 
define remission inadvertently favour a specific treatment type. Finally, it is unclear to what 
degree pooling the results of studies that have used different measures (e.g. the BDI, HRSD, 
or both) risks that the results of meta-analyses are biased (Nugent, 2009). However, they will 
certainly be less precise than results based on studies that employ a standard definition of 
remission on the same outcome measure (Matt and Navarro, 1997). 
 
 
4.4 Discussion 
This systematic review identified seven meta-analytic reviews which summarised the results 
of psychological treatment efficacy studies for major depressive disorder. The eligibility 
criteria ensured  the inclusion of only randomised controlled trials that examined treatment 
effects in samples meeting a formal diagnosis of major depression. The requirement that 
psychological treatments were based on theoretical models of psychopathology meant that 
potentially non bona fide treatments were excluded. Whilst none of the reviews were 
described as systematic reviews, they provided the best meta-analytic evidence concerning 
the current efficacy of individually provided psychological treatments for depression. 
However, reviews varied with respect to the risk of producing biased results. Examination of 
substantive and quality data indicated several methodological factors that risked introducing 
bias into all reviews.  Nevertheless, where reviews made the same treatment comparisons 
they reached the same overall conclusions. The overall conclusions that may be drawn 
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across the results of included reviews will be discussed whilst bearing in mind individual 
review risk of bias. Following this, factors which may have biased all reviews are discussed, 
with a final discussion concerning the limited utility of heterogeneity tests to reveal such 
sources of bias. 
 
4.4.1 Conclusions Based on the Meta-analytic Results of Reviews 
The varying degree by which reviews adhered to the systematic review methodology made it 
difficult to assess to what degree they risked providing biased results. The results indicated 
that, irrespective of the quality of individual reviews, follow-up comparisons were at greater 
risk of bias than post-treatment comparisons due to uncertainties concerning the nature of 
the samples used in analyses. It was unclear whether follow-up analyses were based on all 
patients who entered treatment, all those who completed treatment, or only those who 
remained in contact with investigators during follow-up. Moreover, in all but one analysis 
(Vittengl et al., 2007b), it was unclear whether patients received treatment for depression 
during follow-up. 
 
Comparing psychotherapy types & establishment of psychotherapeutic efficacy 
Two reviews concluded that psychotherapy was superior to controls at post-treatment 
Casacalenda et al., 2002; Vittengl et al., 2007a) and one at follow-up (Vittengl et al., 2007b). 
Two reviews that compared the relative efficacy of specific psychotherapies failed to find 
any difference between therapy types at post-treatment (Leichsenring, 2001) and follow-up 
(Leichsenring, 2001; Vittengl et al., 2007c). The results of these reviews suggest that, 
overall, bona-fide psychotherapies were superior to controls and were equally effective in 
the treatment of depression. However, only Casacalenda et al. (2002) clearly reported the 
type of samples used in analyses which meant that the comparisons made by Leichsenring 
(2001) and Vittengl et al. (2007) were at greater risk of bias. Nevertheless, the comparison 
of C-CT with untreated controls by Vittengl et al. (2007b) was at lowest risk of bias for all 
follow-up comparisons across reviews, as it was the only one where patients were 
guaranteed to receive no treatment. 
 
The overall ITT analysis by Casacalenda et al. (2002) showed that post-treatment remission 
was 47.9% , 46.2% and 27.7%  in psychotherapy, ADM and control samples respectively. 
This suggests that remission in approximately 50% of those receiving an active treatment 
may have been due to placebo effects. However, it was not possible to quantify this 
proportion, as Casacalenda et al.’s inclusion of treatment as usual samples in their analysis 
meant that approximately 23% of their control sample received antidepressant medication. 
Nevertheless, the proportion remitting due to placebo effects was likely to have been close to 
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Casacalenda et al.’s control sample rate of 27.7%, as Posternak & Miller (2001) have 
indicated that up to 20% of patients included in depression treatment studies may remit in 
the absence of treatment.  The evidence also suggests that continuation phase psychotherapy 
provides significant protection against future depressive episodes compared to acute phase 
psychotherapy alone. Vittengl et al. (2007) found that both post-treatment (12% vs 38%)  
and follow-up (40% vs 73%) relapse rates were significantly lower in C-CT samples than in 
samples who received only acute phase psychotherapy. Thus, the most reliable evidence 
showed that that 73% of patients receiving  acute phase psychotherapy relapsed over a 
follow-up period of 153 weeks or approximately 3 years (Vittengl et al., 2007b). 
 
Comparison of psychotherapy with medication 
The overall results of three reviews (Casacalenda et al., 2002; de Maat et al., 2006; Parker et 
al., 2008) provided strong evidence that the efficacies of psychotherapy and medication were 
no different at post-treatment. That neither broad treatment class was superior following the 
acute treatment of major depression was supported by one of the highest quality reviews 
according to our appraisal instrument (de Maat et al., 2006). Moreover, whilst Casacalenda 
et al. (2002) and Parker et al. (2008) demonstrated a greater risk of bias, they reached the 
same conclusion in analyses that included different studies to those of de Maat et al. (2006). 
Parker et al. (2008) and Casacalenda et al. (2002) shared one third and two thirds of included 
studies in common with de Maat et al. (2006) respectively. However, the overall remission 
rate for psychotherapy of 47.9% reported by Casacalenda et al. (2002) was markedly higher 
than the potentially more reliable 37.9% reported by de Maat et al. (2006). Whilst the 
difference will in part have originated in the inclusion of different studies, it is possible that 
Casacalenda et al.’s (2002) higher rate also resulted from their failure to use weighting in 
analyses. Thus, the best available evidence from de Maat et al. (2006) suggests that less than 
40% of patients who started psychotherapy for major depression remitted by the end of 
treatment.  
 
In terms of follow-up, the results of the high quality review by de Maat et al., (2006) were 
similar to those of Vittengl et al. (2007).  Both reviews reported that approximately twice as 
many ADM as psychotherapy patients relapsed over a 1 to 2 year period following 
treatment. De Maat et al. (2006) reported an overall relapse rate of 27% and 57% for 
psychotherapy and ADM respectively, whilst the corresponding figures for Vittengl et al. 
(2007d) were 39% and 61%. Thus, evidence from two reviews indicated that where 
psychotherapy successfully lead to remission, it provided longer lasting benefit than 
discontinued medication. However, the conclusions reached by de Maat et al. (2006) and 
Vittengl et al. (2007) were not wholly independent as the majority of included studies in 
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both reviews were the same (Table 7). This, and uncertainty concerning the nature of the 
samples used in follow-up comparisons suggests that the conclusions reached in these 
reviews were at risk of bias.   
 
Comparison of psychotherapy alone & combined with medication 
Two reviews published the statistical significance levels for their comparisons of  
psychotherapy with combined therapy (de Maat et al., 2007; Vittengl et al., 2007). The high 
quality review by de Maat et al. (2007) concluded that combined therapy was superior to 
psychotherapy at post-treatment. This conclusion was based on an ITT analysis where 
overall remission for combined therapy was 12% greater than for psychotherapy alone (46% 
versus 34% respectively). In contrast, over a 1 to 2 year follow-up period, Vittengl et al. 
(2007) found no significant difference in relapse rates between CT plus medication and CT 
alone (39% versus 33% respectively). However, uncertainty concerning the type of samples 
employed in analysis and the possibility that patients received treatment during follow-up 
meant that Vittengl et al.’s results were at risk of bias. Consequently, the most reliable 
conclusion concerning  combined therapy and psychotherapy is that combined therapy was 
superior to psychotherapy at post-treatment.   
 
Summary  
The results of reviews that closely adhered to systematic review methods were at least risk 
of leading to biased conclusions. In terms of post-treatment outcome, the evidence strongly 
suggests that there was no difference between the efficacy of psychotherapy and ADM 
(Casacalenda et al., 2002; de Maat et al., 2006; Parker et al., 2008). There was also high 
quality evidence suggesting that combined therapy was superior to psychotherapy  alone (de 
Maat et al., 2007). However, this finding will be discussed further in a subsequent section of 
this discussion, as it did not apply to all patients included in de Maat et al.’s analysis. There 
was also tentative evidence from one review that psychotherapy was superior to controls at 
post–treatment (Casacalenda et al., 2002).  
 
In terms of follow-up, the most reliable evidence indicated that continuation phase 
psychotherapy provided greater protection against relapse compared to acute psychotherapy 
alone (Vittengl et al., 2007b). In addition, evidence from one of the highest quality reviews 
also indicated that psychotherapy was associated with a significantly lower probability of 
relapse compared to medication (de Maat et al., 2006). However, it must be borne in mind 
that uncertainty concerning the nature of samples meant that the follow-up results for all 
reviews were at a greater risk of bias than were post-treatment results. 
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4.4.2 Risk of Bias Across Reviews 
Whilst our review quality appraisal instrument indicated that the results of some reviews 
were at less risk of bias than others, an examination of substantive review data revealed 
several factors that may have biased the results of all reviews. It was shown that no review 
searched for unpublished studies, nor checked for publication bias. Consequently, were 
unpublished studies to have been included, it is possible that the result of individual reviews 
would have been different. However, irrespective of whether unpublished studies were 
included or not, four additional factors were identified which risked that reviews provided 
biased results.  
 
Firstly, the integrity of psychological treatments may have been inconsistent across studies 
included in reviews. An examination of original manuscripts for the studies included in de 
Maat et al. (2006, 2007) revealed that they varied considerably in terms of reporting the 
methods by which treatment integrity was assured. Whilst the detail of reporting for primary 
studies may not have reflected the efforts made to ensure or assess treatment integrity, it is 
likely that the results of some were based on poorly implemented psychological treatments. 
Indeed, Bhar & Beck  (2009) have argued that the majority of studies used in recent 
comparisons of CBT with STPP have not adequately implemented procedures that ensure 
the integrity of either treatment type. Consequently, when the results of meta-analyses that 
include such studies find no difference between CBT and STPP they are at best ambiguous 
(Bhar and Beck, 2009). Moreover, it is possible to speculate that ensuring high levels of 
treatment integrity for medications is typically easier to achieve than for psychological 
treatments in comparison studies. If so, then the inclusion of studies that have poorly 
implemented psychotherapy in meta-analysis may be responsible for the frequent finding 
that psychotherapy and ADM are no different at post-treatment.   
 
It was also found that the overall duration of psychotherapy and number of sessions 
available to patients varied considerably between studies included in reviews. In addition, 
the intensity of psychotherapy typically showed marked variability between included studies 
in reviews. That is, the average number of sessions per week in some included studies was 
much higher than in others. Such variability in the overall duration and timing of treatment 
sessions meant that psychological treatments with potentially different efficacies were 
combined as ‘psychotherapy’.  Evidence that treatment duration is correlated with outcome 
for specific psychotherapy models was provided by Shapiro et al. (1994; Shapiro et al., 
2003). By comparing outcomes for cognitive behavioural or psychodynamic-interpersonal 
therapy provided over 8 or 16 weeks, Shapiro et al. (2003) concluded that longer treatment 
was more beneficial for the majority of depressed patients. Moreover, whilst overall 
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symptomatic reduction on the BDI was no different between 8 and 16 week samples, 
symptomatic reduction at 16 weeks was significantly greater than at 8 weeks in patients 
categorised as severely depressed (BDI > 27).  The variation in treatment duration across 
studies in reviews makes it difficult to interpret their results. For example, whilst Parker et 
al. (2008) compared the post-treatment efficacies of CBT and ADM, CBT was provided 
over a range of 12 to 24 sessions in studies lasting between 8 to 15 weeks. Given that the 
onset of ADM efficacy may be more rapid than that of CBT (Watkins et al., 1993; Elkin et 
al., 1989), to what duration and intensity of CBT did Parker et al.’s finding of no difference 
between treatments best refer?  More importantly, perhaps, is the possibility that the 
inclusion of shorter versions of established psychotherapies in future meta-analyses could 
lead to biased overall conclusions that medication is more effective than psychotherapy 
across all treatment durations. The best evidence from the reviews presented here indicated 
that psychotherapy was as effective as medication at post-treatment and was better at 
preventing relapse at follow-up. The intensity of psychotherapy over typical treatment 
durations and the rapidity of onset of treatment efficacy are areas which warrant further 
research. 
 
A third factor that was highly variable between included studies in reviews was the mean  
pre-treatment symptom severity of patient samples. If it is generally the case that an 
individual’s level of pre-treatment severity significantly predicts treatment outcome, then the 
inclusion of studies that vary widely on this factor makes interpretation of review 
conclusions problematic. Again, to what severity of depression do the results of meta-
analysis apply? In addition, it may be important that patient severity is balanced across 
treatment groups within individual studies. An examination of original manuscripts showed 
that the randomisation process in some of the included studies in de Maat et al. (2006) 
stratified patients by pre-treatment severity to ensure the equivalence of treatment groups on 
this variable (e.g. Blackburn et al., 1981). However, where primary studies did not use 
Blackburn et al.’s approach, group equivalence could not be guaranteed solely on the basis 
of non-significant differences between group means. For example, following an examination 
of original study data, DeRubeis et al. (1999) revealed that significantly more severely 
depressed patients (HRSD ≥ 20) were entered into the ADM arm of Murphy et al. (1984) 
according to the BDI. Consequently, because placebo effects are more marked in less 
severely depressed samples (Schatzberg and Kraemer, 2000; Fournier et al., 2010), there 
was a potential source of bias favouring CBT over ADM in Murphy et al. (1984). Whilst 
such bias ought to be random in nature and thus be cancelled out where meta-analyses 
contain many studies, the highest number of studies in any review was 10. Consequently, 
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without stratified randomised allocation by pre-treatment severity it is possible that 
statistically influential studies will bias the results of meta-analysis.  
 
Finally, individual studies included in reviews used idiosyncratic definitions of remission 
which meant that the stringency by which remission was defined was variable. Thus, some 
studies will have underestimated, whilst others overestimated, the proportion of patients who 
achieved remission. Consequently, it is unclear to what degree the overall rates reported by 
reviews actually represented remission. Moreover, whilst this lack of clarity concerning the 
clinical significance of reported outcomes is itself undesirable, the variation in stringency 
between the included studies in reviews raised the possibility that review conclusions were 
biased.  It is possible that the relative efficacy of treatments were confounded with choice of 
outcome measure and remission criterion employed in some studies. Again, where the 
results of a statistically influential study are biased, it is possible that the overall results of 
meta-analysis will also be biased. Unfortunately, this problem cannot be overcome by using 
continuous data effect sizes to compare treatments, as Churchill et al. (2001) revealed  that 
these correlate poorly with clinically significant outcome.  
 
In order to reduce the risk of bias in meta-analyses seeking to compare treatments in terms 
of remission, it is necessary that included studies employ an empirically-based standard 
definition of clinical significance which best represents remission.  The Jacobson method of 
clinical significance is ideally placed to do this and is described in the next chapter. 
However, a limitation of the Jacobson method is that normative data for outcome measures 
and individual patient data (IPD) from primary studies are required. Consequently, the 
Jacobson method cannot be used for conventional meta-analysis where the results are based 
on summary data from already published studies.  
 
The utility of heterogeneity testing for biased results 
Heterogeneity testing is used in meta-analysis to identify whether the observed variation 
between individual studies’ effect sizes is greater than would be expected due to 
measurement error (CRD, 2009). A significant result may indicate that more than one 
population has been included in meta-analysis, or that the effect sizes
9
 of one or more 
included studies may be biased.  However, heterogeneity tests suffer from low power where 
overall information is sparse, or where greater than 50% of included information derives 
from a single study (Hardy and Thompson, 1998). Given that relatively few studies were 
included in review analyses, it was unlikely that heterogeneity tests would have been able to 
                                                 
9 Based on either continuous or categorical outcomes. 
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identify studies that were biased due to the factors discussed above. Indeed, no evidence of 
significant heterogeneity was found between studies in de Maat et al.’s primary comparison 
of combined therapy with psychotherapy (de Maat et al., 2007). However, they conducted a 
sensitivity analysis
10
 which revealed that combined therapy was superior to psychotherapy 
only in patients with moderately severe and chronic depression (de Maat et al., 2007).  Their 
overall primary comparison was biased by a single study of chronic depression which 
contributed 44% of the data to the analysis (Keller et al., 2000). Were de Maat et al. (2007) 
to have ignored the clinical variability between studies and relied solely on heterogeneity 
testing, their primary conclusion risked being interpreted as applicable to all depressed 
patients included in their review.  
 
In addition, the findings of the present review suggest that the interpretation of significant 
statistical heterogeneity is virtually impossible in conventional meta-analyses of depression 
treatment studies. To illustrate this point, imagine that several studies comparing CBT with 
pill placebo are included in meta-analysis. Furthermore, suppose that heterogeneity testing 
has shown that the effect size favouring CBT in one study (study A) is significantly greater 
than that of remaining studies. This situation could arise for several reasons: (i) CBT in 
study A may have been more efficacious than in other studies due to higher levels of 
treatment integrity (ii) patients in study A were more severely depressed than in remaining 
studies; thus a comparatively low placebo response may have led to CBT appearing more 
efficacious than in remaining studies (iii) CBT in study A was provided more frequently 
than in remaining studies which potentially increased its efficacy over remaining studies, 
(iv) the definition of remission used in study A inadvertently resulted in a significantly 
larger effect size favouring CBT than seen across remaining studies. Taken together, these 
examples show that the interpretation of significant heterogeneity between the outcomes of 
depression treatment studies is virtually impossible within conventional meta-analysis as 
currently practised.    
 
Whilst the conclusions of this review may be limited by including only published reviews in 
English, it is unlikely that there were relevant unpublished reviews. A major limitation is 
that initial assessments of review quality were based on the details provided in review 
manuscripts. Thus, it is possible that space limitations imposed by publishers meant that our 
conclusions do not reflect the quality of research undertaken by reviewers. Finally, we did 
not investigate the affiliations nor sources of funding of review authors as a potential source 
of bias. 
                                                 
10 Not reported in this review 
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4.5 Summary & Concluding Remarks 
The increasing use and influence of meta-analysis as a method to summarise the results of 
psychotherapy trials within a systematic review makes an investigation of the potential 
problems with the approach timely. The best evidence from included reviews suggested that 
38% to 48% of patients who start individual psychotherapy will remit by the end of 
treatment. However, remission in approximately half of these patients may be due to placebo 
effects. There was strong evidence that the efficacies of psychotherapy and ADM do not 
differ at post-treatment and limited evidence that psychotherapy is superior to ADM at 
preventing relapse. Nevertheless, approximately 70% of those who remit following 
psychotherapy will relapse over the next three years.  
 
However, confidence in these conclusions is undermined by several important 
methodological factors that may bias the results of all meta-analyses of depression treatment 
studies. Foremost is the likelihood that the integrity of psychological treatments was sub-
optimal in some of the primary outcome studies. Nevertheless, were it the case that all 
treatments were properly provided, there were studywise variations concerning the timing of 
psychotherapy sessions, the definition of outcome, and the average pre-treatment severity of 
patients that were potential sources of bias. These factors may have reduced the validity of 
reviews’ conclusions because it cannot be guaranteed that meta-analysis can control for 
individual study bias (Matt and Navarro, 1997). 
 
Finally, irrespective of the risk that they led to biased conclusions, the use of idiosyncratic 
outcome definitions of treatment efficacy compromised the conclusions that could be drawn. 
A standardised operational definition of the clinical significance of treatment is needed to 
allow a clearer assessment of the absolute efficacy of psychological treatments for 
depression. Study two will attempt to address this issue and is presented in chapter 6 
following a description and critique of the Jacobson method. 
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Chapter Five 
 
A Review and Critique of the Jacobson Method Approach to 
Clinical Significance 
 
5.1 Introduction 
In study 1, the majority of reviews based their meta-analyses on the remission rates reported 
by individual studies. That categorical remission data was used in many of the meta-analyses 
in study 1 reflects an increasing acceptance that overall treatment comparisons using 
standardised mean differences are difficult to interpret (CRD, 2009). Where empirical 
evidence is required to support the use of one treatment in preference to another, it is 
essential that clinical significance rates are included in meta analyses. This is because 
significant between-treatment differences in the magnitude of change over the course of 
treatment may be of little clinical relevance (Chambless and Hollon, 1998). It is not enough 
to know that treatments differ statistically, it is also important to know whether they differ in 
a clinically meaningful way. The clinical relevance of psychotherapy outcome research has 
been greatly enhanced by supplementing inferential statistics with reports of the clinical 
significance of treatment effects. Clinical significance attempts to capture whether therapy 
has produced meaningful change and has been operationalised in several ways. One method 
that has been widely applied across treatment approaches and psychiatric disorders is the 
empirically derived approach of Jacobson and colleagues (Jacobson et al., 1984; Jacobson 
and Revenstorf, 1988; Jacobson and Truax, 1991). Whilst alternative methods exist for 
determining the clinical significance of individual outcomes in treatment studies, the 
‘Jacobson method’ is increasingly popular (Ogles et al., 2001) and has been recommended 
as the method of choice (Lambert and Ogles, 2009). This chapter reviews the development 
of clinical significance methodology from its origins in applied behaviour analysis through 
to Jacobson’s last conceptualisation. The strengths and weaknesses of the Jacobson method 
are then discussed. 
 
 
5.2 The Development of Clinical Significance  
In the late 1950s, concerns that psychotherapy was ineffective saw an increase in the number 
of treatment studies attempting to show that psychotherapy was superior to no-treatment 
(Kiesler, 1966). However, early studies typically suffered from low internal validity due to 
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factors such as biased sampling, poor specification of treatments and the failure to 
differentiate between psychotherapy models (Bergin, 1966; Garfield, 1981). Nevertheless, in 
1966 Bergin identified 7 studies whose methods were sufficiently sound to draw important 
conclusions concerning psychotherapy research and practice. None of Bergin’s included 
studies demonstrated that treatment was superior to no-treatment in terms of mean 
improvement on outcome measures. However, because treatments typically produced greater 
variability on outcome measures than observed in no treatment, Bergin concluded that the 
degree of both improvement and deterioration was more marked in treated groups. Thus, 
inferential statistics had failed to identify important differences between treatment and no 
treatment groups in the 7 studies, This suggests that inferential statistics alone, provide a 
limited assessment of treatment efficacy (Bergin, 1966), because within group variability is 
disregarded (Garfield, 1981; Barlow, 1981; Hugdahl and Ǒst, 1981). 
 
More recently, concerns have been raised that the lack of influence of clinical research on 
clinical practice may be ascribed to the use of traditional methodologies and a reliance on 
inferential statistics (Barlow, 1981; Westen et al., 2004; Boisvert and Faust, 2006). One 
concern is that, although inferential statistics can reveal the relative values of treatments 
under comparison, no conclusions concerning the absolute value of those treatments may be 
drawn. This is because a statistically reliable result may have little clinical relevance. For 
example, a patient may make statistically significant improvement on measures of 
symptomatic state, yet still be considerably impaired in everyday functioning. Another 
concern that may still limit the influence of research findings in clinical settings is the 
patient uniformity myth (Kiesler, 1966) which assumes that patients with the same diagnosis 
will respond similarly to a particular treatment (Westen et al., 2004). However, whilst two 
individuals may share the same diagnostic category, the difference between their symptoms 
may be far more notable than the similarities. For example, where two treatments are equally 
efficacious according to mean comparisons, it is possible that one treatment produces high 
levels of improvement for a minority of patients whilst the other produces minimal 
improvement in most patients (Hugdahl and Ǒst, 1981). Thus, without knowing the 
proportion of patients who benefit, remain unchanged or deteriorate, it is very difficult for 
clinicians to generalise from the research study to clinical practice.  
 
Early proposals for evaluating the individual effects of treatment originated in the field of 
applied behaviour analysis. Risley suggested that interventions should be evaluated in terms 
of both experimental and therapeutic criteria (Risley, 1970; cited in Kazdin and Kazdin, 
1977). The experimental criterion concerns whether or not the intervention was responsible 
for the behaviour change. For example, in an applied behavioural intervention, the 
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experimental criterion is satisfied when the experimental variable is shown to reliably 
control the emergence of a desired behaviour (Baer et al., 1968). The therapeutic criterion 
concerns whether the behaviour change is meaningful to the client. This can be readily 
applied in situations where the presence or absence of behaviours denotes success. For 
example, where treatment eliminates self-injury in a person with autism, it clearly meets a 
therapeutic criterion of no self-injury. However, should treatment result in only a 50% 
reduction in the number of self-injurious episodes, it does not meet the therapeutic criterion 
when the outcome is defined in all or nothing terms, despite the possibility that a reduction 
in self injurious behaviour may represent a significant improvement in wellbeing. This 
illustrates that when symptoms remain, defining what is a meaningful or clinically 
significant outcome is problematic (Kazdin and Kazdin, 1977). 
 
A potential solution to this problem lay in the concept of social validation (Wolf, 1978). In 
an attempt to operationalise the social benefits of treatment, Wolf (1978) argued that the 
effects of behavioural interventions according to objective measures should be compared 
with their effects as judged by consumers. The impetus to socially validate treatment 
efficacy led to the development of empirical procedures that can determine whether 
clinically significant change has occurred (Kazdin and Kazdin, 1977). According to the 
social validation approach, treatment efficacy can be assessed by comparing the behaviour 
of treated patients with well functioning peers (social comparison), or, by the subjective 
evaluation of individuals in everyday contact with the patient. The development of clinical 
significance methods has largely drawn on the social comparison method because it can 
address problems associated with the therapeutic criterion where symptoms remain. 
However, the validity of the social comparison method is highly dependent upon the 
normative reference group. Kazdin & Kazdin (1977) stressed that normative data needs to be 
obtained from a population which is similar to the patient in all but dysfunctional behaviour. 
"The level of behaviour of the peers who did not warrant or receive treatment can serve as 
the criterion by which the success or clinical importance of treatment is evaluated. If 
treatment has effected marked changes in behaviour, the client's performance should fall 
within the normative level of his peers" (Kazdin and Kazdin, 1977, pp 431-432). This notion 
lies at the heart of Jacobson and colleagues’ (Jacobson et al., 1984; Jacobson et al., 1999; 
Jacobson and Truax, 1991) approach to clinical significance. 
 
An increasing recognition of the need to report psychotherapy research findings in a more 
clinically meaningful way, specifically to increase their relevance to clinical practice, has 
resulted in a variety of operational definitions of clinical significance. However, some 
definitions are somewhat arbitrary, such as that of ‘response’ which is often defined as a 
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50% reduction in pre-treatment score on outcome measures (Hiller et al., 2012). 
Alternatively, where definitions are clinically relevant they are essentially subjective, e.g. 
the recommended criterion score of 7 or less for remission on the Hamilton rating scale for 
depression (Rush et al., 2006). Clearly, a standardised approach is required to overcome the 
methodological and interpretative difficulties associated with idiosyncratic definitions of 
clinical significance. In the 1980s Jacobson, Follette & Revenstorf (1984) argued that (i) the 
use of idiosyncratic definitions of clinical significance by researchers represented a rather 
limited advance in psychotherapy outcome research and (ii) an agreed and valid method of 
determining the clinical significance of treatment effects was required that would permit 
between and across study comparisons that was applicable across a wide range of psychiatric 
disorders. 
 
 
5.3 The Jacobson Approach to Clinical Significance 
The Jacobson approach is based on the premise that definitions of clinically significant 
change should incorporate the concept of a return to normal functioning. "Clients entering 
therapy are viewed as part of a dysfunctional population and those departing from therapy as 
no longer belonging to that population" (Jacobson and Truax, 1991, p 13). Two criteria are 
used to determine whether clinically significant change has taken place: (i) patients receiving 
treatment should move from a theoretical dysfunctional population to a functional 
population on symptom measures, and (ii) the change must be statistically reliable. 
Movement into the functional distribution is determined by establishing a cut-off point 
beyond which it is more likely that the patient’s post-treatment symptom score belongs to 
the functional rather than the dysfunctional population. Reliability is assessed using the 
reliable change index (RCI) appropriate to specific outcome measures. Comparing an 
individual’s pre- to post-treatment change score with the RCI ensures that the observed 
change score is genuine and not due to measurement error. 
 
5.3.1 Operational Definition of Clinical Significance 
Cut-off points  
Jacobson et al. (1984) proposed three methods to determine whether an individual’s level of 
functioning falls within the functional distribution following treatment. Each method relies 
on the creation of cut-off points on the target variable chosen to index the clinical problem. 
The cut-off points are: (a), the patient's level of functioning falls outside the range of 
dysfunctional distribution, defined as two standard deviations beyond the mean in the 
direction of functionality; (b), the patient’s level of functioning falls within the range of the 
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normal population defined as falling within two standard deviations of the mean of the 
functional or normal population or (c), the patient's post-treatment score is more likely to be 
drawn from the functional distribution than the dysfunctional distribution. 
 
Reliable change index 
The Reliable Change Index (RCI) is used to account for the less than 100% reliability of 
psychometric instruments and ensures that the magnitude of change is statistically reliable. If 
the RCI is greater than 1.96, then the change is considered significant at the .05 level and 
reliable. The original method for calculating the RCI was amended by Christensen & 
Mendoza (1986) as the original RCI was based on the standard error of measurement 
surrounding a single true score. However, because the RCI is used to judge the reliability of 
change as quantified by two scores, Christensen & Mendoza (1986) proposed that the 
standard error of difference should be used to calculate the RCI. Accordingly,  Jacobson & 
Revenstorf (1988) adopted this amendment and recommend its use. It is important to note 
that the RCI is not itself a measure of clinical significance - it only denotes that the observed 
degree of symptomatic change is greater than that to be expected by measurement error 
alone.  
 
5.3.2 Guidelines for Choosing Cut-off Points 
Using hypothetical examples, Jacobson & Truax (1991) outlined when each cut-off point is 
appropriate. It is important to bear in mind that each cut-off point will give different 
estimates of clinical significance. For overlapping distributions cut off point a is the most 
stringent, cut-off point b the most lenient and cut-off point c occupies an intermediate 
position. Cut-off point c is strongly recommended if appropriate normative data exits for 
both the functional and dysfunctional distributions. It is the least arbitrary method as it is 
based on the relative probability of a patient's post-treatment score belonging to either the 
functional or dysfunctional distribution. This method provides the most accurate estimate of 
a return to normal functioning as a direct comparison is made with a patient's well 
functioning peers. 
 
If data for a normative sample is not available, cut-off point a is the only alternative. This is 
the most stringent of the cut-off points for overlapping distributions. The major limitation of 
cut-off point a is that it is less valid than cut-off point c as the well functioning population is 
not taken into account. A further point is that the more overlap between the two distributions 
the more stringent a becomes relative to c. Cut-off point b can only be used when normative 
data exists. It provides the most lenient cut off point when the distributions are overlapping 
and it would seem ill advised to use this cut-off point in this situation. However, for non-
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overlapping distributions, b is the most stringent cut-off point. Indeed, Jacobson & Truax 
(1991) argue that in the case of non-overlapping distributions only b ensures that a patient 
has entered the functional distribution. As b is solely determined from normative data, the 
cut-off point will not vary from study to study. 
 
The Jacobson approach can assign patients to one of four outcome categories namely, (i) 
recovered, (ii) improved, (iii) unchanged and (iv) deteriorated. The recovered category refers 
to patients who have demonstrated both a statistically reliable improvement and whose post-
treatment score falls within the functional range. Improved refers to patients who have 
demonstrated a reliable improvement in symptom score but have failed to enter the 
functional range. Unchanged refers to patients whose symptom scores have not reliably 
changed, whilst deteriorated patients have demonstrated a reliable worsening of their 
symptoms. 
 
 
5.4 Critique of the Jacobson Approach  
Clinically significant change in Jacobson's terms involves becoming a member of a 
functional or normal population. However, normative data is often unavailable for measures  
(Lambert and Ogles, 2009) and it is not always clear how a functional or normative sample 
should be defined. Jacobson & Revenstorf (1988) stated that an ideal normative sample 
would not include subjects who were dysfunctional but should include outliers if those 
individuals were not seeking therapy. This definition only partially addresses the complexity 
of defining normative samples, as receiving treatment is imperfectly correlated with being 
dysfunctional. For example, in the National Comorbidity Survey (Kessler et al., 1994), more 
than 60% of individuals meeting a lifetime psychiatric disorder had not received 
professional treatment. This means that the majority of individuals diagnosable with a 
psychiatric disorder would be included as outliers in normative samples according to 
Jacobson & Revenstorf’s (1988) recommendation. However, irrespective of their reasons for 
not seeking treatment, such individuals are dysfunctional according to objective assessment. 
Where normative samples include such individuals, the means of the normal and 
dysfunctional populations will be closer than would be the case if they were excluded 
(Saunders et al., 1988). Consequently, the use of treatment seeking as a criterion to exclude 
individuals from normative samples will downwardly bias the amount of symptomatic 
change required to achieve clinically significant change (Saunders et al., 1988).  
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Estimates based on populations which include symptomatic individuals provide a less 
stringent test of a return to normal functioning than a group comprised entirely of 
asymptomatic individuals. However, this problem is overcome where studies have derived 
normative population estimates from  asymptomatic samples (e.g. Ogles et al., 1995). This 
approach does not conflict with the initial recommendations of Jacobson & Revenstorf 
(1988) which Tingey et al. (1996a) criticised as being too vague for the operationalisation of  
normative samples.  Follette & Callaghan (1996) pointed out that the major purpose of the 
Jacobson methodology is to define a clinically significant outcome in terms of what patients 
may reasonably expect from therapy. Thus, individual researchers must decide on what type 
of normative data to employ in analyses, depending on its availability and intended use 
(Follette and Callaghan, 1996). This approach allows the Jacobson method to be applied in 
situations where it is unlikely that treatment will return the client to normal functioning; 
investigators may quantify clinical significance by comparing treatment with the normative 
population of patients who have previously received the most effective treatment to date 
(Follette and Callaghan, 1996). Thus, it is clear that investigators should carefully describe 
the normative reference group used in analyses in order that the psychotherapy field may 
draw informed conclusions concerning treatment efficacy (Saunders et al., 1988). However, 
one limiting factor in employing the Jacobson approach is the lack of suitable normative 
data for many relevant measures of psychopathology (Lambert and Ogles, 2009). 
 
Another area of concern relates to the conceptualisation of distinct normative and 
dysfunctional populations by Jacobson et al. (1984). Both Wampold & Jenson (1986) and 
Hollon & Flick (1988) argued that discrete functional and dysfunctional distributions 
typically do not exist on symptom measures. Rather, the scores of both groups form a 
continuum and scores for the dysfunctional group occupy one tail of a single distribution. 
Accordingly, the derivation of cut-scores according to the Jacobson approach  was deemed 
inappropriate (Wampold and Jenson, 1986). A further criticism was that even where such 
discrete distributions exist, variations in the mean level of dysfunctional severity between 
individual treatment studies would make comparison of their results difficult because each 
study would produce different estimates for the cut-points a and c (Hollon and Flick, 1988). 
A proposal to overcome these difficulties (Hollon and Flick, 1988) was that the 
dysfunctional population should be ignored and that clinical significance should be 
determined by assessing how much closer an individual’s score has moved towards the 
general population mean following treatment.  However, Hollon & Flick’s recommendation 
to use unscreened and demographically representative normative samples represents a major 
threat to the notion that clinically significant change equates with a return to normal 
functioning, as such reference groups will contain individuals with notable levels of 
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psychopathology. Indeed, it has been estimated that up to 20% of the general population 
suffer from emotional disorders (Saunders et al., 1988). Another major limitation of Hollon 
& Flick’s approach is that it provides no empirically based method capable of categorising  
whether a patient has entered the normative range as the degree of improvement required for 
clinical significance is arbitrary (Hollon and Flick, 1988). Jacobson & Revenstorf (1988) 
rejected Hollon & Flick’s methodological criticisms by pointing out that within any 
distribution there are two distinct groups, (i) those who actively seek or receive treatment 
and (ii) those who do not. If such distinct groups exist, a cut off point could be established 
where there is equal probability of an individual being a member of either group.  
 
The two-criterion approach of the Jacobson method has been criticised for being too 
conservative which leads to two problems. First, mildly symptomatic individuals with pre-
treatment scores below the cut-off point can never make clinically significant change, only 
reliable improvement. Second, a severely symptomatic individual could demonstrate vast 
symptomatic improvement yet not reach the cut-off point. This means that they will be 
classified as having made reliable improvement rather than having made clinically 
significant change. In an attempt to address these issues, Tingey et al. (1996a) suggested 
using adjacent samples to distinguish between asymptomatic, mildly distressed, moderately 
distressed, and severely distressed levels of clinical significance. Whilst this would provide 
greater detail concerning client change, one limitation of Tingey et al.’s approach is that it 
requires more normative data than Jacobson et al.’s approach. However, a major limitation 
of Tingey et al.’s approach is that the typically poor validity of factors used to define 
adjacent samples means that it is less precise than the Jacobson method (Martinovich et al., 
1996) and is likely to be clinically meaningless (Follette and Callaghan, 1996). That the 
Jacobson method is too conservative and might be abandoned by some researchers led 
Follette & Callaghan to propose that such researchers must be willing to state that “ We have 
abandoned the goal of returning clients to normal functioning” (p140, Follette and 
Callaghan, 1996). However, it would appear that abandoning this goal is never justifiable as 
shown by the work of Lovaas who developed behavioural treatments for autistic children 
over a 30 year period (Lovaas, 1993). Following intensive treatment over 2 years, Lovaas 
showed that 47% of children achieved normal intellectual and educational functioning in 
contrast to 2% of controls.  
 
There are several remaining methodological issues pertinent to the Jacobson approach. The 
Jacobson approach assumes that both functional and dysfunctional populations are normally 
distributed. However, many instruments used in clinical research have restricted ranges and 
therefore skewed distributions which may lead to errors in the calculation of cut-point c  
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(Jacobson and Revenstorf, 1988; Tingey et al., 1996b). The problem of skewed data is 
particularly evident when psychopathology measures are used  in well functioning samples 
(Seggar et al., 2002; Martinovich et al., 1996). However, no empirical research has been 
conducted to examine to what degree this problem affects the precision of cut-off scores. 
Another issue that has concerned researchers is that the most recent formulation of the 
Jacobson approach (Jacobson et al., 1999) was not designed to control for regression to the 
mean which may reduce accuracy (Lambert and Ogles, 2009). Several researchers have 
modified the original formula for the RCI in order to account for this. For example Hsu 
(1989) modified the formula to include estimates of the mean and standard deviation of the 
population which scores would be expected to regress towards, whereas Speer (1992) used 
the reliability of the outcome measure to reduce pre-treatment scores toward the pre-
treatment mean. However, Atkins et al. (2005) performed simulations that compared such 
modifications to the original RCI proposed by Jacobson et al. and found that there were no 
practical differences between their results when the reliability of outcome measures is high.   
 
Researchers have also attempted to examine whether the four statistically defined Jacobson 
outcome categories are noticeably different according to patients (Ogles et al., 2001). For 
example, Ankuta & Abeles (1993) found that in a sample of outpatients with varied 
diagnoses, self-reported satisfaction following therapy was significantly higher in recovered 
than unchanged patients (as assessed on the SCL -90-R; Derogatis, 1983).  These findings 
were later supported by Lunnen & Ogles (1998)  who found that patients who made any 
reliable improvement (e.g. recovered or improved) demonstrated higher levels of perceived 
change and therapeutic alliance than unchanged or deteriorated patients. They concluded that 
the RCI was an effective index of symptomatic improvement but not deterioration (Lunnen 
and Ogles, 1998). Taken together, the results of these studies provided empirical evidence 
that both the recovered and improved categories of the Jacobson approach may be valid 
indicators of change that is meaningful to patients. However, this was not the case for 
deterioration, as Lunnen & Ogles (1998) found that unchanged and deteriorated patients 
were indistinguishable. 
 
Finally, where multiple measures have been used to assess outcome, it has been found that 
recovery on one measure does not guarantee recovery on another. For example, Ogles et al. 
(1995) used the Jacobson approach to determine the clinical significance of outcomes in the 
Treatment of Depression Collaborative Research Program (TDCRP, Elkin et al., 1989). It 
was found that BDI and HRSD recovery rates showed considerable differences in completer 
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samples. For example, in the CBT group, the BDI recovery rate
11
 was 28% whilst the HRSD 
rate was 45% (Ogles et al., 1995).  Such differences could have arisen because some patients 
were already within the functional range on the BDI at the start of treatment. However, it is 
more likely that the rate difference between two measures assessing the severity of 
depression arose because each measure taps into different facets of the same construct 
(Jacobson and Revenstorf, 1988). Such findings indicate the desirability of reporting 
clinically significant outcomes for more than one measure and highlight the importance of 
developing a consensus on valid and appropriate measures for specific clinical populations. 
However, this objective has not been fully realised as  researchers are free to use whichever 
measures they prefer and frequently fail to properly implement the Jacobson method (Ogles 
et al., 2001). 
 
 
5.5 Summary & Concluding Remarks 
The assessment of the clinical significance of treatment should utilise a methodology that is 
rigorous, objective and provides rigorous and non-ambiguous outcomes to providers and 
users of healthcare. The Jacobson approach fulfils this criterion and represents a meaningful 
and appropriate way of assessing change following treatment.  However, the approach does 
have several limitations and each requires a resolution.  
 
First, until adequate normative samples exist, there will be limitations of the applicability of 
the optimal Jacobson approach employing criterion ‘c’. However, there are difficulties 
associated with obtaining normative data for many primary measures as they are not 
applicable to well functioning samples. Nevertheless, the Jacobson approach provides the 
alternative ‘a’ and ‘b’ criteria which, though not optimal, still provide an empirical basis by 
which to quantify clinical significance.  Second, there has been relatively little empirical 
investigation into the validity of the four treatment outcome categories which can be derived 
from the Jacobson approach.  For example, no studies appear to have investigated the 
concurrent validity of recovery according to the Jacobson method with diagnostic status 
following treatment. It would be reasonable to expect that recovered patients no longer meet 
diagnostic criteria and that unchanged patients to continue to do so. Certainly if there were 
no differences between these treatment outcome categories in terms of diagnostic status, 
then the clinical utility and validity of the Jacobson approach would be seriously 
undermined. Third, different outcome measures will result in somewhat different 
                                                 
11 These rates were based on comparisons with screened normative samples. The BDI and HRSD results for 
comparisons with unscreened samples also showed considerable differences 
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proportions of patients being allocated to each of the treatment outcomes. In their reanalysis 
of TDCRP data, Ogles et al. (1995) showed that for the CBT group recovery rates according 
to the HRSD were approximately twice those for the BDI. These results show that the 
Jacobson approach will produce widely differing estimates of treatment efficacy, depending 
on the outcome measure employed. Thus, it is important that researchers reach consensus on 
which measure, or combination of measures, should be used to quantify clinically significant 
change.  
 
Finally, the Jacobson approach has been criticised as being too stringent. Indeed, 
psychotherapy looks far less effective if clinical significance is used as the index of efficacy. 
For example, Jacobson, Wilson & Tupper (1988) found that although exposure treatments 
for agoraphobia were significantly better than control conditions, only 27% of clients 
achieved clinically significant change. This highlights the fundamental advantage of the 
Jacobson approach over standard inferential statistics; clinicians, researchers and patients 
will have an extremely clear idea as to whether a treatment works in terms of the probability 
that an individual receiving this treatment will make a return to normal functioning. A 
standardised approach to clinical significance provides a meaningful baseline by which to 
judge improvements in efficacy over time, thereby allowing healthcare providers and 
purchasers to determine whether novel pharmacological and psychological interventions 
represent a clinical advance.  This form of benchmarking strategy allows efficient between 
and within study comparisons to be made, which is a fundamental component of effective 
evidence based practice. 
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Chapter Six 
 
Study 2  
 
Investigating Depression Treatment Outcomes Using the Jacobson 
Method of Clinical Significance 
 
6.1 Introduction  
Accurate estimates of treatment efficacy are fundamental to evidence-based medicine.  
However, the primary outcome studies that contributed to each meta-analysis included in the 
systematic review in study1 frequently used different methods to quantify treatment 
efficacy. These primary treatment studies operationalised treatment efficacy on the basis of 
the proportion of patients achieving remission according to post-treatment and follow-up 
scores on either a self report measure, the Beck Depression Inventory (BDI) or on a clinician 
rated measure, the Hamilton Rating Scale for Depression (HRSD). Pooling the results from 
such studies in meta-analysis is problematic. Because each measure assesses different 
aspects of depressive symptomatology, correlations between BDI and HRSD scores may be 
as low as .54 in depressed samples (Steer et al., 1987). Also, in patients assessed on both 
measures, symptomatic improvement is typically greater according to the HRSD than the 
BDI (Uher et al., 2008; Lambert et al., 1986). These factors raise the possibility that a 
proportion of patients categorised as remitted in studies using the HRSD would not be 
remitted according to the BDI and vice versa. Consequently, it is difficult to reach a 
balanced appraisal of the absolute and relative efficacy of interventions for major 
depression. 
 
Even when studies used the same outcome measure to define remission between study 
variation was evident.  For example, in the meta-analysis by de Maat et al. (2006), the 
stringency used to define remission on the HRSD in studies ranged from  a score of less than 
7 to a score of less than 10 points. As highlighted in study 1, the use of idiosyncratic 
definitions across studies is problematic because; (i) treatment differences observed between 
individual studies may be confounded with the definition of remission employed, (ii) 
published results of such studies may over or underestimate treatment efficacy. An 
alternative method of defining treatment efficacy in controlled evaluations of treatments for 
MDD is required. As detailed in the previous chapter, the Jacobson ‘c’ method (Jacobson 
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and Truax, 1991) provides a standardised approach that can be applied across studies to 
provide an index of both the relative and absolute merits of treatments. 
 
The primary aim of this chapter was to use the Jacobson method to quantify recovery in 
published randomised controlled trials for the treatment of depression.  A major advantage 
of the Jacobson ‘c’ method is that recovery rates are based on the proportions of patients 
who reliably return to the normative range on measures and are thus an estimate of absolute 
recovery. An additional advantage of the Jacobson method is that the identification of 
reliable symptomatic change enables patients to be allocated to one of four treatment 
outcomes; (i) recovered, (ii) improved, (iii) no change and (iv) worse. However, the 
Jacobson method required that individual patient data (IPD) was made available by study 
authors. Data were obtained for published studies where outcomes had been assessed using 
the BDI and/or HRSD.  These measures were chosen as they were the most commonly used 
in the studies included in the meta-analyses in chapter 4.  
 
There were two secondary aims to this study. Firstly, to compare the published clinical 
significance rates of studies with recovery as determined by the Jacobson method. It was 
hypothesised that both the relative and absolute published efficacies of treatments could 
differ markedly from those based on the Jacobson method.  Secondly, to determine the level 
of agreement concerning recovery between the BDI and HRSD in samples that had been 
assessed on both measures. Given that Jacobson recovery represents a return to the 
normative range in terms of depressive symptomatology, it was hypothesised that there 
would be high levels of agreement between the BDI and the HRSD. 
  
The results will firstly describe the studies that were used to assess the clinical significance 
of depression treatments according to the Jacobson method. Following this, the Jacobson 
clinical significance findings in studies are presented separately for the BDI and HRSD.  
Next, the published clinical significance results of individual studies are compared with the 
corresponding Jacobson method recovery rates.  The final section of the results will examine 
the level of agreement for Jacobson recovery between the BDI and HRSD in the same 
patient sample. 
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6.2 Method 
6.2.1 Search for Studies & Obtaining Individual Patient Data 
The following sources were searched for references to studies that employed psychological 
treatments for depression: 
 Reference sections of the reviews identified in study 1. 
 A published database of 115 randomised controlled trials investigating 
psychological treatments for depression (Cuijpers et al., 2008). 
 A database containing references to 149  controlled studies of psychotherapy for 
depression from the Free University of Amsterdam (Downloaded from 
http://www.psychotherapyrcts.org 19
th
 November 2009). 
 Electronic databases:  SCOPUS, Web of Science, & OVID (final search 29th January 
2010). 
 References contained in Appendix 17b of, “Depression: the treatment and 
management of depression in adults.”  (NICE, 2009). 
Studies were required to be methodologically similar to those included in the systematic 
review.  Eligible studies had to meet the following criteria:    
 Adult patients diagnosed with major depressive disorder (MDD) via structured 
clinical interviews according to DSM III, DSM III-R or DSM IV diagnostic criteria.  
Studies involving older adults, or studies treating depression in the context of 
substance abuse, personality disorder, psychotic or medical disorders were excluded. 
 Face to face individual psychotherapy provided in at least one treatment condition 
with or without follow-up assessment.  Preventative, maintenance, and therapies not 
based on a theoretical model of depression were excluded.  
 Comparison conditions were treatment as usual, wait list control, attentional control, 
psychotherapy, pharmacotherapy, pill placebo.   
 Studies were randomised controlled trials published in English from 1990.  
 Depressive severity was assessed using the BDI and/or HRSD at both pre and post-
treatment 
 
A flow chart depicting the selection of studies is presented in Figure 2. The titles of all 
identified references were used to screen out articles that obviously did not meet the 
inclusion criteria. Following an examination of the abstracts for the 282 remaining 
references, the full text of 51 were obtained to determine eligibility. Figure 2 indicates the 
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Eligible studies following 
screening on title 
n = 282 
Eligible studies  
n = 17 
Individual Patient Data 
received for study 
n = 7 
Declined to participate or data unavailable 
n = 10 
Full text articles assessed 
for eligibility 
n = 51 
Full text articles excluded: 
 
No DSM diagnosis   n = 5 
Not specifically MDD study n = 7 
Used data from previous study  n = 7 
 
Non directive psychotherapy,  
no BDI or HRSD,  
not published in English  n = 3 
 
Combined therapy was sole comparator n = 4  
Psychotherapy patients received ADM  n = 3 
 
Prevention/maintenance treatment  n = 3 
Geriatric patients     n = 2 
 
reasons why 34 of the 51 studies were ineligible. The final decision concerning the 
eligibility of individual studies was reached following discussion with PF.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Identification of Eligible IPD Studies. 
 
 
 
The authors of the 17 eligible studies were contacted via email in order to explain the 
purpose of the study and to request anonymous patient data.  If authors did not reply after 2 
weeks they were contacted two more times over the following 3 months.  One author made 
no reply to requests for data, four did not wish to cooperate and four reported that original 
patient data was no longer available.  One willing author was unable to participate due to the 
disruption caused by a large earthquake.  
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The individual patient data specifically requested from authors were: 
 pre and post-treatment outcome data for the BDI (Beck et al., 1961) and/or HRSD 
(Hamilton, 1960) 
 treatment type  
 completer status 
 number of treatment sessions 
 number of previous episodes of depression 
 concurrent dysthymia 
 sex and age  
 
IPD was obtained for the following 7 studies: Constantino et al. (2008), David et al. (2008), 
Dekker et al. (2008), DeRubeis et al. (2005), Jacobson et al. (1996), Jarrett et al. (1999), and 
Salminen et al. (2008).   
 
6.2.2 Determining  Jacobson Clinical Significance Criteria for the BDI & HRSD 
Calculating clinical significance according to the Jacobson ‘c’ method, required that both the 
reliability and distribution of scores in non-depressed samples were known for measures.  
Consequently, electronic databases and review bibliographies were searched to obtain 
reliability and normative data for the BDI and HRSD.  However, approximately 30% of U.S. 
adults have been shown to meet DSM IIIR criteria for psychiatric disorder in any year 
(Kessler et al., 1994). Thus, it is likely that the mean scores observed in the general 
population for both the BDI and HRSD will be elevated by a substantial minority of 
undiagnosed psychiatric ‘cases’. In order to ensure that the Jacobson criteria for both 
measures represented psychiatric wellbeing, normative data were obtained only from studies 
where individuals had been screened for psychological disorder.   
 
For the BDI a test-retest reliability of .81 (n = 74) was obtained from (Hatzenbuehler et al., 
1983).  The normative range for the BDI was obtained from the asymptomatic sample  
reported in Seggar et al. (2002) (mean = 2.88, SD = 2.44, n = 81).  Whilst version one of the 
BDI was used in studies (Beck et al., 1961), two versions of the HRSD were used.  Despite 
this, a single reliability and normative range were used to calculate the Jacobson clinical 
significance criteria for both HRSD versions.  The reasons for this are described below. 
 
Four studies (Dekker et al., 2008; Jacobson et al., 1996; Salminen et al., 2008; DeRubeis et 
al., 2005) used the 17-item version of the HRSD.  However, DeRubeis et al. (2005) modified 
the original to make it sensitive to changes in atypical depressive symptomatology.  These 
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minor modifications enabled increases in sleep, appetite or weight to be scored in contrast to 
the original version.  Consequently, typically depressed patients would score the same on 
either version, whereas, atypical patients could score higher on the modified version 
(personal communication).  It was assumed that the reliability of the modified version in 
DeRubeis et al. (2005) would not differ substantially from the original 17-item version as the 
modifications were minor.  The 21-item version of the HRSD was used by Jarrett et al. 
(1999) which consists of the 17-item version plus four additional items (diurnal variation, 
derealisation & depersonalisation, paranoid symptoms and obsessional symptoms; Hamilton, 
1960).  Because Williams et al. (1988) found a difference of only .01 between the 
reliabilities of the 17- and 21-item versions in the same sample, it was assumed that the 
reliability for the 17-item version was appropriate for Jarrett et al.’s (1999) results. 
Consequently, a reliability of .85 for the 17-item version of the HRSD reported by Akdemir 
et al. (2001) was used to calculate Jacobson clinical significance criteria in all studies. This 
was the Pearson’s correlation between independent raters in a sample of 93 depressed 
patients over a retest interval of 5 days (Akdemir et al., 2001).   
 
The normative range for the HRSD was derived from a sub-set of control studies reviewed 
by Zimmerman et al. (2004a).  Eight studies were identified where healthy controls had been 
screened for psychological disorder (Atmaca et al., 2002; Fassino et al., 2002; Grundy et al., 
1996; Lanquillon et al., 2000; Rehm and O’Hara, 1985; Rubin et al., 2002; Wahby et al., 
1990; Williams et al., 1991: cited Zimmerman et al., 2004a).  However, the HRSD version 
in these studies was varied as 3 used the 17-item version, 3 used the 21-item version and one 
used a 24-item version.  The version used in one study was unknown.  It was decided to 
combine the results of the 8 studies as Zimmermann et al. (2004a) found no difference 
between the mean scores of controls in studies that used different versions of the HRSD. 
Consequently, the means and standard deviations of the 8 studies were weighted by sample 
size to produce a mean HRSD score of 2.80 and standard deviation of 1.60. 
 
The distribution of scores seen in depressed samples for each measure was obtained from the 
pre-treatment scores of patients in the IPD studies. The data used to calculate the Jacobson’s 
clinical significance criteria for both measures are summarised in Table 14. 
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Table 14. Data Used to Determine Jacobson Clinical Significance Criteria for                        
the BDI & HRSD 
Symbol Definition BDI HRSD 
M1 Mean of  depressed sample 28.52
a 
20.59
b
 
S1 Standard deviation of depressed sample 8.74 4.44 
M2 Mean of  asymptomatic sample
* 
2.88
c 
2.80
d 
S2 Standard deviation of asymptomatic sample
* 
2.44
c 
1.60
d 
rxx Reliability of scale 0.81
e
 0.85
f
 
SE Standard error of measurement for scale 3.81 1.72 
Sdiff Standard error of difference score 5.39 2.43 
*  Asymptomatic samples were screened to exclude psychiatric cases. 
a  Comprises all available pre-treatment scores (n = 499) from 5 IPD studies using the BDI. 
b   Comprises all available pre-treatment scores (n = 651) from 5 IPD studies using the HRSD. 
c  Seggar et al. (2002). 
d   Weighted result of 8 screened control studies (n = 399) in Zimmerman et al. (2004a).   
e  Hatzenbuehler et al. (1983). 
f   Akdemir et al. (2001). 
 
 
Jacobson’s ‘c’ for each measure was calculated using the formula: 
 
 
According to the values in Table 14 Jacobson’s ‘c’ for the BDI and HRSD were determined 
to be 8.48 and 7.51 respectively. Consequently, the respective cut-off points for recovery on 
the BDI and HRSD were deemed to be a score of 8 or less and 7 or less respectively.  
 
The reliable change index (RCI) for each measure was calculated using the formulae: 
RCI = (X2 – X1)/Sdiff        
where  Sdiff = √(2SE
2
)     
and     SE = S1√(1- rxx) 
 
for the BDI    for the HRSD 
SE    = 8.74√(1- 0.81)  = 3.809   SE   = 4.44√(1- 0.85)  = 1.719 
Sdiff  = √2(3.8096)
2
      = 5.387   Sdiff = √2(1.7196)
2
      = 2.432 
 
An RCI greater than 1.96 is required for reliable change at the 5% level.  Thus, the minimum 
reliable change in score from pre to post-treatment on the BDI was 11 points on the BDI and 
5 points  on the HRSD.   
 
 
c =  S1M2 + S2M1 
       S1 + S2 
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6.2.3 Data Analytic Strategy 
Comparisons of mean pre-treatment severity between studies  
Received IPD were used to calculate the mean pre-treatment severity of patients within each 
study for both the BDI and HRSD. Significant between-study differences in pre-treatment 
severity were then examined using separate analyses of variance (ANOVA) for both 
measures.  
 
Determining Jacobson clinical significance rates  
The clinical significance of individual patient outcomes was determined according to the 
Jacobson criteria for the BDI and/or HRSD. Only post-treatment data were analysed as 
insufficient data were provided for follow-up outcomes.  One of four mutually exclusive 
clinical significance categories was assigned to each patient: (i) recovered, (ii) improved, 
(iii) no change, and (iv) worse. Where IPD was missing for patients, the clinically significant 
outcome assigned was ‘no change’. Individual outcomes for each study were then used to 
calculate the percentage of patients in treatments occupying each of the four clinical 
significance categories.  Whilst improvement is a clinically desirable outcome, it was not 
used to assess treatment efficacy. This was because the improved category in individual 
studies included unrecovered patients with an unknown range of symptom severity. 
Consequently, improvement rates were an unsuitable measure of clinical significance for 
both within- and between-study treatment comparisons. Jacobson recovery status was used 
to investigate the relative efficacy of treatments in each study via goodness of fit testing.   
 
 
6.3 Results 
6.3.1 Study Characteristics 
All studies were based on outpatients attending for treatment. The majority of studies (5/7) 
used DSM IV criteria to diagnose MDD, the remaining two used DSM III criteria (Jacobson 
et al., 1996; Jarrett et al., 1999).  Of the five studies that used the HRSD to assess depressive 
symptomatology, four reported that raters were blinded to patients’ treatment condition. The 
exception was Salminen et al. (2008) who reported that HRSD raters were not blinded.  Six 
of the seven studies reported that psychotherapy was manualised.  Again, the exception was 
Salminen et al. (2008) who reported that STPP was not manualised. Only three studies 
clearly reported treatment adherence checks (David et al., 2008; Dekker et al., 2008; 
Jacobson et al., 1996).  Selected characteristics of the 7 included studies are presented in 
Table 15. Studies varied considerably in terms of treatment type, number of patients, 
duration of psychotherapy, and the operational definitions of clinically significant outcomes. 
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Treatment groups were stratified on potential moderators of outcome during the 
randomisation process in four studies (David et al., 2008; DeRubeis et al., 2005; Jacobson et 
al., 1996; Jarrett et al., 1999). 
 
Treatment comparisons 
Three studies compared alternative types of psychotherapy (Constantino et al., 2008; David 
et al., 2008; Jacobson et al., 1996); two compared psychotherapy with antidepressant 
medication alone (Dekker et al., 2008; Salminen et al., 2008); and two included a pill 
placebo control arm in addition to ADM and psychotherapy (DeRubeis et al., 2005; Jarrett et 
al., 1996).  The placebo condition in DeRubeis et al. (2005) was terminated after 8 weeks.  
The majority of studies used CBT where it was provided according to the principles outlined 
by Beck et al. (1979).   However, Table 15 reveals that no study was a direct replication of 
any other.  For example, whilst CBT was compared directly with ADM in 3 studies (David 
et al., 2008; DeRubeis et al., 2005; Jarrett et al., 1999) none used exactly the same type of 
medication.  Two studies compared CBT with selective serotonin re-uptake inhibitors 
(David et al., 2008; DeRubeis et al., 2005), whilst  Jarrett et al. (1999) used the monoamine 
oxidase inhibitor, Phenelzine.  
 
Minimum intake severity 
All studies specified a minimum level of depressive symptoms to be eligible for inclusion. 
However, studies used different measures and different levels of severity to define 
eligibility.  For example, Table 15 shows that eligibility was assessed using only the BDI in 
a single study (Constantino et al., 2008) and that four used only the HRSD (Dekker et al., 
2008; DeRubeis et al., 2005; Jarrett et al., 1999; Salminen et al., 2008). Two studies assessed 
intake severity using both the BDI and HRSD (David et al., 2008; Jacobson et al., 1996).   
 
Table 15 shows that the minimum BDI severity score was 20 points in all studies using the 
BDI (Constantino et al., 2008; David et al., 2008; Jacobson et al., 1996). However, the 
minimum HRSD severity score differed across studies. Four studies used a minimum HRSD 
score of 14 (David et al., 2008; Dekker et al., 2008; Jacobson et al., 1996; Jarrett et al., 
1999). In contrast, DeRubeis et al. (2005) and Salminen et al. (2008) used a minimum 
HRSD score of  20 and 15 points respectively. Finally, only two studies examined the 
stability of depressive symptomatology  prior to starting treatment (DeRubeis et al., 2005; 
Jarrett et al., 1999). DeRubeis et al. (2005) excluded patients who failed to meet the severity 
criterion at both screening and baseline assessments which were separated by at least 7 days.  
Jarrett et al. (1999) excluded those who initially met the severity criterion at the screening 
phase but failed to do so after a 14 day non-treated interval.  
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Number of sessions & duration of psychotherapy. 
Psychotherapy sessions in all studies lasted between 50 to 60 minutes.  However, there was 
considerable variation between studies in terms of the frequency of sessions. Table 15 shows 
that a full course of psychotherapy lasted for 20 sessions in four studies (David et al., 2008; 
DeRubeis et al., 2005; Jacobson et al., 1996; Jarrett et al., 1999) and for 16 sessions in two 
studies (Constantino et al., 2008; Salminen et al., 2008).  The 8 sessions provided by Dekker 
et al. (2008) did not represent a full course of psychotherapy. Table 15 also shows that the 
duration of a full course of psychotherapy ranged from a minimum of 10 weeks (Jarrett et 
al., 1999) to a maximum of 16 weeks (DeRubeis et al., 2005; Jacobson et al., 1996; 
Salminen et al., 2008).  Completer status was defined as receiving 12 sessions or more in 
David et al. (2008) and Jacobson et al. (1996) and 5 sessions in Dekker et al. (2008). The 
remaining studies did not define completer status in terms of sessions.  
 
Table 15 reveals that duration or session data alone poorly represented studywise differences 
concerning the timing of therapeutic interventions. Some studies reported providing a fixed 
number of sessions per week for the duration of therapy (Dekker et al., 2008; Jarrett et al., 
1999; Salminen et al., 2008), whereas others reported more frequent sessions at the 
beginning of treatment (Constantino et al., 2008; DeRubeis et al., 2005). Whilst no 
information was available concerning the timing of treatment in 2 studies (David et al., 
2008; Jacobson et al., 1996), bi-weekly session were provide at some stage as both provided 
20 sessions in less than 20 weeks.  
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Table 15. Characteristics of the Seven IPD Studies 
Study 
 
 
Treatment 
 
 
Number  
Starting 
Treatment 
Attrition 
(percent) 
Minimum 
Intake 
Severity 
Number of Sessions  
& Duration of  
Psychotherapy 
Randomisation; 
Sample  stratified on: 
 
Criterion for 
Clinical Significance 
 
IPD data 
received 
 
Constantino et al. (2008)  CBT  11 27.3 BDI    ≥ 20 16 sessions over 13 weeks not reported. BDI  ≤  15  BDI 
 ICT 11 0  (6 bi-weekly then 10 weekly)   & reliable changeα  
David et al. (2008)  Fluoxetine 55 14.0 HRSD ≥ 14 20 sessions over 14 weeks  no of previous episodes,  HRSD  ≤  6  BDI 
 CBT 57 10.7 BDI     ≥ 20 (frequency not reported) sex,  marital status, & no MDD  
 REBT 44 8.8   dysthymia.    
Dekker et al. (2007)  Venlafaxine 44 4.5 HRSD ≥ 14 8 sessions β over 8 weeks   not reported. none given HRSD-17 
 SPSP 59 8.5  (weekly)    
DeRubeis et al. (2005)  Paroxetine 120 15.8 HRSD ≥ 20 20 sessions over 16 weeks no. of  previous episodes,  HRSD  ≤  7 HRSD -17 
 CBT 60 16.7  (8 bi-weekly then 12 weekly) sex.   
 Placeboγ 60 n/a      
Jacobson et al. (1996)  AT 43 11.6 HRSD ≥ 14 20 sessions over 16 weeks  no. of  previous episodes,  BDI  ≤  8  HRSD-17 
 BA 56 12.5 BDI     ≥ 20 (frequency not reported) sex,  marital status,  & no MDD BDI 
 CBT 50 6.0   dysthymia,  severity.   
Jarrett et al. (1999)  Phenelzine 36 25.0 HRSD ≥ 14 20 sessions over 10 weeks marital status,  HRSD  ≤  9 HRSD -21 
 CBT 36 13.9  (bi-weekly) length of current episode.   BDI 
 Placebo 36 63.9      
Salminen et al. (2008)  Fluoxetine 25 24.0 HRSD ≥ 15 16 sessions over 16 weeks  not reported. HRSD  ≤  7 HRSD -17 
 STPP 26 19.2  (weekly)   BDI 
Key: AT = Coping with Automatic thoughts;  BA = Behavioural activation;  BDI = Beck Depression Inventory;  CBT = Cognitive behavioural therapy;   
HRSD = Hamilton Rating Scale for Depression;  ICT = Integrative cognitive therapy;  IPD = Individual patient data;  n/a = not applicable. 
 
α: Reliable change determined using the Jacobson method;   
β: Interim outcomes: study was first 8 weeks of a longer study;  
γ: Placebo condition terminated at 8 weeks;  
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Randomisation & sample stratification 
No study adequately described the randomisation process according to CONSORT 
recommendations  (Begg et al., 1996). The random allocation sequence used to assign 
patients to treatment condition was generated or implemented was not described by any 
study.  Only Jarrett et al. (1999) reported that patient allocation was undertaken by an 
independent statistician. Table 15 shows that four studies stratified samples to balance 
groups on potential prognostic factors and that no study stratified samples using exactly the 
same set of factors (David et al., 2008; DeRubeis et al., 2005; Jacobson et al., 1996; Jarrett et 
al., 1999). 
 
Published clinical significance criteria for post-treatment outcomes 
Table 15 presents the published clinical significance criteria that formed the basis for 
comparisons between published and the Jacobson method post-treatment results. Only 
Dekker et al. (2008) did not use an index of clinical significance to compare treatments.  The 
published criteria for Jarrett et al. (1999) correspond to the findings in their published 
abstract.  Overall, studies demonstrated considerable variability in the definition of clinical 
significance;  two compared treatments in terms of response (Constantino et al., 2008; Jarrett 
et al., 1999) and four compared treatments in terms of remission (David et al., 2008; 
DeRubeis et al., 2005; Jacobson et al., 1996; Salminen et al., 2008).   
 
Constantino et al. (2008) used Jacobson and Truax’s (1991) clinical significance method to 
quantify response rates according to the BDI.  Response was defined as a score of 15 or less 
which included patients who were either ‘non-distressed’ (BDI = 0 to 9) or ‘minimally 
distressed’ (BDI = 10 to15)  (Constantino et  al., 2008).  However, Constantino et al. 
provided limited information concerning the application of the Jacobson method to their data 
and did not report the minimum reliable score change required for the BDI.  Response in 
Jarrett et al. (1999), was defined as a post-treatment HRSD score of 9 or less.     
 
The definition of remission in DeRubeis et al. (2005) and Salminen et al. (2008) required 
only that patients meet a criterion score on the HRSD.  However, DeRubeis et al. (2005) also 
employed an algorithm
12
 to ensure that patients who demonstrated consistent remission 
during the final weeks of treatment were not excluded due to any transient symptom 
worsening at the final (post-treatment) assessment. Finally, Table 15 shows that the 
definition of remission in David et al. (2008) and Jacobson et al. (1996) required that 
patients no longer met diagnostic status in addition to meeting a criterion score on a 
symptom measure;  the former study used the HRSD, the latter used the BDI. 
                                                 
12 This was omitted from the table to simplify presentation. 
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Individual Patient Data received  for outcome measures 
Table 15 shows the measures for which IPD was received.  All authors provided IPD for 
either the BDI and/or HRSD, treatment group, completer status and sex.  Two studies 
provided outcome data for the BDI, (Constantino et al., 2008; David et al., 2008), two for 
the HRSD (Dekker et al., 2008; DeRubeis et al., 2005) and three provided outcome data for 
both measures (Jacobson et al., 1996; Jarrett et al., 1999; Salminen et al., 2008).   As David 
et al. (2008) provided data for the BDI but published remission rates only for the HRSD,  a  
direct comparison of published and Jacobson method results was not possible.  Only one 
study (Salminen et al., 2008) failed to provide any last observation carried forward data 
(LOCF) for patients who dropped out of treatment. Two studies provided IPD for patients 
assessed at follow-up (Jacobson et al., 1996; Salminen et al., 2008).  Both provided IPD for 
12 month follow-up assessment. Six of the seven studies provided data for a complete course 
of treatment. Only interim results were obtained for Dekker et al. (2008) as the treatments 
provided after the first 8 weeks no longer met the inclusion criteria of this study (Dekker, 
personal communication).  Finally, authors did not consistently provide IPD concerning the 
number of treatment sessions received, number of previous episodes of depression, 
dysthymia or age.   
 
As described earlier in section 6.2.2 the 17-tem and 21-item  versions of the HRSD were 
used in studies.  Consequently, the maximum possible symptom score on the HRSD differed 
across studies. Three studies (Dekker et al., 2008; Jacobson et al., 1996; Salminen et al., 
2008) used the 1967 version of the 17-item HRSD which provided a maximum score of 52 
points (Hamilton, 1967).  DeRubeis et al. (2005) used the 1960 version of the 17-item 
HRSD (Hamilton, 1960) which provided a maximum score of 50 points.  The modifications 
for atypical depression made by DeRubeis et al. (2005) described in section 6.2.2 did not 
alter the maximum score from 50, but did allow atypical patients to score higher than on the 
1960 version of the 17-item  HRSD.  Finally, Jarrett et al. (1999) used the 1960 version of 
the 21-item HRSD which consists of the 17-item version plus four additional items 
(Hamilton, 1960).   Consequently, the maximum possible score for the HRSD version used 
by Jarrett et al. (1999) was 62 points. However, 3 of the items (derealisation & 
depersonalisation, paranoid symptoms and obsessional symptoms) are rarely endorsed by 
patients (Hamilton, 1967).   
 
Pre-treatment severity differences between studies 
Table 16 presents the mean pre-treatment scores of the total sample in studies according to 
received IPD.  Only DeRubeis et al. (2005) published a pre-treatment mean score on the 
HRSD (mean 23.4, s.d.= 2.9) that differed to that in the table (mean 23.9, s.d.= 3.4). The 
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difference occurred because DeRubeis et al. (2005) provided IPD obtained during the 
screening phase but published results for the baseline assessment 1 week later (personal 
communication).   
 
Significant differences between the mean pre-treatment scores in studies were identified via 
one way analyses of variance (ANOVA), for both the BDI (F4, 494 = 11.09, p < .0001) and 
HRSD  (F 4, 646 = 88.42, p < .0001).  As post-hoc testing showed that the variances in BDI 
studies and HRSD studies were not homogeneous Tamahane tests were used to investigate 
significant differences between the pre-treatment means in studies (Tamahane: BDI: F4, 494 = 
16.42, p < .001; HRSD: F2,646 = 2.44, p = .046). 
 
 
Table 16. Total Sample Mean Pre-treatment Severity in IPD Studies* 
Study BDI  (s.d.)  HRSD  (s.d.) 
Constantino et al. (2008) 29.1 5.6  - - 
David et al. (2008) 30.9 10.5  - - 
Dekker et al. (2007) - -  20.2 3.7 
DeRubeis et al. (2005) - -  23.9 3.4 
Jacobson et al. (1996) 29.4 6.6  18.5 4.1 
Jarrett et al. (1999) 25.6 8.0  17.5 3.2 
Salminen et al. (2008) 23.8 6.6  18.6 3.2 
All studies 28.5 8.7  20.6 4.4 
* Calculated using IPD.  
 
Post hoc tests  identified two groups of studies whose BDI pre-treatment mean scores did not 
significantly differ (p < .05). The first group consisted of Constantino et al. (2008), David et 
al. (2008) and Jacobson et al. (1996). The second group consisted of Jarrett et al. (1999) and 
Salminen et al. (2008). The BDI pre-treatment means of both David et al. (2008) and 
Jacobson et al. (1996) were significantly higher than those of both Jarrett et al. (1999) and 
Salminen et al. (2008).  However, the BDI pre-treatment mean of Constantino et al. (2008) 
was only significantly higher than that of Salminen et al. (2008) and was no different to that 
of Jarrett et al. (1999). 
 
In terms of the HRSD, post hoc tests (p < .05) revealed that the pre-treatment mean score in 
DeRubeis et al. (2005) was higher than that of all the remaining studies (Dekker et al., 2008; 
Jacobson et al., 1996; Jarrett et al., 1999; Salminen et al., 2008).  Pre-treatment means did 
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not differ between Jacobson et al. (1996), Jarrett et al. (1999) and Salminen et al. (2008). 
However, the pre-treatment mean in Dekker et al. (2008) was significantly higher than that 
of  both Jacobson et al. (1996) and Jarrett et al. (1999) but no different to that of Salminen et 
al. (2008). 
 
6.3.2 Jacobson Clinical Significance Rates for the BDI & HRSD in IPD Studies 
Complete Jacobson clinical significance rates for each of the seven studies are presented in 
Table 17 and Table 18 for the BDI and HRSD respectively. With the exception of Dekker et 
al. (2008) the results are presented for post-treatment outcomes.  Also, insufficient follow-up 
data was received to warrant an analysis and is not presented. The results for both ITT and 
completer samples revealed that the BDI did not categorise any patient as ‘worse’ in contrast 
to the HRSD. An examination of IPD for the completer sample in Jarrett et al. (1999) 
confirmed that 2 patients who were unchanged on the BDI were worse according to the 
HRSD. The tables show that, overall, the majority of patients receiving an active treatment 
were categorised as improved or recovered following a full course of treatment for both 
measures and sample type.  Patient attrition typically led to higher recovery rates in 
completer samples than in ITT samples. However, an analysis of IPD indicated that attrition 
was not confined to those patients who were unchanged or became worse during treatment. 
 
BDI rates 
In terms of ITT samples, BDI results in Table 17 show that the percentage recovery rate for 
active treatments varied widely between studies. Recovery rates ranged from only 27.3% for 
ICT in Constantino et al. (2008) to 62% for CBT in Jacobson et al. (1996).   However, Table 
17 also shows that in most studies the majority of patients in active treatments were typically 
improved or recovered at post-treatment.  Salminen et al. (2008) was the only exception 
where 52% of ADM and 53.8% of STPP patients were unchanged (i.e. ‘no change’).  In 
addition, active treatments were associated with greater overall improvement (i.e. improved 
or recovered) than controls, as placebos in Jarrett et al. (1999) demonstrated both the lowest 
recovery rate (22%) and highest rate of ‘no change’ (66.7%).  Finally, recovery across all 
active treatments was 48.1% . 
 
In terms of completer samples, an examination of Table 17 shows that recovery rates for 
active treatments demonstrated a similar range to those observed in ITT samples. Recovery 
rates ranged from only 25% for CBT in Constantino et al. (2008) to 63.8% for CBT 
Jacobson et al. (1996).  However, with the exception of the CBT group in Constantino et al. 
(2008), recovery in completer samples was higher than that in ITT samples. In contrast to 
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the ITT sample, the majority of patients had either improved or recovered in all active 
treatment groups as the percentage of ‘no change’ in the ADM and STPP groups in 
Salminen et al. (2008) were now 36.8% and 42.9% respectively. The 63.9% attrition rate for 
placebos in Jarrett et al. (1999) resulted in a 61.5% recovery rate that was higher than that of 
the CBT group . Recovery across all active treatments was 53.0%. 
 
HRSD rates 
Comparing the results of Dekker et al. (2008) with the remaining studies in Table 18 is 
problematic as they corresponded only to 8-week outcomes. Consequently, they are not 
considered here as post-treatment results.   
 
In terms of ITT samples, the results for active treatments in Table 18 show that the 
percentage range of post-treatment recovery varied widely between studies. Post-treatment 
recovery ranged from 38.3% for CBT in DeRubeis et al. (2006) to 66.0% for CBT in 
Jacobson et al. (1996).  As seen for the BDI, the majority of patients receiving an active 
treatment were either improved or recovered at post-treatment.  However, unlike the BDI, 
the results in Table 18 show that the HRSD categorised a small percentage of patients as 
‘worse’ at post-treatment (DeRubeis et al., 2005; Jarrett et al., 1999) and 8 weeks (Dekker et 
al., 2008). The highest overall rate of worsening was 11.9% for the SPSP group in Dekker et 
al. (2008) whilst the highest post-treatment rate was 8.3% for both the CBT and placebo 
groups in Jarrett et al. (1999). In common with BDI results, active treatments were 
associated with greater overall post-treatment improvement than controls, as placebos in 
Jarrett et al. (1999) demonstrated both the lowest recovery rate (22%) and highest rate of ‘no 
change’ (55.6%).  However, the 8 week recovery rates for ADM (11.4%) and SPSP (8.5%) 
in Dekker et al. (2008) were substantially lower than the post-treatment rate for placebos in 
Jarrett et al. (1999). Finally, recovery across all active treatments was 50.7%. 
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Table 17. Percentage of Patients Allocated to four Categories of Clinical Significance using Jacobson Criteria for the BDI at Post-treatment. 
Study Treatment Intention to Treat Analysis (ITT)  Completer Analysis 
  n Worse No Change Improved Recovered  n Worse No Change Improved Recovered 
Constantino et al.  (2008) CBT 11 - 36.4 27.3 36.4  8 - 37.5 37.5 25.0 
 ICT 11 - 9.1 63.6 27.3  11 - 9.1 63.6 27.3 
             
David et al. (2008) ADM 57 - 19.3 35.1 45.6  49 - 14.3 34.7 51.0 
 CBT  56 - 23.2 30.4 46.4  50 - 20.0 30.0 50.0 
 REBT 57 - 15.8 42.1 42.1  52 - 15.4 40.4 44.2 
             
Jacobson et al. (1996) AT 43 - 25.6 18.6 55.8  38 - 15.8 21.1 63.2 
 BA 56 - 16.1 26.8 57.1  49 - 16.3 22.4 61.2 
 CBT 50 - 20.0 18.0 62.0  47 - 17.0 19.1 63.8 
             
Jarrett et al. (1999) ADM 36 - 36.1 13.9 50  27 - 18.5 18.5 63.0 
 CBT 36 - 36.1 16.7 47.2  31 - 32.3 16.1 51.6 
 Placebo 36 - 66.7 11.1 22.2  13 - 23.1 15.4 61.5 
             
Salminen et al. (2008) ADM 25 - 52.0 16.0 32.0  19 - 36.8 21.1 42.1 
 STPP 26 - 53.8 7.7 38.5  21 - 42.9 9.5 47.6 
All Active Treatments*  464 - 26.1 25.9 48.1  402 - 20.4 26.6 53.0 
Key: AT = Coping with automatic thoughts; BA = Behavioural activation;  BDI = Beck Depression Inventory;  CBT = Cognitive Behavioural Therapy;   ICT = Integrative 
Cognitive Therapy;  REBT = Rational Emotive Behavioural Therapy;   STPP = Short Term Psychodynamic Psychotherapy. 
* excluding placebo 
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Table 18. Percentage of Patients Allocated to four Categories of Clinical Significance using Jacobson Criteria for the HRSD at Post-treatment. 
Study Treatment Intention to Treat Analysis (ITT)  Completer Analysis 
  n Worse No Change Improved Recovered  n Worse No Change Improved Recovered 
DeRubeis et al. (2005) ADM 120 1.7 16.7 37.5 44.2  101 - 9.9 37.6 52.5 
 CBT 60 1.7 13.3 46.7 38.3  50 - 10.0 46.0 44.0 
             
Jacobson et al. (1996) AT  43 - 18.6 18.6 62.8  38 - 10.5 18.4 71.1 
 BA  56 - 17.9 23.2 58.9  49 - 16.3 24.5 59.2 
 CBT  50 - 20.0 14.0 66.0  47 - 14.9 14.9 70.2 
             
Jarrett et al. (1999) ADM 36 - 27.8 22.2 50.0  27 - 14.8 18.5 66.7 
 CBT 36 8.3 22.2 22.2 47.2  31 6.5 19.4 22.6 51.6 
 Placebo 36 8.3 55.6 13.9 22.2  13 - 15.4 23.1 61.5 
             
Salminen et al. (2008) ADM  25 - 40.0 8.0 52.0  19 - 21.1 10.5 68.4 
 STPP  26 - 34.6 19.2 46.2  21 - 19.0 23.8 57.1 
             
Dekker et al. (2008)α ADM 44 6.8 52.3 29.5 11.4  42 4.8 52.4 31.0 11.9 
 SPSP 59 11.9 59.3 20.3 8.5  54 13.0 55.6 22.2 9.3 
All Active Treatments*  452 1.3 20.6 27.4 50.7  383 0.5 13.6 27.7 58.2 
Key: AT = Coping with automatic thoughts;  BA = Behavioural activation;    CBT = Cognitive Behavioural Therapy;  HRSD = Hamilton Rating Scale for Depression;   SPSP = Short 
Psychodynamic Supportive Psychotherapy;   STPP = Short Term Psychodynamic Psychotherapy.  
α:  8 week results.  
* excluding placebos & 8 week results for Dekker et al. (2008).
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In terms of completer samples, the HRSD results in Table 18 show that post-treatment 
recovery for active treatments demonstrated a similar range to those observed in ITT 
samples. Post-treatment recovery rates ranged from 44.0% for CBT in DeRubeis et al. 
(2005) to 71.1% for AT in Jacobson et al. (1996).  An examination of the results in Table 18 
shows that post-treatment recovery in completer samples was higher than in ITT samples 
and that the proportion of patients categorised as ‘worse’ was reduced.  Again, the majority 
of patients in active treatments were either improved or recovered at post-treatment. In 
contrast to the results for post-treatment outcomes the majority of ADM and SPSP patients 
in Dekker et al. (2008) were unchanged at 8 weeks.  As seen for the BDI, the 63.9% attrition 
rate for placebos in Jarrett et al. (1999) resulted in a higher recovery rate in placebos (61.5%) 
compared to CBT (51.6%). Recovery across all active treatments was 58.2%. 
 
Post-treatment Jacobson recovery rates by treatment class  
Table 17 and Table 18 reveal that post-treatment recovery rates for similar classes of active 
treatment varied considerably between studies in both ITT and completer samples.  The 8 
week results for Dekker et al. (2008) are not described.  Psychotherapy type was classed as 
either CBT according to Beck et al. (1979), or non-CBT, whilst all medications were classed 
as ADM.  
 
BDI recovery 
In terms of ITT samples, Table 17 shows that ADM recovery on the BDI ranged from 32% 
in  Salminen et al.  (2008) to 50%  in Jarrett et al., 1999. CBT recovery ranged from 36.4%  
in Constantino et al. (2008) to 62% in Jacobson et al. (1996). Recovery for non-CBT 
psychotherapies ranged from 27.3% for the ICT group in Constantino et al. (2008)  to 57.1% 
for the BA group in Jacobson et al., (1996). The overall rates for ADM and all types of 
psychotherapy across studies were 44.1% and  49.4% respectively.  
 
In terms of completer samples, ADM recovery on the BDI ranged from 42.1% in Salminen 
et al. (2008) to 63% in Jarrett et al. (1999). CBT recovery ranged from 25.0% in Constantino 
et al. (2008) to 63.8% in Jacobson et al. (1996).  The CBT completer rate in Constantino et 
al. (2008) was lower than the ITT rate because 2 recovered CBT patients failed to complete 
treatment. Recovery for non-CBT psychotherapies ranged from 27.3% for ICT in 
Constantino et al. (2008)  to 63.2% for AT in Jacobson et al. (1996). The overall rates for 
ADM and all types of psychotherapy across studies were 52.6%  and 53.1% respectively. 
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HRSD recovery 
In the ITT samples, Table 18 shows that ADM recovery on the HRSD ranged from 44.2% in 
DeRubeis et al. (2005) to 52% in Salminen et al. (2008).  CBT  recovery ranged from 38.3% 
in DeRubeis et al. (2005) to 66% in Jacobson et al. (1996).  Recovery for non-CBT 
psychotherapies ranged from 46.2% for STPP in Salminen et al. (2008) to 62.8% for AT  in 
Jacobson et al, (1996).  The overall rates for ADM and all types of psychotherapy across 
studies were 46.4%  and 53.5% respectively. 
 
In the completer samples, ADM recovery ranged from 52.5% in DeRubeis et al. (2005) to 
68.4%  in Salminen et al. (2008). CBT recovery ranged from 44.0% in DeRubeis et al. 
(2005) to 70.2% in  Jacobson et al. (1996). Recovery in non-CBT psychotherapies ranged 
from 57.1% for STPP in Salminen et al., (2008)  to 71.1%  for AT  in Jacobson et al. (1996).  
The overall rates for ADM and all types of psychotherapy across studies were 57.1%  and 
58.9% respectively. 
 
Summary 
The results for both measures and sample type indicate that the range of post-treatment 
recovery rates for psychotherapy was typically greater than for ADM. In addition, overall 
ITT psychotherapy  recovery rates were 5.3% higher than ADM rates on the BDI and 7.1% 
higher on the HRSD. However, not all studies contributing to these overall figures had 
directly compared ADM with psychotherapy (Constantino et al., 2008; Jacobson et al.; 
1996). For the pooled ITT sample of studies that directly compared ADM with 
psychotherapy, the overall BDI recovery rates for ADM and psychotherapy were 44.1% and 
44% (David et al., 2008; Jarrett et al., 1999; Salminen et al., 2008) respectively. The 
corresponding HRSD rates were 46.4% and 42.6% respectively (DeRubeis et al., 2005; 
Jarrett et al., 1999; Salminen et al., 2008). For the pooled completer sample, the overall BDI 
recovery rates for ADM and psychotherapy were 52.6% and 48.1% respectively (David et 
al., 2008; Jarrett et al., 1999; Salminen et al., 2008). The corresponding HRSD rates  were 
57.1% and 49%  respectively (DeRubeis et al., 2005; Jarrett et al., 1999; Salminen et al., 
2008). Thus, with the exception of the ITT sample results for the BDI, ADM appeared to 
produce higher overall recovery rates than psychotherapy in direct comparisons. However, 
goodness of fit testing for the results of individual studies failed to show that any active 
treatment was superior to another in any sample and on either measure. Nevertheless, 
goodness of fit tests showed that both CBT and ADM in Jarrett et al. (1999) were superior to 
placebo on both measures in ITT samples (Χ2(2)  = 7.03, p = .03 for both measures).  Active 
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treatments in Jarrett et al. (1999) were no different to placebo in completer samples on both 
measures. 
 
Patient attrition In clinical significance categories 
The overall attrition rate for the 747 patients in active treatments across studies was 13.7%.  
In studies that compared psychotherapy directly with ADM the attrition was 15.6% for 
ADM and 11.6% for psychotherapy ( p > .1). An analysis of pooled LOCF 
13
 data and IPD 
completer status for the BDI showed that 54.9% of dropouts in active treatments were 
unchanged, 25.5% improved and 19.6% recovered at their last observation (n = 51). The 
same analysis for the HRSD showed that 55.4% of dropouts were unchanged, 7.7% were 
worse, 27.7% improved and 9.2% recovered at their last observation (n = 65).  
 
 
6.3.3 Comparing Published Clinical Significance Rates with Jacobson Recovery 
Table 19 presents the post-treatment clinical significance rates reported in studies along with 
the criteria on which they were based. The corresponding Jacobson method rates are 
presented for comparison. These were based on the same outcome measure as used for 
published results with the exception of David et al. (2008).  An analysis of IPD showed that 
unreliable change had not contributed to published results in 5 studies (Constantino et al., 
2008; DeRubeis et al., 2005; Jacobson et al., 1996; Jarrett et al., 1999; Salminen et al., 
2008). The minimum published HRSD entry criterion of 14 points in David et al. (2008) 
indicated that patients scoring 6 or less had demonstrated reliable change. A comparison of 
published and Jacobson results revealed that (i) published and Jacobson rates were identical 
in only one study, (ii) published rates were higher where published criterion scores on 
measures were less stringent than Jacobson score criteria, (iii) the use of additional outcome 
criteria in studies that used identical score criteria to those of the Jacobson method produced  
rates that differed substantially from Jacobson rates. 
 
Table 19 shows that the published clinical significance criteria closely approximated those 
of the Jacobson method in two studies where the HRSD score criterion was identical to that 
of the Jacobson method (DeRubeis et al., 2005; Salminen et al., 2008).  Consequently, the 
published completer sample remission rates in Salminen et al. (2008) were identical to 
Jacobson recovery rates for both ADM and STPP at 68% and 57% respectively.  However, 
DeRubeis et al. (2005) included a small number of patients with an HRSD score greater than 
7 as remitted in their results. Consequently, the published remission rates of 46% for ADM 
and 40% for CBT were both 2% higher than the corresponding Jacobson recovery rates.  
                                                 
13 Salminen et al. (2008) was excluded as no LOCF data was available 
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Table 19. Post-treatment Clinical Significance Rates: A Comparison of Results based on  
Published & Jacobson Method Criteria. 
 
Study Treatment  n Published criterion Sample Published 
(%) 
Jacobson 
(%) 
Constantino et al. (2008) CBT 11 BDI ≤ 15 ITT 55 36 
 ICT 11   82 27 
David  et al. (2008) ADM 57 HRSD ≤ 6 & no MDD ITT 50 46α 
 CBT 56   50 46α 
 REBT 57   45 42α 
DeRubeis et al. (2005) ADM 120 HRSD ≤ 7 ITT 46 44 
 CBT 60   40 38 
Jacobson  et al. (1996) AT 43 BDI ≤ 8 & no MDD ITT 51 56 
 BA 56   46 57 
 CBT 50   56 62 
Jarrett et al. (1999) ADM 36 HRSD ≤ 9 ITT 58 50 
 CBT 36   58 47 
 Placebo 36   28 22 
Salminen et al. (2008) ADM 19 HRSD ≤ 7 Completer 68 68 
 STPP 21   57 57 
Key: AT = Coping with automatic thoughts;  BA = Behavioural activation;  BDI = Beck Depression Inventory;  
CBT = Cognitive Behavioural Therapy;  HRSD = Hamilton Rating Scale for Depression;  ICT = Integrative 
cognitive therapy;  REBT = Rational Emotive Behavioural Therapy;   STPP = Short Term Psychodynamic 
Psychotherapy.   
α: BDI data only 
 
 
 
The use of idiosyncratic criteria in the remaining studies could lead to published clinical 
significance rates that (i) differed markedly from Jacobson method rates (ii) changed the 
observed relative efficacy of treatments. For example, the published response criterion (BDI 
≤ 15) in Constantino et al. (2008) was far less stringent than the Jacobson method (BDI ≤ 8).  
This produced published clinical significance rates of 55% for CBT and 82% for ICT which 
contrasted greatly with the corresponding Jacobson rates of 36% and 27% respectively. 
Consequently, the published advantage for ICT was reversed in favour of CBT according to 
Jacobson rates. This was the most extreme example of the difference between published and 
Jacobson rates. However, Table 19 shows that substantial differences also occurred in 
Jacobson et al. (1996) and Jarrett et al. (1999).   
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The BDI score criterion in Jacobson et al. (1996) was identical to that of the Jacobson 
method (BDI ≤ 8). Despite this, the requirement that patients were no longer depressed 
resulted in Jacobson recovery rates that were at least 5% higher than published.  In addition 
Table 19 reveals that the differences between published and Jacobson rates were not 
consistent between treatments. For example, the Jacobson recovery rates for the AT and 
CBT groups were 5% and 6% higher than published rates respectively.  This contrasted with 
the BA group where Jacobson rates were 11% higher than published. Consequently, the 
Jacobson method identified that BA was more efficacious than AT in contrast to published 
results.   
 
In Jarrett et al. (1999), the criterion for response only required that patients score less than 9 
on the HRSD. However, the use of a less stringent criterion than that of the Jacobson method 
produced published rates that were between 6% and 11% higher than the corresponding 
Jacobson rates. For example, the published rates for placebo and CBT were 28% and 58% 
respectively whilst the corresponding Jacobson rates were 22% and 47%. In addition, the 
Jacobson method revealed that more patients recovered in the ADM group (50%) compared 
to CBT (47%). This contrasted with published results where response rates were identical. 
Finally, a comparison of results for David et al. (2008) shows that published remission rates 
were consistently higher than Jacobson recovery rates.  However, it was not possible to 
determine the reason for this as Jacobson method and published rates were based on 
different measures.  
 
 
6.3.4 Jacobson Recovery: Agreement Between Measures in the Same Sample 
An examination of the results in Table 17 and Table 18 for the 3 studies that used both the 
BDI and HRSD showed that (i) only the HRSD categorised any patient as worse, (ii) HRSD 
recovery rates were always higher or equal to BDI recovery rates in ITT samples. However, 
because BDI and HRSD data for drop-outs may have been obtained at different points 
during treatment, the ITT results in Table 17 and Table 18 were unsuitable for comparing 
the level of agreement between measures. Consequently, agreement between the BDI and 
HRSD for recovery was examined using the completer
14
 samples of Jacobson et al. (1996), 
Jarrett et al. (1999) and Salminen et al. (2008).  Table 20 presents a breakdown of the overall 
BDI and HRSD recovery rates for groups in studies in terms of the percentage who 
recovered according to (i) both the BDI and HRSD, (ii) the BDI only, (iii) the HRSD only.  
In Table 20 the ‘BDI & HRSD’ recovery rate (the ‘dual rate’) for each group denotes the 
                                                 
14 All patients were assessed on both measures at pre- and post-treatment. 
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percentage of patients who recovered on both the BDI and HRSD. The ‘BDI only’ and 
‘HRSD only’ rates denote the percentage of patients who recovered only on the BDI or 
HRSD respectively.  
 
 
Table 20. Overall Percentage Recovery Rates on the BDI or HRSD:  Comparisons with 
Recovery on Both Measures, the BDI Alone and the HRSD Alone. 
 
Study Treatment  Recovered on:  Overall recovery: 
  n 
BDI & 
HRSD* 
BDI 
only 
HRSD 
only 
 BDI HRSD 
Jacobson et al. (1996) AT 37 59.5  2.7 13.5  62.2 73.0 
 BA 48 47.9 12.5 12.5  60.4 60.4 
 CBT 47 55.3  8.5 14.9  63.8 70.2 
Jarrett et al. (1999) ADM 27 51.9 11.1 14.8  63.0 66.7 
 CBT 31 41.9  9.7  9.7  51.6 51.6 
 placebo 13 53.8  7.7  7.7  61.5 61.5 
Salminen et al. (2008) ADM 19 42.1 0 26.3  42.1 68.4 
 STPP 21 47.6 0  9.5  47.6 57.1 
Pooled total  243 50.6 7.4 13.6  58.0 64.2 
* ‘dual recovery’ 
 
 
 
The pooled results across all treatments show that the overall recovery rate for the HRSD 
was 6.2% higher than the overall rate for the BDI (64.2% versus 58% respectively). 
However, the finding that only 50.6% recovered according to both measures, that 7.4% 
recovered only on the BDI and that 13.6% recovered only on the HRSD suggested that 
agreement between measures was low. In addition, within some individual studies the 
agreement between overall BDI and HRSD rates was poor for some treatments. For 
example, in Jacobson et al. (1996) overall CBT recovery according to the BDI was 63.8%, 
whereas on the HRSD it was 70.2%. The poor agreement between overall BDI and HRSD 
rates meant that the rank order of treatments in Jacobson et al. (1996) and Salminen et al. 
(2008) differed according to the BDI and HRSD.  
 
An inspection of the results in Table 20 for each group shows that the overall recovery rate 
for a specific measure equalled the dual rate plus the proportion of patients who recovered 
only on that measure.  The table reveals that the identical overall BDI and HRSD rates in 3 
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of the 8 groups were the same only because the same percentage of patients recovered only 
on the BDI as only recovered on the HRSD (BA in Jacobson et al., 1996; CBT and placebo 
in Jarrett et al., 1999). Thus, the apparently perfect agreement between overall BDI and 
HRSD rates for these groups obscured the fact that 25% of the BA group in Jacobson et al. 
(1996) and 19.4% of the CBT and 15.4% of the placebo groups in Jarrett et al. (1999) 
recovered on only a single measure.  
 
In the remaining 5 groups the percentage recovered only on the HRSD was higher than the 
percentage recovered only on the BDI. Consequently, the overall HRSD rate for each group 
was higher than the overall BDI rate. The magnitude of the difference between overall 
HRSD and overall BDI rates was equal to the ‘HRSD only’ rate minus the ‘BDI only’ rate. 
An examination of the table reveals that the difference between the ‘HRSD only’ and ‘BDI 
only’ rates in each of the 5 groups ranged from 3.7% for ADM in Jarrett et al. (1999) to 
26.3% for ADM in Salminen et al. (2008). This variability produced variable agreement 
between overall BDI and overall HRSD rates in the 5 groups and was partly responsible for 
the BDI and HRSD ranking treatments differently in Jacobson et al. (1996) and Salminen et 
al. (2008).  
 
 
Table 21. Pooled Comparison of Recovery Status according to the BDI or HRSD for 
Completers Assessed on Both Measures (n). 
  HRSD (n)  
  Recovered Unrecovered Total 
BDI (n) 
Recovered  123 18 141 
Unrecovered 33 69 102 
 Total 156 87 243 
 
 
 
In order to quantify agreement concerning Jacobson recovery between the BDI and HRSD, 
the number of patients recovering and not recovering on measures was tabulated. Table 21 
shows the number of patients across studies who recovered according to both the BDI and 
HRSD (dual recovery), the BDI only and the HRSD only. The table shows that 123 (50.6%) 
were recovered and 69 (28.4%) were unrecovered according to both measures. Thus, 
agreement in simple percentage terms between measures was 79%. However, the chance 
adjusted agreement rate between the BDI and HRSD was only 56%  (Kappa = .56, p <.001).  
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6.4 Discussion   
6.4.1 Treatment Efficacy According to the Jacobson Method 
The primary aim of this study was to use a standard recovery definition to quantify the 
efficacy of psychological treatments for depression. Of the seven studies that provided IPD 
for the present study, only one (Dekker et al., 2008) provided data that was unsuitable. By 
classifying patients as recovered, improved, unchanged or worse, the Jacobson method 
enabled a clearer understanding of the current level of treatment efficacy than previously 
existed. The overall ITT recovery rates across BDI and HRSD studies of 48.1% and 50.7% 
respectively revealed that approximately 50% of patients entering active treatments did not 
recover.  However, ITT recovery rates in different studies were highly variable and ranged 
from 27.3% (ICT in Constantino et al., 2008) to 62% (CBT in Jacobson et al., 1996) on the 
BDI, and from 38.3% (CBT in DeRubeis et al. 2005) to 66% (CBT in Jacobson et al., 1996) 
on the HRSD.  
 
An analysis of IPD showed that the overall attrition rate for active treatments across studies 
was 13.7% and that the majority of drop-outs were unchanged on measures. This suggested 
that patients who did not benefit from treatment were more likely to drop-out than those who 
experienced an improvement in symptoms. Whilst this could not be investigated using the 
IPD provided by authors, it was found that post-treatment recovery rates in completer 
samples were typically higher than in ITT samples. Overall completer recovery for active 
treatments was 53% in BDI studies and 58.2% in HRSD studies. These results show that the 
provision of a full course of treatment left a large proportion of patients unrecovered. As 
seen for ITT samples, completer recovery rates in individual studies were highly variable 
and ranged from 25% (CBT in Constantino et al., 2008) to 63.8% (CBT in Jacobson et al., 
1996) on the BDI and from 44% (CBT in DeRubeis et al., 2005) to 71.1% (AT in Jacobson 
et al., 1996) on the HRSD. However, no significant differences were found on either 
measure between the active treatments within studies in both ITT and completer samples.   
 
It is important to consider the efficacy rates reported here in light of research which 
demonstrates that that approximately 20% of mildly
15
 depressed wait-list control patients 
will spontaneously recover over a 4 to 8 week period (Posternak and Miller, 2001). The 
placebo recovery rate in Jarrett et al.’s (1999) ITT sample did show that 22% of those 
receiving a sham treatment recovered over 10 weeks. This suggested that the active 
components of ADM and psychotherapy increased recovery over placebo in ITT samples by 
28% and 25% respectively. Unfortunately, the lack of non-treatment control data for 
                                                 
15 Pre-treatment BDI or HRSD score of 20 or less  
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remaining studies meant it was not possible to estimate the benefit of treatments over 
placebo nor to definitively confirm that treatments were more efficacious than placebo 
(Klein, 1996) .  
 
6.4.2 Comparisons of Published & Jacobson Method Clinical Significance Rates 
The published clinical significance rates of studies were compared with Jacobson method 
rates for the corresponding outcome measure. The one exception was David et al. (2008) 
where published rates based on the HRSD were compared with Jacobson rates based on the 
BDI. Comparisons showed that published rates were consistently higher than Jacobson rates 
in 4 studies (Constantino et al., 2008; David et al., 2008; DeRubeis et al., 2005; Jarrett et al., 
1999) and consistently lower in one (Jacobson et al., 1996). Only Salminen et al. (2008) 
published clinical significance rates that were identical to Jacobson method rates. The rank 
order of treatment efficacy differed according to published and Jacobson criteria in 3 studies 
(Constantino et al., 2008; Jacobson et al., 1996; Jarrett et al., 1999). These results revealed 
that the use of idiosyncratic clinical significance criteria typically overestimate recovery and 
prohibit a meaningful comparison of study outcomes. 
 
An analysis of IPD showed that every patient who achieved a clinically significant outcome 
according to published criteria had changed reliably on measures. This meant that any 
disagreement between published and Jacobson method rates was due to differences in the 
definition of a clinically significant outcome.  The published and Jacobson method recovery 
rates in Salminen et al. (2008) were identical because published and Jacobson criteria were 
effectively the same. However, two studies using the same score criterion as the Jacobson 
method published different results to those of the Jacobson method (DeRubeis et al., 2005; 
Jacobson et al., 1996). The disagreement between published and Jacobson method rates in 
DeRubeis et al. (2005) and Jacobson et al. (1996) occurred because additional published 
recovery criteria were employed. DeRubeis et al. (2005) published recovery rates that were 
2% higher than the Jacobson rates for ADM and CBT because they included patients who 
had consistently met the HRSD recovery criterion prior to post-treatment assessment. 
Because DeRubeis et al.’s published rates were based on multiple assessments it may be 
argued that they were more accurate than Jacobson rates which were calculated using only 
pre- and post-treatment data. However, the consistent  2% difference between published and 
Jacobson rates suggested that unreliable symptomatic worsening is relatively rare and 
unlikely to bias conclusions based on the Jacobson method. Jacobson et al. (1996) used the 
same BDI score criterion as the Jacobson method but published lower recovery rates due to 
an additional requirement that patients were no longer depressed according to DSM III 
criteria. The published recovery rates for individual treatments in Jacobson et al. (1996) 
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were between 5% to 11% lower than Jacobson method rates. This meant that 12.6% of all 
patients that recovered according to the Jacobson method in this study were still depressed. 
This indicated that the BDI provided insufficient coverage of the symptom criteria required 
for a DSM III diagnosis of MDD. 
 
The published score criteria used to define clinical significance in the three remaining 
studies differed from those of the Jacobson method (Constantino et al., 2008; David et al., 
2008; Jarrett et al., 1999). The published HRSD recovery criteria in David et al. (2008) were 
more stringent than the Jacobson method HRSD criteria because patients were required to 
score 1 point lower on the HRSD and no longer be depressed according to DSM IV 
diagnostic criteria. The finding that David et al.’s published rates based on the HRSD were 
at least 3% higher than Jacobson rates based on the BDI suggested that Jacobson method 
BDI rates were more stringent than published criteria. However, the unavailability of HRSD 
data for patients in David et al. (2008) meant that the reason for this could not be explored 
further. In Constantino et al. (2008) and Jarrett et al. (1999) published comparisons were 
based on different definitions of treatment response. Constantino et al. (2008) defined 
response as a score of 15 or less on the BDI
16
, whereas Jarrett et al. (1999) employed a score 
of 9 or less on the HRSD. Therefore, the published criteria employed in both of these studies 
were less stringent than the corresponding Jacobson method criteria. Consequently, 
published rates for the groups in Constantino et al. (2008) and Jarrett et al. (1999) could 
exceed Jacobson rates by as much as 55% and 11%  respectively.  
 
6.4.3 Agreement Between the BDI & HRSD 
The BDI and HRSD are two of the most widely used outcome measures used in depression 
treatment studies. Consequently, the degree to which these measures agree concerning 
depressive symptomatology is of fundamental importance where study results are compared 
or combined in meta-analysis.  A comparison of overall Jacobson recovery on the BDI with 
Jacobson recovery on the HRSD in the same sample revealed that the chance adjusted 
agreement between measures was 56% (kappa = 0.56) and that the rank order of treatments 
in studies could change between measures. The relatively low level of agreement between 
the BDI and HRSD was due to a substantial minority of patients recovering only on a single 
measure. However, twice as many patients recovered only on the HRSD as did only on the 
BDI. This finding accords with previous research showing greater symptomatic reduction on 
the HRSD compared to the BDI in the same sample (Lambert et al., 1986). However, the 
comparison of Jacobson recovery rates with the published results in Jacobson et al. (1996) 
                                                 
16 Constantino et al. (2008) also required that symptomatic change was reliable. 
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indicated that the BDI provided insufficient coverage of depressive symptomatology. This, 
and the evidence that recovery on the HRSD may be a less stringent test of efficacy than 
recovery on the BDI suggests that Jacobson recovery on both measures is a better indicator 
of no longer meeting diagnostic status for an MDE. The symptomatic coverage offered by 
the use of both measures may thus accord with ACNP Task Force (Rush et al., 2006) 
recommendation that all of the DSM IV criteria (Table 1) assessed in diagnosis be assessed 
at post-treatment. 
 
There are limitations which may affect the conclusions reached in this study. Firstly, IPD 
was not available for all eligible treatment studies which might have limited the 
representativeness of results. Also, studies varied in the exact version of the HRSD 
employed which was a potential confound. More importantly, the paucity of follow-up data 
meant it was not possible to assess whether the gains made during treatment persisted, or 
whether an increasing percentage of patients recovered during follow-up. A final limitation 
was that it was not possible to compare individuals’ Jacobson recovery status with 
diagnostic status.  
 
 
6.5 Summary & Concluding Remarks 
The results of the primary analysis showed that, overall, between 50% to 60% of patients 
entering an active treatment failed to achieve  recovery as assessed by the Jacobson method. 
This indicated that there is considerable room to improve the efficacy of treatments for 
major depression.  
 
However, whilst there was a considerable range of recovery rates between studies, there was 
no evidence to suggest that the relative efficacies of specific types of active treatment in 
individual studies were significantly different. Thus, there was no evidence that the efficacy 
of specific psychotherapy types were different, or that medication was superior to 
psychotherapy. These latter conclusions were consistent with the published findings of 
individual  studies which frequently employed different criteria to those of the Jacobson 
method. However, the use of idiosyncratic recovery criteria meant that published recovery 
rates were typically higher than those of the Jacobson method, and, considerably so where 
published results were based on less stringent score criteria on measures. Moreover, in 
addition to overestimating the efficacy of treatments, the use of idiosyncratic published 
recovery criteria could lead to changes in the rank ordering of treatments in individual 
studies in comparison to rates based on the Jacobson method. Consequently, the use of 
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idiosyncratic recovery criteria means that a balanced appraisal of outcomes for specific 
treatments across studies is problematic. 
 
Finally, the results showed that agreement between measures was low and that Jacobson 
recovery rates  on the HRSD were higher than on the BDI in samples assessed on both.  A 
potential explanation for this was that neither of these measures adequately captures the full 
range of depressive symptomatology.  This may suggest that Jacobson recovery on both 
measures is a better indicator of a return to the normative range of depressive 
symptomatology, or that a measure with better construct validity for major depressive 
disorder is required to accurately assess  treatment outcomes in major depressive disorder. 
 
 
 
 
 114 
 
Chapter Seven  
 
Study 3   
 
Does Severity of Depression at Pre-treatment Predict  Recovery and 
Response Following Acute Treatment?  
 
7.1 Introduction  
In the previous chapter, the post-treatment efficacy of psychological and pharmacological 
treatments for major depressive disorder was evaluated across 6 studies (Constantino et al., 
2008; David et al., 2008; DeRubeis et al., 2005; Jacobson et al., 1996; Jarrett et al., 1999; 
Salminen et al., 2008) according to the Jacobson method of clinical significance (Jacobson et 
al., 1999). The results showed that no active treatment intervention was superior to any other 
within individual studies. However, it was found that recovery rates following an active 
treatment intervention varied considerably between studies.  Jacobson recovery in intention 
to treat samples (ITT) ranged from 27.3% (Constantino et al., 2008) to 62.0% (Jacobson et 
al., 1996) on the self-rated Beck Depression Inventory (BDI, Beck et al., 1961), and from 
38.3% (DeRubeis et al., 2005) to 66.0% (Jacobson et al., 1996) on the clinician rated 
Hamilton  Rating Scale for Depression (HRSD, Hamilton, 1960). 
 
The patient characteristic with most empirical support concerning its influence on outcome 
is pre-treatment symptom severity (Hamilton and Dobson, 2002). Evidence indicates that 
higher levels of depressive symptoms at pre-treatment are predictive of poorer treatment 
outcomes and the need for longer lasting treatment (Shapiro et al., 1994). For example, in a 
sample of 37 CBT patients, Jarrett et al. (1991) found that increased BDI or HRSD pre-
treatment severity predicted higher scores on the same measure following acute treatment.  
More recently, in a sample of 318 outpatients, Frank et al. (2011) found that increasing pre-
treatment HRSD score was a non-specific predictor of increased time to remission (defined 
as an HRSD score ≤ 7) across both anti-depressant medication (ADM) and interpersonal 
therapy (IPT). Thus, Frank et al. (2011) found no evidence for an interaction between pre-
treatment severity and the efficacy of specific treatments.  
 
However, the results of the influential Treatment of Depression Collaborative Research 
Program (TDCRP, Elkin et al., 1989) revealed that, when compared to placebo, the relative 
efficacy of treatments did significantly change as a function of HRSD pre-treatment severity. 
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For example, Elkin et al. (1989) compared HRSD symptomatic improvement between 
ADM, IPT and CBT separately for two levels of pre-treatment HRSD severity. Less severe 
depression was defined as a pre-treatment HRSD score of 19 points or less, whilst more 
severe depression was defined as a score of 20 points and above (Elkin et al., 1989). 
Treatments were compared using analysis of covariance (ANCOVA) with marital status as 
covariate. The results showed that whilst ADM, IPT and CBT were no different to placebo 
in less severe samples, both ADM and IPT were superior to placebo in more severe samples. 
The same conclusions were reached when treatments for each sample were compared in 
terms of remission which was defined as a post-treatment HRSD score of 6 or less (Elkin et 
al., 1989). The finding that CBT was no different to placebo in either severity group 
contrasted with those for ADM and IPT. It also suggested that significant differences 
between the efficacy of active treatments may emerge at different pre-treatment severities. 
Indeed, in a more recent analysis of the TDCRP results, Elkin et al. (1995) did show that 
symptomatic improvement according to the BDI or HRSD in both ADM and IPT groups 
was superior to CBT in severe depression. Elkin et al. (1995) compared treatments using 
random regression models that provided greater statistical power than previously due to the 
inclusion of interim outcome data  (Elkin et al., 1995). However, the validity of Elkin et al.’s 
(1995) findings has been challenged on the basis that slower response to treatment in the 
CBT group led to a biased estimate of its post-treatment efficacy within ITT analyses 
(Jacobson and Hollon, 1996).  
 
The TDCRP results (Elkin et al., 1995; Elkin et al., 1989) have influenced the development 
of guidelines that recommended the use of medication over psychotherapy in the treatment 
of severe depression (DeRubeis et al., 1999; Driessen et al., 2010). However, conclusions 
concerning the efficacy of any treatment needs to be based on empirical evidence from more 
than one study (Chambless and Hollon, 1998).  In order to determine whether the efficacy of 
ADM was superior to CBT in severe depression, DeRubeis et al. (1999) conducted a ‘mega-
analysis’ of ITT post-treatment BDI and HRSD data from 4 methodologically similar studies 
(Rush et al., 1977; Murphy et al., 1984; Hollon et al., 1992; Elkin et al., 1989). DeRubeis et 
al. (1999) obtained individual patient data (IPD) from original study authors which enabled 
them to compare symptomatic improvement between ADM and CBT in patients who scored 
20 or more on the HRSD. In deriving more severely depressed sub-samples from original 
study data, DeRubeis et al. (1999) found that the BDI mean pre-treatment severities for 
ADM and CBT in Murphy et al. (1984) were significantly different. Consequently, 
symptomatic improvement following ADM or CBT was compared using ANCOVAs that 
controlled for patients’ pre-treatment severity (DeRubeis et al., 1999). Results for both the 
BDI (n = 132) and HRSD (n = 169) failed to demonstrate a significant difference between 
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ADM and CBT both within and across the four studies (DeRubeis et al., 1999). Thus, after 
controlling for individual differences in pre-treatment severity, DeRubeis et al. (1999) found 
no empirical evidence to support the superiority of ADM over CBT in severe depression.  
 
It is apparent then, that pre-treatment severity is likely to be an important prognostic factor 
in the treatment of depression. The evidence indicates that higher severity patients 
demonstrate lower levels of symptomatic improvement (Jarrett et al., 1991) and that active 
treatments may be no more efficacious than placebo in less severe depression (Elkin et al., 
1995; Elkin et al., 1989). In addition, the TDCRP results (Elkin et al., 1989) also highlighted 
the possibility that some types of treatment may be more effective than others in severe 
depression. Nevertheless, Elkin et al.’s (1995) controversial conclusion that ADM was 
superior to CBT has not been supported in analyses of evidence from multiple studies that 
controlled for pre-treatment severity (DeRubeis et al., 1999).  
 
However, there are several methodological limitations that may have influenced the results 
of the studies described here. Firstly, no study controlled for the less than 100% reliability of 
the symptom measures employed in treatment comparisons. It is possible that the 
conclusions reached in individual studies were confounded by symptomatic change that 
could not be attributed to the effect of treatment. For example, it is impossible to know to 
what degree unreliable symptomatic change influenced the conclusions in Jarrett et al. 
(1991). It is also unclear to what degree unreliable symptomatic change affected estimates of 
mean symptomatic improvement that both Elkin et al. (1989) and DeRubeis et al. (1999) 
used to compare treatments. However, this method is itself unsatisfactory as it provides no 
information concerning the clinical significance of treatment differences which may 
themselves be statistically significant (Jacobson et al., 1999).  A second limitation was that 
whilst Elkin et al. (1989) did compare clinically significant outcomes for ADM, IPT and 
CBT with placebo in more severe samples, they used an HRSD remission criterion of 6 or 
less. This was more stringent than the recovery criterion of 7 or less which was  shown to 
best represent a return to normal functioning according to the Jacobson Method in chapter 6.  
Consequently, Elkin et al.’s (1995) finding that both ADM and IPT, but not CBT, were 
superior to placebo in severe samples was possibly based on an analysis that excluded some 
non-depressed patients. Finally, in the TDCRP Elkin et al. (1989) investigated the influence 
of pre-treatment severity on the relative efficacy of treatments compared to placebo using 
dichotomised samples. Consequently, their finding that CBT was no different to placebo in 
more severe depression may have capitalised on chance, as the HRSD cut-score used to 
define more severe depression was exploratory despite being selected a priori (Elkin et al., 
1989).  
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The main purpose of this study was to determine whether pre-treatment severity on the BDI 
or HRSD predicted clinically significant recovery according to the methodology outlined by 
Jacobson and colleagues (Jacobson et al., 1984; Jacobson and Truax, 1991). Individual 
patient data derived from the studies described in chapter 6 were employed in hierarchical 
binary logistic regression analyses that used pre-treatment severity as the independent 
variable and Jacobson recovery status as the dependent variable. The use of Jacobson 
recovery status as a common outcome metric meant that limitations arising from 
idiosyncratic definitions of clinical significance and unreliable symptomatic change were 
avoided. It was hypothesised that increasing pre-treatment severity would significantly 
reduce the probability of Jacobson recovery on either measure. A secondary aim was to 
determine whether pre-treatment severity on the BDI or HRSD predicted Jacobson response, 
which was defined as a statistically reliable reduction in symptom score according to the 
Jacobson methodology (Jacobson and Truax, 1991).  Hierarchical binary logistic regression 
analyses similar to those for Jacobson recovery status were undertaken but with Jacobson 
response status as the dependent variable. The exploratory nature of the Jacobson response 
analyses meant that no hypothesis was formed. 
 
 
7.2 Method 
The present study consisted of four one-stage fixed-effects IPD meta-analyses (Simmonds et 
al., 2005) employing hierarchical binary logistic regression. The four analyses examined 
whether pre-treatment severity predicted (i) Jacobson recovery and (ii) Jacobson response on 
the BDI and HRSD. Each analysis was stratified by study, treatment type and gender in 
order to reduce potential confounds due to baseline differences in recovery or response 
between the levels of each covariate (Simmonds et al., 2005; van Walraven, 2010). This 
method provided a more flexible and powerful approach than conventional meta-analysis by 
which to (i) examine the effect of pre-treatment severity on recovery or response and (ii) 
detect the existence of significant interactions between covariates (Higgins et al., 2001; 
Simmonds et al., 2005).   
 
7.2.1 Individual Patient Data Used In Logistic Regression Analyses 
The sample comprised selected individual patient data (IPD) from the BDI and HRSD 
studies described in study 2.  Data for each patient consisted of pre-treatment severity and 
Jacobson recovery/response status on measures, study, treatment type (ADM or 
psychotherapy) and gender.  To ensure that  patient attrition did not confound results as a 
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result of swifter onset of ADM effects, only IPD for active treatment completers were used 
in analyses.  IPD from 4 of 5 available studies were employed in BDI analyses (David et al., 
2008; Jacobson et al., 1996; Jarrett et al., 1999; Salminen et al., 2008). Constantino et al. 
(2008) was excluded from BDI analyses because the inclusion of IPD for only 22 patients 
meant that sparse data (Cohen et al., 2003) led to poor model fit in preliminary analyses.  
IPD from 4 of 5 available studies were employed in HRSD analyses (DeRubeis et al., 2005; 
Jacobson et al., 1996; Jarrett et al., 1999; Salminen et al., 2008). Dekker et al. (2008) was 
excluded because IPD from this study did not correspond to a full course of treatment. 
Because a variety of pharmacological and psychological interventions were used across 
studies, treatment type was broadly categorised as either ADM or psychotherapy (see study 
2 for details).   
 
7.2.2 Data Analytic Strategy 
The method below applies to all four regression analyses. For ease of presentation, the 
descriptions refer only to Jacobson recovery.  
 
Included variables 
Each analysis was a two-step, forced hierarchical binary logistic regression, with Jacobson 
recovery status as the dependent variable. Pre-treatment severity was entered as the predictor 
variable. The categorical variables study, treatment type and gender were entered as 
covariates. The inclusion of covariates meant that the existence of significant 1
st
 order 
interactions between variables could be examined at the second step. Apart from study and 
treatment type, the only covariate provided for all patients across  IPD studies was gender. 
This was included in regression models as some studies have reported significant 
interactions between gender and treatment type (Bigos et al., 2009; Parker et al., 2011). 
 
Order of variables entered and coding scheme 
Variables were entered into regression models according to the order shown in Table 22. 
The method of variable entry followed recommendations by Frazier et al. (2004). At step 1, 
the covariates study, treatment type (treatment), gender and pre-treatment severity (severity) 
were entered simultaneously. At step 2, all 1
st
 order interaction terms for the variables 
entered at step 1 were included in the model. Table 22 also describes the meaning of a 
significant regression coefficient for each variable.  
 
For categorical variables, effects coding was employed to ensure that the effect of each 
individual variable was calculated at the average effect of remaining variables (Cohen et al., 
2003). For example, the two levels of the categorical variable ‘treatment’ were coded as -1 
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for ADM and +1 for psychotherapy, whilst ‘gender’ was coded as -1 for males and +1 for 
females.  This meant that where Btreatment = 0, the Bgender coefficient referred to the log-odds 
of recovery in either males (-Bgender) or females (+Bgender) averaged across both ADM and 
psychotherapy. The difference between the log-odds of male and female recovery in this 
example is given by the difference between their respective coefficients (2 x Bgender). The use 
of effects coding also meant that the constant (B0) at each step in regression models 
represented the log-odds of recovery after controlling for the effects of all included 
variables.  The continuous variable pre-treatment severity (BDI or HRSD) was centred at the 
sample mean in order to eliminate non-essential collinearity and produce interpretable 
regression coefficients (Cohen et al., 2003). To obtain a centred score for each patient, the 
sample mean pre-treatment severity was subtracted from their pre-treatment score. Centring 
meant that the regression coefficients of categorical variables referred to patients whose pre-
treatment severity was equal to the sample mean severity.  
 
The validity of results and their interpretation 
Multicollinearity tests for the variables entered at step 1 were performed and tolerance 
values greater than 0.2 were taken to indicate that unstable regression coefficients did not 
threaten the validity of final models (Cohen et al., 2003). Models were also checked for bias 
arising from influential cases by examining the predicted probability, standardised residual, 
Cook’s distance analogue, leverage and DFBeta values for each case in analyses (Cohen et 
al., 2003).   
 
The results of each valid regression analysis were examined to determine the significance of 
each step, of the overall model, and of individual regression coefficients. Where a significant 
B coefficient was identified for a variable within a significant model, the predicted log-odds 
of recovery were calculated for each level of that variable. Subsequently, the predicted log-
odds for each level were transformed into odds in order to calculate the more interpretable 
predicted probability of recovery (p) as given by the following relationship:  
 
p = odds/(1 + odds). 
 
The predicted probabilities of recovery for each level of significant variables were then 
plotted as a function of pre-treatment severity on the BDI or HRSD.  The statistical package 
SPSS (version 12) was used to perform the regression analyses whose results are presented 
in tabular form.  Microsoft Excel 2007 was used to calculate and plot the predicted 
probabilities across the range of BDI and HRSD pre-treatment severities.  
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Table 22. Variables Entered in Hierarchical Binary Logistic Regression Analyses 
Investigating  Jacobson Method Recovery & Response. 
Variable  Significant Result for Variable Indicates: 
STEP 1  
Study† Recovery* rates differed between studies 
Treatment Recovery rates differed between treatments 
Gender Recovery rates differed between genders 
Severity Recovery rates differed as a function of pre-treatment severity  
STEP 2  
Study x Treatment Recovery rates for ADM and psychotherapy differed in at least one study 
Study x Gender Recovery rates for males and females differed in at least one study.  
Study x Severity Recovery rates differed between studies as a function of pre-treatment severity 
Treatment x Gender Recovery rates differed between genders across treatments 
Treatment x Severity Recovery rates differed between treatments as a function of pre-treatment severity 
Gender x Severity Recovery rates differed between genders as a function of pre-treatment severity  
† Refers to the overall significance of including Study in the model. To aid clarity, individual study coefficients 
are not described for Study nor its interaction terms. 
 
* Response may be substituted for recovery throughout the table  
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7.3 Results 
The first sections present the following descriptive statistics for each level of treatment type 
and gender across BDI and HRSD studies; (i) comparisons of the mean pre-treatment 
severity between recovered and unrecovered groups, (ii) comparisons of the mean pre-
treatment severity between responders and non-responders (‘no change’), (iii) Jacobson 
recovery and response rates.  Following this, the results of the binary logistic regression 
analyses for Jacobson recovery and response in BDI and HRSD studies are presented.  
 
7.3.1 Pre-treatment Severity, Recovery & Response across BDI & HRSD Studies  
Table 23 presents the pre-treatment means of recovered versus unrecovered completers by 
treatment type and gender across BDI and HRSD studies. Table 24 presents the pre-
treatment means of responders versus non-responders by treatment type and gender across 
BDI and HRSD studies. Significant differences between the pre-treatment means of the 
groups in Table 23 and Table 24 were examined using t-tests with Bonferroni corrections to 
adjust for multiple comparisons.   
 
In terms of Jacobson recovery, Table 23 shows that  there were no significant differences 
between the mean pre-treatment severity of recovered and unrecovered patients in any BDI 
group. For the HRSD, the overall mean pre-treatment severity was higher in unrecovered 
patients than in recovered (t = 4.03, p < .01). However, no differences were found between 
the pre-treatment means of the remaining HRSD groups in Table 23.  A comparison of  the 
post-treatment means between recovered and unrecovered patients within the groups in 
Table 23 was undertaken using t-tests adjusted for multiple comparisons. The results showed 
that for both the BDI and HRSD, the post-treatment mean of unrecovered patients within all 
groups was significantly higher than that of recovered patients (all p < .01). 
 
In terms of Jacobson response, Table 24 shows that the overall mean pre-treatment severity 
of responders was significantly higher than that of non-responders in BDI studies (t = 6.6, p 
< .01). Furthermore, Table 24 reveals that the BDI pre-treatment mean in responders was 
significantly higher than in non-responders for the ADM (t = 3.8, p < .01), psychotherapy (t 
= 5.5,  p < .01), male (t = 6.6,  p < .01) and female groups (t = 3.6, p < .05). In contrast, there 
were no significant differences between the pre-treatment means of responders and non-
responders within any of the HRSD groups in Table 24. A comparison of post-treatment 
means within the groups in Table 24 showed that for both measures, the post-treatment mean 
of non-responders was significantly higher than that of responders (all p < .01). 
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Table 23. BDI & HRSD Pre-treatment Mean Severity by Jacobson Recovery Status for 
Treatment Type & Gender.  
   Recovered  Unrecovered    
Group N  n Mean s.d.  n Mean s.d.  t df 
BDI             
 Overall† 383  208 28.0  8.4  175 29.5  9.7  1.6 346.0 
 ADM 95  50 27.1 10.0  45 28.4  11.1  0.6 93 
 Psychotherapy 288  158 28.2  7.8  130 29.9  9.2  1.6 286 
 Males 109  56 29.4 10.1  53 27.1  10.5  1.1 107 
 Females 274  152 27.4  7.6  122 30.5  9.2  3.0 233.3 
HRSD             
  Overall† 383  223 19.6  4.3  160 21.4  4.3  4.0* 381 
 ADM 147  84 20.9  4.3  63 22.9  4.1  2.9 145 
 Psychotherapy 236  139 18.8  4.2  97 20.4  4.2  2.9 234 
 Males 123  63 19.8  4.5  60 22.0  4.2  2.9 121 
 Females 260  163 19.5  4.3  97 21.0  4.4  2.7 258 
 p  < .01 adjusted for multiple comparisons (Bonferroni). 
†   Identical overall patient numbers in BDI and HRSD studies was coincidental. 
 
 
 
Table 24. BDI & HRSD Pre-treatment Mean Severity by Jacobson Response Status for 
Treatment Type & Gender.  
   Responded  No Change    
Group N  n Mean s.d.  n Mean s.d.  t df 
BDI             
 Overall† 383  305 29.9 9.2  78 23.9 6.4  6.6* 166.6 
 ADM 95  76 29.3 10.6  19 21.3 7.5  3.8* 38.2 
    Psychotherapy 288  229 30.1 8.7  59 24.8 5.9  5.5* 131.0 
 Males 109  81 30.8 10.4  28 20.9 5.1  6.6* 94.8 
 Females 274  224 29.5 8.7  50 25.6 6.5  3.6α 92.1 
HRSD             
 Overall† 383  329 20.6 4.4  54 18.8 3.9  2.8 381 
 ADM 147  129 22.0 4.3  18 20.1 4.0  1.8 145 
    Psychotherapy 236  200 19.7 4.3  36 18.2 3.8  2.0 234 
 Males 123  105 21.2 4.5  18 19.7 4.4  1.3 121 
 Females 260  224 20.3 4.4  36 18.4 3.6  2.5 258 
*    p  < .01 adjusted for multiple comparisons (Bonferroni). 
α    p  < .05 adjusted for multiple comparisons (Bonferroni). 
†   Identical overall patient numbers in BDI and HRSD studies was coincidental 
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7.3.2 Percentage Recovering & Responding across BDI & HRSD Studies 
Table 25 presents the percentage of active treatment completers across BDI and HRSD 
studies who recovered or responded
17
 at post-treatment according to Jacobson’s criteria. The 
results presented in Table 25 should be considered as descriptive as they did not take the 
following potential confounds into account; (i) ADM and psychotherapy rates were not 
derived from studies that had all made direct comparisons between treatments, (ii) male and 
female rates did not control for treatment or study differences.   
 
 
Table 25. Percentage Recovering & Responding by Treatment Type & Gender across      
BDI & HRSD Studies. 
   Recovered  Responded 
 N  n %  n % 
BDI                        Overall† 383  208 54.3  305 79.6 
ADM 95  50 52.6  76 80.0 
   Psychotherapy 288  158 54.9  229 79.5 
Males 109  56 51.4  81 74.3 
Females 274  152 55.5  224 81.8 
HRSD                    Overall† 383  223 58.2  329 85.9 
ADM 147  84 57.1  129 87.8 
   Psychotherapy 236  139 58.9  200 84.7 
Males 123  63 48.8  105 85.4 
Females 260  163 62.7  224 86.2 
†  Identical patient numbers for BDI and HRSD was coincidental. 
 
 
In terms of Jacobson recovery on the BDI, Table 25 shows that the overall rate was 54.3% in 
a sample of 383 completers. Thus, 45.7% of completers were unrecovered across BDI 
studies at post-treatment. Goodness of fit tests showed that BDI recovery rates did not 
significantly differ between ADM and psychotherapy (52.6% versus 54.9% respectively; χ2 
= 0.14, p = .70), nor between males and females (51.4% versus 55.5% respectively; χ2 = 
0.53,  p = .47).  In terms of Jacobson response on the BDI, Table 25 shows that the overall 
rate was 79.6%.  Thus, 20.4% of completers across the overall BDI sample demonstrated no 
reliable change in symptomatology at post-treatment.  Goodness of fit tests showed that BDI 
response rates did not significantly differ between ADM and psychotherapy (80.0% versus 
79.5% respectively; χ2 = 0.01, p = .92), nor between males and females (74.3% versus 
81.8% respectively; χ2 = 2.66, p = .10).  
                                                 
17 N.B. response = statistically reliable reduction in symptom score 
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In terms of Jacobson recovery on the HRSD, Table 25 shows the overall rate was 58.2% in a 
sample of 383 patients. Thus, 41.8% of completers across the HRSD sample were 
unrecovered at post-treatment. Goodness of fit tests showed that recovery rates did not 
significantly differ between ADM and psychotherapy patients (57.1% versus 58.9% 
respectively; χ2 = 0.12, p = .7). However, goodness of fit tests revealed that the female 
recovery rate across HRSD studies was significantly higher than the male recovery rate 
(62.7% versus 48.8%, χ2 = 6.64, p = .01). In terms of Jacobson response on the HRSD, Table 
25 shows that the overall rate was 85.9%. Thus, 14.1% of completers across the overall 
HRSD sample demonstrated no reliable change in symptomatology at post-treatment. 
Goodness of fit tests showed that response rates did not significantly differ between ADM 
and psychotherapy (87.8% versus 84.7% respectively; χ2 = 0.68, p = .41), nor between males 
and females (85.4% versus 86.2% respectively; χ2 = 0.04, p = .84). 
 
 
7.3.3 Binary Logistic Regression Analyses for Jacobson Recovery  
BDI results  
Table 26 presents the results of the binary logistic regression analysis for Jacobson recovery 
across BDI studies. The independent variables study, treatment type, gender and pre-
treatment severity were regressed on Jacobson recovery status. Pre-treatment BDI severity 
was centred using the overall mean of 28.7 points. Collinearity tests indicated that the 
regression analysis was appropriate as the lowest tolerance value for any of the 1st order 
terms in Table 26 was 0.92.  
 
The results in Table 26 reveal that the variables entered at step1 did not produce a model that 
significantly predicted recovery (step χ2 = 11.3, p = .08). Also, step 2 did not improve 
prediction above that of step 1 (step χ2 = 18.90, p = .06). However, the inclusion of all 
interaction terms at step 2 did produce an overall model that significantly predicted recovery 
(χ2 = 30.2, p = .025). The results for step 2 show that the only the gender x severity 
interaction coefficient was significant (B = -0.03, p = .02).  In order to better understand the 
interaction between gender and severity on BDI recovery, the 1st step analysis presented in 
Table 26 was undertaken separately for males and females (see Table 27). The pre-treatment 
BDI severity used in the male and female analyses were centred using a mean pre-treatment 
BDI score of 28.3 and 28.8 points respectively. Collinearity tests indicated that the 
regression analysis was appropriate as the lowest tolerance value for any of the 1st order 
terms in Table 27 was 0.87. 
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Table 26. Results of Logistic Regression Analysis for BDI Recovery. 
 Step χ2 ΔR2α Variable B p S.E. Odds 
Step 0    Constant   0.17 .09 0.10 1.19 
Step 1 11.30 .04   .08   
   Constant   0.10 .48 0.14 1.11 
   Studyβ  .05   
   Treatment - 0.08 .53 0.13 0.92 
   Gender   0.06 .58 0.12 1.06 
   Severity - 0.02 .08 0.01 0.98 
Step 2
†
 18.90 .06   .06   
   Constant   0.04 .90 0.31 1.04 
   Studyβ  .16   
   Treatment - 0.18 .54 0.30 0.83 
   Gender   0.19 .24 0.16 1.21 
   Severity - 0.04 .09 0.02 0.96 
   Studyβ x Treatment  .87   
   Studyβ x Gender  .81   
   Studyβ x Severity  .08   
   Treatment x Gender - 0.18 .24 0.15 0.84 
   Treatment x Severity   0.00 .80 0.01 1.00 
   Gender x Severity - 0.03 .02 0.01 0.97 
† Model significance = .025;  β: Results for individual studies not shown 
Note: Effects coding employed for all categorical variables. Males, Salminen et al. 
(2008) and ADM served as baseline for Gender, Study and Treatment respectively. 
 
 
Table 27. Results of Logistic Regression Analyses for BDI Recovery by Gender. 
 Step χ2 ΔR2α Variable B p S.E. Odds 
Male:         Step 0   Constant  0.06 .77 0.19 1.06 
Step 1 5.32 .06   .38   
   Constant  - 0.04 .86 0.26 0.96 
   Study
β  .47   
   Treatment  0.11 .66 0.24 1.11 
   Severity  0.02 .34 0.02 1.02 
        
Female:      Step 0   Constant  0.22 .07 0.12 1.25 
Step 1 15.96 .08   .01   
   Constant   0.21 .18 0.16 1.24 
   Studyβ  .08   
   Treatment - 0.19 .24 0.17 0.83 
   Severity - 0.05 .01 0.02 0.95 
α: Nagelkerke’s pseudo R2 ;  β: Results for individual studies not shown 
Note:  Effects coding employed for all categorical variables. Salminen et al. (2008) 
and ADM served as baseline for Study and Treatment respectively. 
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The results for males in Table 27 show that the step 1 model was not significant (χ2 = 5.32, p 
= .38) and that no covariate significantly predicted recovery.  In contrast, the step 1 model 
for females was significant (χ2 = 15.96, p = .01) and revealed that pre-treatment severity 
alone significantly predicted recovery (B = -0.05, p = .01).  However, the results in Table 27 
also suggest a trend for a significant difference between studies (p = .08) for female recovery 
which is not considered further. In order to clarify the meaning of the results in Table 26 and 
Table 27,  Figure 3 presents the predicted probability of recovery for males and females as a 
function of BDI pre-treatment severity (across studies and treatments). The figure was based 
on the coefficients in the 2
nd
 step model in Table 26 and used the following regression 
equation 
 
Log-odds (recovery) = B0 + Bseverity. Xseverity + Bgender. Xgender  + Bgender x severity. Xgender.Xseverity 
 
where pre-treatment severity was centred at the mean for both genders of 28.7 points with 
Xgender  coded as -1 and +1 for males and females respectively. 
 
 
Figure 3. Predicted Probability of Male & Female Recovery as a Function of BDI              
Pre-treatment Severity. 
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Figure 3 shows that the predicted probability of male recovery was effectively constant 
across the range of BDI pre-treatment severity. This finding agreed with the results for males 
in Table 27 where Bseverity  was not significantly different from zero.  In contrast, Figure 3 
shows that the predicted probability of female recovery reduced with increasing BDI pre-
treatment severity. This finding also agreed with the results for females in Table 27, where a 
significant Bseverity coefficient  indicated that the predicted probability of recovery reduced 
with increasing BDI pre-treatment severity.  However, whilst the predicted probability of 
recovery was the same for both sexes at a BDI pre-treatment score of approximately 35 
points, Figure 3 indicates that significantly fewer males recovered at lower BDI scores than 
females and vice versa. Thus, despite an overall finding that gender did not significantly 
predict recovery (Bgender =  0.19, p = .24; Table 26), Figure 3 indicates that the significant 
gender x severity interaction term identified significant gender differences at both the lower 
and upper ranges of BDI pre-treatment severity. However, an analysis
18
 using the 95% 
confidence intervals for Bgender x severity suggested that the significant difference between 
predicted male and female recovery occurred for BDI scores of only 31 points and below. 
 
Summary 
The step 2 model BDI results showed that, overall, pre-treatment severity was not predictive 
of recovery (Bseverity = -0.04, p = .09). However, it was revealed that BDI pre-treatment 
severity was a significant predictor of recovery in females. Despite no difference in the 
overall recovery rate between genders (Bgender = 0.19, p = .24), the significant gender x 
severity interaction (Bgender x severity = -0.03, p = .02) indicated that the probability of recovery 
differed between genders as a function of BDI pre-treatment severity. This interaction 
revealed that the probability of recovery in females significantly reduced as pre-treatment 
severity increased, whereas, in males the probability of recovery was effectively constant 
(Figure 3). Moreover, it was shown that for the same pre-treatment score, the predicted 
probability of recovery was significantly higher in females than males for BDI scores of 31 
points and below.   The non-significant results for remaining 1
st
 order covariates study (p = 
.16) and treatment (Btreatment = -0.18, p = .54) at step 2  indicated that the probability of 
recovery did not differ between studies or treatments. Also, the non-significant interaction 
between treatment and severity (Btreatment x severity = 0.00, p = .80) provided no evidence that 
ADM and psychotherapy were differentially effective at differing pre-treatment severities on 
the BDI.  Finally, the goodness-of-fit statistic, Nagelkerke’s pseudo R2 for the 2 step model 
in Table 26 was 0.1. This indicated that the overall model accounted for 10% of the null 
deviance (Cohen et al., 2003). 
                                                 
18 This did not account for the error in Bseverity or Bgender 
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HRSD results  
Table 28 shows the results of the binary logistic regression analysis for the HRSD. The 
independent variables study, treatment type, gender and pre-treatment severity were 
regressed on Jacobson recovery status. Pre-treatment HRSD severity was centred using the 
overall mean of 20.3 points. Collinearity tests indicated that the regression analysis was 
appropriate as the lowest tolerance value for any of the 1
st
 order terms in Table 28 was 0.72.  
 
 
Table 28. Results of Logistic Regression Analysis Investigating the effect of HRSD          
Pre-treatment Severity on the Probability of Recovery. 
 Step χ2 ΔR2α Variable B    p S.E. Odds 
Step 0    Constant 0.33 .001 0.10 1.39 
Step 1  24.71 .08   .001   
   Constant 0.25 .07 0.14 1.29 
   Studyβ  .38   
   Treatment - 0.20 .14 0.14 0.82 
   Gender 0.26 .03 0.03 1.29 
   Severity - 0.10 .001 0.003 0.91 
α: Nagelkerke’s pseudo R2   
β: results for individual studies not shown. 
Note: Effects coding employed for all categorical variables. Males, Salminen et al. (2008) and ADM served 
as baseline for Gender, Study and Treatment respectively. 
 
 
 
The step 1 results in Table 28 show that that the inclusion of study, treatment, gender and 
pre-treatment severity resulted in a model that significantly predicted recovery on the HRSD 
(χ2 = 24.71, p = .001).  Step 2 results are not presented as (i) the step was not significant 
(step χ2 = 4.81, p = .94),  (ii) no significant interactions were identified despite a significant 
overall model  (model χ2 = 29.52, p = .03).  The significant predictors of HRSD recovery in 
Table 28 were gender (B = 0.26, p = .03) and pre-treatment HRSD severity (B = -0.1, p = 
.001). Figure 4 presents the predicted probabilities of male and female recovery (across 
studies and treatments) as a function of HRSD pre-treatment severity. Figure 4 was based on 
the results in Table 28 and used the following  regression equation: 
 
Log-odds (recovery)  = B0 + Bgender. Xgender  + Bseverity . Xseverity 
 
Here, Bseverity was centred at the overall mean pre-treatment severity of 20.3 points and Xgender 
was -1 and +1 respectively for males and females.  
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Figure 4. Predicted Probability of Male & Female Recovery as a Function of                   
HRSD Pre-treatment Severity. 
 
 
 
 
 
Figure 4 shows that (i) the predicted probability of recovery for both genders reduced with 
increasing pre-treatment severity and (ii) the magnitude of the probability of male recovery 
was significantly lower than female recovery at the mean HRSD score of 20.3 points. Whilst 
the figure also suggests that the difference between male and female recovery was 
significant across the entire range of HRSD pre-treatment severity, an examination of the 
results using the 95% confidence intervals
19
 for Bseverity suggested that the difference was 
significant only for HRSD pre-treatment scores ranging from 16 to 24 points.   
 
Summary 
The step1 model HRSD results showed that both pre-treatment severity and gender 
significantly predicted recovery (Bseverity = -0.10, p = .001; Bgender = 0.26, p = .03). The result 
for severity indicated that the probability of recovery significantly reduced with increasing 
pre-treatment severity in both males and females. However, the significant result for gender 
also revealed that the probability of male recovery was significantly lower than that of 
females at the pre-treatment HRSD mean of 20.3 points. Moreover, for equivalent pre-
treatment scores, it was shown that the predicted probability of recovery was significantly 
                                                 
19 These are omitted for clarity. 
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lower in males than females for HRSD scores between approximately 16 and 24 points. The 
non-significant results for the remaining covariates study (p = .38) and treatment (Btreatment = -
0.20, p = .14) meant that the probability of recovery was not significantly different between 
studies or treatments.  The use of a step 1 model for the HRSD meant that it was not possible 
to test for interactions between 1
st
 order covariates. Finally, Nagelkerke’s pseudo R2 for the 
1 step model in Table 28 was 0.08 indicating that the model accounted for 8% of the null 
deviance (Cohen et al., 2003). 
 
 
7.3.4 Binary Logistic Regression Analyses for Jacobson Response   
The role of pre-treatment severity on Jacobson response was investigated using the same 
method as for Jacobson recovery. Patients were classified as responding to treatment if they 
recovered or demonstrated a statistically reliable reduction in symptoms at post-treatment 
according to Jacobson criteria (Jacobson and Truax, 1991).  
 
BDI results  
Table 29 presents results of the binary logistic regression analysis for Jacobson response 
across BDI studies. The independent variables study, treatment type, gender and pre-
treatment severity were regressed on Jacobson response status. Pre-treatment BDI severity 
was centred using the overall mean of 28.7 points. Collinearity tests indicated that the 
regression analysis was appropriate as the lowest tolerance value for any of the 1
st
 order 
terms in Table 29 was 0.92.  
 
The results in Table 29 show that the step 1 model was significant (step1 χ2 = 39.92, p < 
.001) and that only pre-treatment severity (B = 0.09, p = .001) was predictive of Jacobson 
response on the BDI. Neither study, treatment or gender were significant predictors of 
response in the step 1 model. However, Table 29 shows that the step 2 model also 
significantly predicted Jacobson response on the BDI (step 2 χ2 = 21.55, p = .03; overall 
model χ2 = 61.47, p < .001). For the step 2 model the variables severity (B = 0.14, p = .001), 
study (p = .045), study x severity (p < .05) and gender x severity (B = -0.07, p = .03) were 
all predictive of response. Thus, the inclusion of interaction terms in the step 2 model led to 
a significant improvement in the prediction of response over that of the step 1 model.  
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Table 29. Results of Logistic Regression Analysis for BDI Response. 
 Step χ2 ΔR2α Variable B p S.E. Odds 
Step 0   Constant   1.36 .001 0.13 3.91 
Step 1     .001   
 39.92 .16 Constant   1.48 .001 0.20 4.38 
   Studyβ  .19   
   Treatment - 0.23 .18 0.17 0.79 
   Gender   0.19 .20 0.14 1.21 
   Severity   0.09 .001 0.02 1.10 
Step 2†  21.55 .08   .03   
   Constant   2.13 .001 0.5 8.44 
   Studyβ  .045   
   Treatment - 0.90 .09 0.54 0.41 
   Gender - 0.02 .93 0.27 0.98 
   Severity   0.14 .001 0.04 1.15 
   Studyβ x Treatment  .70   
   Studyβ x Gender  .51   
   Studyβ x Severity  .03   
   Treatment x Gender - 0.18 .36 0.20 0.83 
   Treatment x Severity - 0.05 .21 0.04 0.95 
   Gender x Severity - 0.07 .03 0.03 0.94 
† Model significance < .001 
S.E. = Standard error of  B   
α: Nagelkerke’s pseudo R2 
β: results for individual studies not shown. 
 
Note: Effects coding employed for all categorical variables. Males, Salminen et al. (2008) and ADM 
served as baseline for Gender, Study and Treatment respectively. 
 
 
 
An interpretation of the step 2 results in Table 29 is presented separately for each significant 
predictor of response on the BDI.  
 
Severity 
The significant finding for severity (Bseverity = 0.14, p < .001) indicated that, overall, the 
probability of response increased with increasing BDI pre-treatment severity. This finding 
was similar to that for the step 1 model, where pre-treatment severity was the only 
significant predictor of response. However, the inclusion of 1
st
 order interactions in the step 
2 model meant that Bseverity increased from 0.09 to 0.14 at the second step (see Table 29).  
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Study 
The significant finding for study (p = .045) indicated that there were significant differences 
in overall response rates between studies. An examination of the Bstudy coefficient for each 
study
20
 showed that the Bstudy coefficient for Salminen et al. (2008) was the only one that 
significantly differed from zero (B = -1.64, p < .05). This revealed that the odds of response 
in Salminen et al. (2008) were 0.19 that of the overall rate based on all studies  (David et al., 
2008; Jacobson et al., 1996; Jarrett et al., 1999; Salminen et al., 2008) at a BDI pre-treatment 
severity of 28.7 points whilst controlling for treatment and gender.  
 
Study x Severity 
The significant study x severity interaction indicated that the predicted probability of 
response significantly differed between studies as a function of pre-treatment severity. An 
examination of individual study coefficients revealed that the Bstudy x severity coefficient in two 
of the four studies was significantly different from zero (David et al., 2008; Salminen et al., 
2008;).  A significant Bstudy x severity of  +0.11 ( p < .05) for David et al. (2008) indicated that 
the predicted increase in the log-odds of response for a 1 point increase on the BDI above 
28.7  points in this study was significantly greater than the predicted increase based on all 
studies (David et al., 2008; Jacobson et al., 1996; Jarrett et al., 1999; Salminen et al., 2008). 
Conversely, a Bstudy x severity of  -0.14 (p < .05) for Salminen et al. (2008) indicated that the 
increase in the predicted log-odds of response for a 1 point increase on the BDI above 28.7 
points in this study was significantly lower than the predicted increase based on all studies 
(David et al., 2008; Jacobson et al., 1996; Jarrett et al., 1999; Salminen et al., 2008). 
 
In order to better understand the effect of the significant study x severity interaction on 
overall response in David et al. (2008) and Salminen et al. (2008), the probability of 
response as a function of pre-treatment severity was derived for both the 1
st
 and 2
nd
 step 
regression models in Table 29. The regression equations employed for each model were:
21
 
 
 
 Step 1.   Log-odds (response) = B0 + Bstudy + Bseverity.Xseverity 
 
 
Step 2.   Log-odds (response) = B0 + Bstudy + Bseverity.Xseverity + Bstudy x severity.Xseverity 
 
 
 
                                                 
20 Individual Bstudy coefficients are not presented in the table. 
21 Whilst study was not significant according to the step 1 results in Table 29, the step 1 Bstudy values for David et 
al. (2008) and Salminen et al. (2008) were included for the purpose of comparison. 
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Figure 5 presents a comparison of the predicted probability of response by BDI pre-
treatment severity for David et al. (2008) and Salminen et al. (2008) according to both step 1 
and step 2 regression results.    
 
Figure 5 shows that for the step 1 model the probability of response in both David et al. 
(2008) and Salminen et al. (2008) increased with increasing pre-treatment severity. This 
corresponded to the significant result for Bseverity in the step 1 model in Table 29 where no 
other variable was predictive of response.  In addition, Figure 5 shows that the probability of 
response in David et al. (2008) was higher than that in Salminen et al. (2008) for every pre-
treatment BDI score. This was solely due to the (non-significant) difference between the 
Bstudy coefficients for David et al. (2008) and Salminen et al. (2008).   
 
 
Figure 5. Predicted Probability of Response as a function of BDI Pre-treatment Severity:     
A Comparison of Steps 1 & 2 Regression Results for David et al. (2008)     & 
Salminen et al. (2008). 
 
  
 
 
 
In contrast to the step 1 model, the results for the 2
nd
 step model in Figure 5 show that 
including the study x severity interaction led to dramatically different results. Here, the 
probability of response in David et al. (2008) was reduced at lower pre-treatment severities 
and increased at higher pre-treatment severities in comparison to step 1 results. 
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Nevertheless, the 1
st
 and 2
nd
 step model plots for David et al. (2008) broadly agree in that the 
probability of response significantly increased with increasing pre-treatment severity. 
However, Figure 5 reveals that the step 1 and 2 plots for Salminen et al. (2008) were very 
different. Here, the plot for  the 2
nd
 step model indicates that the probability of response was 
constant across all BDI pre-treatment severities. This finding cannot be attributed to the 
significantly lower probability of response in Salminen et al. (2008) (see page 132), as the 
Bstudy coefficient affects only the intercept and not the gradient of predicted probability plots. 
Thus, despite the 2 step model finding that severity was predictive of response overall, the 
significant study x severity interaction revealed that pre-treatment severity was not 
predictive of response in Salminen et al. (2008).   
 
 
Figure 6. Predicted Probability of Male & Female Response as a function of BDI  
 Pre-treatment Severity. 
 
 
 
 
Gender x Severity 
The significant gender x severity interaction for the 2
nd
 step model in Table 29 revealed that 
the effect of pre-treatment severity on response was not consistent between genders. Figure 
6 presents the predicted probability of response as a function of BDI pre-treatment severity 
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for males and females. Figure 6 was derived using the 2
nd
 step coefficients in Table 29 in the 
following regression equation: 
  
Log-odds (response) = B0 + Bgender.Xgender + Bseverity.Xseverity + Bgender x severity.Xgender. Xseverity 
 
Here, pre-treatment severity was centred at the mean for both genders of 28.7 points with 
Xgender  coded as -1 and +1 for males and females respectively.  
 
Figure 6 shows that the probability of response increased more rapidly in males than females 
with increasing BDI pre-treatment score. Also, Figure 6 shows that the predicted probability 
of response was lower in males for BDI scores below 29 points. An analysis
22
 using the 95% 
confidence intervals for Bgender x severity suggested that the probability of male response was 
significantly lower than that of females for BDI scores below 24 points but significantly 
higher than for females above 31 points. However, Figure 6 shows that the difference 
between the probability of recovery for equivalent scoring males and females was very much 
smaller for BDI scores above 31 points than it was below 24 points. Consequently, the 
probability of BDI response was practically equivalent between genders for pre-treatment 
scores of 24 points and above. Thus, females were significantly more likely to demonstrate a 
reliable post-treatment reduction in BDI score than equivalent scoring males for BDI pre-
treatment severities less than 24 points. Finally, Nagelkerke’s pseudo R2 for the 2 step model 
in Table 29 was 0.24 indicating that the model accounted for 24% of the null deviance 
(Cohen et al., 2003). 
 
Summary 
The results showed that, overall, increasing BDI pre-treatment severity was significantly 
associated with an increased probability of response. However, a significant  finding for the 
covariate study revealed that the overall response rate in Salminen et al. (2008) was lower 
than seen in remaining studies (David et al., 2008; Jacobson et al., 1996; Jarrett et al., 1999). 
Furthermore, the significant study x severity interaction revealed that, in contrast to 
remaining studies,  the probability of response in Salminen et al., 2008 did not change as a 
function of BDI pre-treatment severity. Whilst the 1
st
 order covariate gender was not a 
significant predictor of response, the significant gender x severity interaction revealed a that 
the predicted probability of response in males was significantly lower than that of equivalent 
scoring females for BDI pre-treatment severities below approximately 24 points.  
 
 
                                                 
22 This did not account for error in Bseverity or Bgender 
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HRSD results  
Table 30 presents the results of the binary logistic regression analysis for response in HRSD 
studies. The independent variables study, treatment type, gender and pre-treatment severity 
were regressed on Jacobson response status. Pre-treatment HRSD severity was centred using 
the overall mean of 20.3 points. Collinearity tests indicated that the regression analysis was 
appropriate as the lowest tolerance value for any of the terms in Table 30 was 0.72. Only the 
results for the 1st step analysis are presented as sparse data at step 2 led to the model being 
highly influenced by individual cases.  
 
Table 30. Results of Logistic Regression Analysis for HRSD Response. 
 Step χ2 ΔR2α Variable B   p S.E. Odds 
Step 0   Constant   1.81 .001 0.15 6.1 
Step 1 10.04 .05   .12   
   Constant   1.79 .001 0.19 6.00 
   Studyβ  .58   
   Treatment - 0.13 .50 0.19 0.88 
   Gender   0.08 .62 0.16 1.08 
   Severity   0.09 .049 0.05 1.10 
α: Nagelkerke’s pseudo R2 
β: results for individual studies not shown. 
Note: Effects coding employed for all categorical variables. Males, Salminen et al. (2008) and ADM 
served as baseline for Gender, Study and Treatment respectively. 
 
  
 
The results in  Table 30 show that the step 1 model was not significant (χ2 = 10.04, p = .12) 
and that pre-treatment severity was only just predictive of HRSD response (B = 0.09, p = 
.049).  If the significance of the overall model is ignored, the results for pre-treatment 
severity alone indicate that the probability of response significantly increased with 
increasing pre-treatment HRSD severity. Finally, Nagelkerke’s pseudo R2 for the non-
significant step 1 model in Table 30 was 0.05 indicating that the model accounted for 5% of 
the null deviance (Cohen et al., 2003). 
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7.4 Discussion 
The primary aim of this study was to determine whether pre-treatment severity was a 
significant predictor of Jacobson recovery on either a self- or clinician-rated measure (BDI 
or HRSD respectively) across the IPD studies obtained for study 2.  A secondary aim was to 
determine whether pre-treatment severity on either measure was predictive of Jacobson 
response. The results showed that, with the exception of males on the BDI, the probability of 
recovery significantly decreased with increasing pre-treatment severity. The probability of 
response was found to increase with increasing pre-treatment severity on both measures. The 
inclusion of gender as a covariate in analyses revealed that the probability of female 
recovery was significantly higher than that of males at lower pre-treatment severities on both 
the BDI and HRSD. The results of all analyses failed to provide evidence that ADM was 
superior to psychotherapy on either measure across any range of pre-treatment severity.  
 
The BDI recovery analysis showed that, overall, pre-treatment severity was not predictive of 
recovery (B = -0.04, p = .09; Table 26). However, the identification of a significant gender x 
severity interaction (B = - 0.03, p = .02) revealed that the null overall finding for BDI pre-
treatment severity occurred because BDI pre-treatment severity was not predictive of male 
recovery. In contrast, the probability of female recovery significantly reduced with 
increasing BDI pre-treatment severity (Figure 3). The BDI gender x severity interaction also 
indicated that females were significantly and increasingly more likely to recover than 
equivalent scoring males as BDI pre-treatment scores fell below 31 points (see Figure 3). 
This gender difference could have occurred because females typically just met the BDI 
recovery criterion of 8 points or less, whereas males typically just missed it. If so, then the 
relatively small clinical difference between genders according to continuous outcome data 
might have become statistically significant when analysed in terms of categorical outcomes.  
However, the results of the BDI response analysis (Table 29) indicated that this was not the 
case. The BDI response results showed that, overall, increased BDI pre-treatment severity 
predicted an increased probability of response (B = 0.14, p = .001). However, the significant 
gender x severity interaction identified within the BDI response analysis (B = -0.07, p = .03) 
revealed that female response was significantly more likely than that of equivalent scoring 
males for pre-treatment severities below 24 points (Figure 6). Thus, the probability of 
reliable symptomatic improvement on the BDI was significantly lower in males than females 
at lower pre-treatment severities. This meant that the significantly higher probability of 
female recovery at pre-treatment BDI severities below 31 points was due to lower levels of 
reliable improvement in males and not an artefact of categorical data analysis.   
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The HRSD recovery analysis showed that, overall, HRSD pre-treatment severity was 
predictive of recovery (B = -0.10, p = .001; Table 28). The probability of recovery on the 
HRSD significantly reduced with increasing pre-treatment severity in both males and 
females. However, because gender was also a significant predictor of recovery on the HRSD 
(Bgender = 0.26, p = .03), the probability of female recovery was significantly higher than that 
of males with equivalent pre-treatment HRSD scores (Figure 4). An analysis of the 95% 
confidence intervals for Bseverity  indicated that the probability of female recovery was 
significantly higher than that of equivalent scoring males for HRSD pre-treatment scores 
between 16 to 24 points. The results of the HRSD response analysis showed that increased 
pre-treatment severity significantly predicted an increased probability of response (B = 0.09, 
p = .049), albeit within a non-significant model (Table 30). The unavailability of a valid step 
2 model within the HRSD response analysis meant it was not possible to determine whether 
there was a significant gender x severity interaction.  
  
The results for both the BDI and HRSD revealed that, when study and treatment type were 
controlled for, there was a range of pre-treatment severity where the probability of female 
recovery was significantly higher than that of equivalent scoring males. In the BDI 
completer sample used in analyses, 66.8% (n = 256) of patients scored 31 points or below, 
whilst 66.6% (n = 255) of the HRSD sample scored from 16 to 24 points at pre-treatment. 
Thus, for the majority of patients, females were significantly more likely to recover than 
equivalent scoring males on both measures.  The reason for this finding cannot be 
determined on the basis of the data used in analyses.  According to the Centre for Cognitive 
Studies a BDI score greater than 30 denotes severe depression (Beck et al., 1988). In terms 
of the HRSD, the National Institute for Health and Clinical Excellence (NICE) has 
recommended that a score of 23 or denotes severe depression (Kriston and von Wolff, 
2011). Consequently, the results of this study indicate that the probability of recovery in 
males and females with identical pre-treatment scores on the BDI or HRSD will only be 
equivalent in the most severely depressed samples. This significant interaction of pre-
treatment severity with gender has the potential to confound the results of individual 
treatment studies that employ the BDI or HRSD to assess outcome. In order to minimise this 
risk of bias in individual studies it is necessary to satisfy two conditions. Firstly, the male to 
female ratio of treatment groups should be closely matched. Secondly, patients need to be 
assigned to treatment type using stratification on pre-treatment severity.  
 
However, these findings need to be interpreted in terms of the explicatory power of the 
logistic regression analyses. The Nagelkerke’s pseudo R2 values indicated that the null 
deviance in the BDI recovery analysis was found to be 10%, whilst that for the HRSD 
 139 
 
recovery analysis was 8%. These low null deviance values indicated that the regression 
models for recovery, and hence the variables entered in recovery analyses, accounted for a 
relatively small proportion of the variability in outcome. Consequently, it appears that the 
variables study, treatment, pre-treatment severity and gender were not major determinants of 
recovery in treatment completers. Clearly, there are important variables predictive of 
recovery that could not be included in regression models. In contrast, within the BDI 
response analysis Nagelkerke’s pseudo R2 for the 2 step model was 0.24. This indicated that 
the same variables taken together played a more important role in predicting BDI response 
as they accounted for 24% of the overall variability in outcome. However, it is likely that the 
higher pseudo R
2
 value for the BDI response analysis was due to the significantly lower 
overall response in Salminen et al. (2008) plus significant between-study differences in the 
probability of response with increasing pre-treatment severity (Bstudy and Bstudy x severity 
respectively). The significant finding for Bstudy x severity in particular indicate that patients 
within studies did not respond equivalently after controlling for pre-treatment severity, 
treatment type and gender. Whilst the nature of the analyses in this study mean that it is 
impossible to know the reasons for these differences, it is possible that studywise differences 
in treatment integrity, or the intensity/duration of treatment were responsible. Whatever the 
reason, the results indicate that controlling only for pre-treatment severity in pooled analyses 
of primary studies is unlikely to eliminate potential sources of bias. 
 
Finally, the finding that females were more likely to benefit from treatment than equivalent 
scoring males contrasts with the recent review by Parker et al. (2011).  Parker et al. (2011) 
reviewed 15 studies that had investigated whether gender significantly influences 
psychotherapy outcome. Whilst several studies failed to identify any significant gender 
effects, Parker et al. (2011) reported that those finding superior outcomes in females were 
counterbalanced by those finding superior outcomes in males. On the basis of what was 
effectively a vote-counting analysis (Hedges and Olkin, 1980), Parker et al. (2011) 
concluded there was insufficient evidence to argue that gender significantly influences 
psychotherapy outcome. That the statistically more powerful and flexible method of IPD 
meta-analysis was able to detect significant gender differences using fewer studies supports 
its future use for the identification of predictors of treatment outcome.   
 
There are several limitations that apply to this study. The broad division of  treatments into 
ADM or psychotherapy meant that it was not possible to investigate the relative efficacy of 
specific types of ADM or psychotherapy in analyses. However, this rough division of 
treatments is not uncommon in meta-analytic comparisons of treatments for depression and 
the use of IPD overcame some of the limitations applying to conventional meta-analyses. 
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Perhaps the most important limitation was that because IPD studies differed in terms of 
duration and the variables investigated, it was not possible to include additional covariates 
currently believed to moderate treatment outcome. For example, it was not possible to 
include chronicity (MDD > 2 years), age, marital status and comorbidity in analyses, all of 
which have been reported to moderate treatment outcome (Fournier et al., 2009; Jarrett et al., 
1991; Rush et al., 2005). Thus, it is possible that the significantly higher probability of 
female recovery at lower pre-treatment severities was due to confounds arising from one or 
more of these factors. Finally, the absence of controls meant that it was not possible to be 
certain that the results applied to treatments with demonstrable efficacy (Klein, 2000). This 
concern is particularly pertinent concerning treatment outcomes in less severely depressed 
patients, as both the TDCRP study (Elkin et al., 1989) and a recent patient-level meta-
analysis (Fournier et al., 2010) showed that treatments were superior to placebo only in more 
severely depressed samples.  
 
 
7.5 Summary & Concluding Remarks 
Increasing pre-treatment severity predicted a lower recovery rate for both genders on the 
HRSD and for females on the BDI. Thus, pre-treatment severity moderated treatment 
outcome assessed by the BDI and HRSD. Males and females appear to have a different 
recovery pattern, with recovery in females significantly more likely than in males of 
equivalent pre-treatment score in all but the most severely depressed samples. Thus, gender 
is a significant moderator of outcome on these measures which suggests that to avoid 
confounded results, future treatment studies will need to balance comparison groups in terms 
of their male to female ratio and stratify groups by pre-treatment severity.  
 
No evidence was found to suggest that ADM was superior to psychotherapy across the range 
of pre-treatment severity on either measure. However, the amount of outcome variation 
explained by the variables included in recovery analyses was relatively small. Nevertheless, 
the fact that IPD meta-analysis was capable of identifying significant gender differences in 
addition to theoretically important interactions supports their use in future investigations of 
factors that predict treatment outcome. A more complete understanding of such factors 
should enable the development of more efficacious treatments and assist clinicians in 
deciding which treatments work best for specific patient types. 
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Chapter Eight 
 
General Discussion & Conclusions  
 
This thesis has examined several methodological issues which contribute to the variability in 
outcome typically observed between psychological treatment studies for major depression. 
Because meta-analysis is now widely used to summarise the findings of such studies, the 
starting point was to survey the results of meta-analytic reviews that had included 
methodologically rigorous studies.  In addition, it is recognised that effect sizes based on 
continuous data can be of limited clinical utility, therefore several meta-analytic reviews 
compared  treatment outcomes in terms of the proportion of patients achieving an outcome 
criterion: (e.g. Casacalenda et al., 2002). The most reliable evidence obtained from the 
reviews in study 1 showed that at most 48% of patients starting psychotherapy
23
 remitted by 
post-treatment (de Maat et al., 2006; de Maat et al., 2007). However, there was evidence that 
approximately half of patients  receiving a placebo achieve remission (Casacalenda et al., 
2002). There was robust evidence that the relative efficacy of psychotherapy and medication 
were no different at post-treatment (Casacalenda et al., 2002; de Maat et al., 2006; Parker et 
al., 2008) and limited evidence that acute phase psychotherapy conferred superior protection 
against recurrence in comparison to acute medication (Vittengl et al., 2007). Nevertheless,  
73% of patients who achieve remission following a course of psychotherapy experienced a 
new major depressive episode within three years (Vittengl et al., 2007). These results 
suggest that psychotherapy is a relatively ineffective prophylactic intervention against 
further episodes of depression, although it may be the case that the intervention increases the 
duration between discrete episodes.  Nonetheless, there remains  a clear need to develop 
interventions that can improve the short and long term efficacy of psychological treatments 
for depression.  
 
An examination of substantive review data in study 1 revealed that all reviews were at risk 
of producing biased results due to methodological factors that increase the variability in 
outcome between primary studies. Two factors were identified which could not be directly 
examined in this thesis due to the unavailability of appropriate information. First amongst 
these was the finding that some of the studies included in reviews provided insufficient 
detail concerning the establishment of therapist competence or adherence to treatment 
protocols. This meant that the integrity of psychological treatment could not be guaranteed 
across all studies and raised the possibility that some of the ‘psychotherapy’ offered to 
                                                 
23 Aggregated across several psychotherapy models. 
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patients may have been no more effective than sham treatment. If true, this bias would have 
served to reduce overall estimates for the efficacy of psychotherapy in meta-analyses (Matt 
and Navarro, 1997) and could potentially obscure its superiority to medication when 
adequately provided. However, following an in-depth review of seven influential Cognitive 
Behavioural Therapy (CBT) studies for depression, Roth et al. (2010) found that 
investigators typically devote much effort to therapist selection, training and monitoring 
during clinical trials. This suggests that psychological treatments in many of the studies 
included in reviews were likely to have been provided to a high standard and that the risk of 
bias from this factor was low. Nevertheless, it is impossible to judge the validity of the 
results of individual studies, nor meta-analyses based on them, without clear evidence that 
treatments were provided as intended. Thus, it is important that psychotherapy researchers 
do not continue to neglect this important issue when reporting empirical research 
(Perepletchikova, 2009).  
 
The second factor which could not be directly examined was that the primary studies in 
study 1 varied considerably in terms of the overall duration of psychological treatment. 
Because evidence suggests that medication may act more rapidly to reduce depressive 
symptoms than psychological treatments (Watkins et al., 1993; Elkin et al., 1989), it is 
possible that the inclusion of very brief studies comparing psychotherapy with medication 
biased the overall results of reviews in favour of medication. However,  Dekker et al. (2008) 
has suggested that the more rapid symptomatic reduction afforded by medication over 
psychotherapy occurs only during the first month of treatment. Consequently, it is unlikely 
that treatment duration served as a source of bias in comparisons of psychotherapy with 
medication in the reviews in study 1, as the minimum duration of any study was 8 weeks. 
Nevertheless, as increasing symptomatic benefit is associated with increasing treatment 
duration (Howard et al., 1986; Shapiro et al., 1994), it is to be expected that a higher 
proportion of patients will remit in psychotherapy studies of longer duration. Consequently, 
the inclusion of such studies in meta-analysis will serve to increase the variability in 
remission estimates on which analyses are based. This in turn will reduce the power of meta-
analysis to identify any significant overall differences between treatments that may exist. In 
addition, it will be difficult to determine how many patients should be expected to remit 
following treatment of a specific duration. A potential solution to this problem is that clinical 
significance rates are published for standard assessment intervals during treatment in future 
studies. Thus, reviewers could include only outcome data for patients treated over a specific 
time interval in meta-analysis. However, this approach is itself likely to be problematic, as 
Shapiro et al. (1994) have shown that therapists may adjust the pace of psychotherapy to 
correspond with the time available.  
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The first methodological factor that could be directly investigated in terms of its contribution 
to outcome variability and the risk of bias in meta-analysis was the use of idiosyncratic 
clinical significance criteria in primary studies. In study 2 post-treatment recovery rates 
calculated using Jacobson method criteria for the Beck Depression Inventory (BDI, Beck et 
al., 1961) and Hamilton Rating Scale for Depression (HRSD, Hamilton, 1960) were 
compared with published clinical significance rates based on the same measures. The 
primary studies providing individual patient data (IPD) for comparisons in study 2 met the 
same eligibility criteria as those in study 1. Study 2 showed that the published criteria for 
IPD studies typically led to published clinical significance rates that were higher than those 
of the Jacobson method. It was also found that all patients who met published clinical 
significance criteria demonstrated reliable change according to Jacobson method criteria. 
This meant that published and Jacobson method criteria were effectively the same where 
studies used a score of 8 or less on the BDI, or a score of 7 or less on the HRSD to define 
remission. However, where published criteria were much less stringent than Jacobson 
criteria, published rates could be up to 55% higher than Jacobson rates (e.g. Constantino et 
al., 2008). The evident outcome variability due to the idiosyncratic definitions in primary 
studies makes it difficult to know how closely published rates represent the optimum 
outcome of remission (APA 2000). This difficulty is compounded when the results of such 
studies are pooled in meta-analysis. Consequently, where the goal of meta-analysis is to 
compare treatments in terms of remission, it is necessary that included studies have 
employed appropriate definitions. However, such an approach is problematic, as study 1 
showed that where primary studies publish clinical significance rates for the BDI or HRSD, 
they are frequently based on different criteria to those of the Jacobson method.   
 
Study 2 also revealed that the rank order of treatment efficacy is not invariant to changing 
definitions of clinical significance. Therefore, it is possible that the use of idiosyncratic 
outcome criteria may inadvertently bias the results of individual studies in favour of one 
type of treatment.  Whilst such bias ought to be random and thus cancel out in meta-analyses 
that include many studies, there is no guarantee that this will  occur  (Matt and Navarro, 
1997). Moreover, the results of study 1 showed that there were relatively few high quality 
primary studies available in this area, as the maximum number included in reviews was 10. 
This indicates that statistically influential primary studies have the potential to bias the 
overall results of methodologically rigorous meta-analyses of psychological treatments for 
major depression. Indeed, that individual studies may influence review conclusions was 
illustrated by de Maat et al. (2007), who reported that their overall conclusions applied only 
to patients in Keller et al. (2000) and not the overall sample included in analysis.   
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When outcomes were compared between the BDI and HRSD in the same sample, the results 
of study 2 revealed poor agreement between measures in terms of Jacobson recovery (Kappa 
=  0.56). As fewer patients recovered on the BDI than on the HRSD it was shown that 
recovery on the BDI was a more stringent test of recovery. However, comparisons between 
IPD and published results for Jacobson et al. (1996) indicated that the BDI provided 
insufficient coverage of DSM III depressive symptomatology. Taken together, these findings 
indicated that recovery according to Jacobson criteria on either measure was a less stringent 
test of a return to normative symptomatic levels than remission identified via diagnostic 
criteria. Therefore, a better operationalisation of remission in future treatment studies would 
be to require that patients demonstrate recovery on both the BDI and HRSD according to 
Jacobson method criteria. Finally, study 2 showed that approximately 50% of patients 
starting psychotherapy in IPD studies recovered according to Jacobson method criteria on 
the BDI or HRSD by post-treatment.   
 
The last study of this thesis examined whether pre-treatment severity on the BDI or HRSD 
was a significant predictor of recovery defined according to Jacobson criteria. This was the 
final methodological factor identified in study 1 with the potential to increase between-study 
outcome variability and bias the results of meta-analysis. The results of the IPD meta-
analyses in study 3 showed that (i) increased pre-treatment severity on the BDI or HRSD 
generally predicted a reduced probability of recovery, (ii) there was no evidence that ADM 
was superior to psychotherapy at any pre-treatment severity. However, an interaction 
between pre-treatment severity and gender revealed that increased BDI pre-treatment 
severity was predictive of recovery only in females. It is impossible to rule out that this latter 
finding was due to unknown confounds. Nevertheless, the findings of the BDI response 
analysis, that males were less likely to demonstrate reliable change than equivalently 
depressed females, supports Sigmon et al.’s assertion that gender biases on self-reported 
depression measures warrant further research (Sigmon et al., 2005). The results for both 
measures revealed that females were significantly more likely to recover than equivalently 
depressed males at all but the most severe levels of pre-treatment severity. This suggests that 
a gender bias may also exist for clinician rated measures. Taken together, the findings of 
study 3 suggest that gender differences may serve to bias the results of individual studies 
unless, (i) gender ratios are matched between treatment groups, (ii) males and females are 
independently randomised to treatment group according to pre-treatment severity.  
 
In summary, several methodological factors serve to increase outcome variation typically 
observed between primary studies of psychological treatments for major depression. Some 
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of this variation is random error which serves to reduce the ability of meta-analyses to detect 
significant treatment differences (Wilson and Lipsey, 2001) and risks that results are biased. 
The factor likely to contribute the most random error to meta-analyses of depression 
treatment studies is the method by which outcome is defined (Wilson and Lipsey,2001). This 
implies that future meta-analyses will be better placed to compare the relative efficacy of 
psychological treatments for depression only when a standard and appropriate definition of 
clinical significance is universally accepted. However, the moderating effects of treatment 
integrity, treatment duration, pre-treatment severity and other unknown factors will still lead 
to variability in outcome between individual studies. These moderators will still serve to 
reduce the power and precision of meta-analysis and render their results difficult to interpret.  
 
Given the clinical heterogeneity associated with a single diagnosis of major depression, it is 
necessary to understand whether some treatments work better for particular patient types. 
For example, de Maat et al. (2007) fortuitously found that combined therapy is more 
efficacious only in moderately depressed patients with chronic depression. Unfortunately, it 
is very unlikely that the limitations of meta-regression (Higgins et al., 2001) will enable a 
clear understanding of the role that moderating variables such as chronicity play in affecting 
treatment outcome, even should a standard outcome definition be employed across studies. 
However, the finding that gender significantly moderated outcome in the IPD meta-analyses 
of study 3 indicate that this approach has greater power and flexibility to do so. Therefore, in 
the broadest terms, the results of this thesis indicate that IPD meta-analyses are to be 
preferred over those using summary data, as the latter can provide only very limited 
information concerning the efficacy of psychological treatments for major depression.  
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Search Filters used to Search Electronic Databases in Study One 
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Cochrane Library DARE    Searched 11/03/2009 
 
 
Search   Filter Results 
1 explode Psychotherapy/ 569 
2 psychotherap* or "behavior* NEAR/6 therap*" or  behaviour* 
NEAR/6 therap*  or  biofeedback and psycho*  or  cognitive NEAR/6 
therap*  or  desensiti* and psychol*  or "implosive therap*" or  relax* 
NEAR/6 therap*  or  relax* NEAR/6 techniq*  or  therap* NEAR/6 
touch*  (all text) 
622 
3 bibliotherapy or  imagery and psychotherap*  or counsel* or "milieu 
therap*" or psychosoc* or psycholog* or  support* NEAR/6 group*  or  
guide* NEAR/6 image*  or "gestalt therap*" or "nondirective therap*" 
or "play therap*" or  psychoanaly* NEAR/6 therap*  or 
"psychotherap* process*"  (all text) 
1549 
4 OR 1-3   1716 
5 explode Depression/ 103 
6 depressi* NEAR/3 disorder* or  depressi* NEAR/3 symptom*  
depression  or depressive* or depressed or dysthymia*  (all text) 
350 
7 explode  Depressive Disorder/ 232 
8 OR 5-7 410 
9 4 AND 8 252 
10 meta-analy* or metaanal* (all text) or meta-analysis.pt,ab,ti. 4494 
11 explode Meta-Analysis as Topic explode all trees 300 
12 systematic* NEAR/4  review* or  systematic* NEAR/4  overview* (all 
text) 
7732 
13 extraction.ab. 0 
14 letter or comment or editorial pt. 0 
15 10 or 11 or 12 or 13 8402 
16 15AND NOT 14 8402 
17 9 and 16 222 
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Cochrane Database of Controlled Trials   Searched 11/03/2009 
 
 
Search   Filter Results 
1 explode Psychotherapy/ 8429 
2 psychotherap* or "behavior* NEAR/6 therap*" or  behaviour* 
NEAR/6 therap*  or  biofeedback and psycho*  or  cognitive NEAR/6 
therap*  or  desensiti* and psychol*  or "implosive therap*" or  relax* 
NEAR/6 therap*  or  relax* NEAR/6 techniq*  or  therap* NEAR/6 
touch*  (all text) 
10890 
3 bibliotherapy or  imagery and psychotherap*  or counsel* or "milieu 
therap*" or psychosoc* or psycholog* or  support* NEAR/6 group*  or  
guide* NEAR/6 image*  or "gestalt therap*" or "nondirective therap*" 
or "play therap*" or  psychoanaly* NEAR/6 therap*  or "psychotherap* 
process*"  (all text)  
45982 
4 OR 1-3   50722 
5 explode Depression/ 3042 
6 depressi* NEAR/3 disorder*  or  depressi* NEAR/3 symptom*  
depression  or depressive* or depressed or dysthymia*  (all text) 
11955 
7 explode  Depressive Disorder/ 4761 
8 OR 5-7 13714 
9 4 AND 8 6660 
10 meta-analy* or metaanal* (all text) or meta-analysis.pt,ab,ti. 1420 
11 explode Meta-Analysis as Topic explode all trees 172 
12 systematic* NEAR/4  review* or  systematic* NEAR/4  overview* (all 
text) 
292 
13 extraction.ab. 2589 
14 letter or comment or editorial .pt.  0 
15 10 or 11 or 12 or 13  4172 
16 15AND NOT 14 4172 
17 9 and 16 31 
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Cochrane Database of Economic Evaluations   Searched 11/03/2009 
 
 
Search   Filter Results 
1 explode Psychotherapy/ 281 
2 psychotherap* or "behavior* NEAR/6 therap*" or  behaviour* NEAR/6 
therap*  or  biofeedback and psycho*  or  cognitive NEAR/6 therap*  
or  desensiti* and psychol*  or "implosive therap*" or  relax* NEAR/6 
therap*  or  relax* NEAR/6 techniq*  or  therap* NEAR/6 touch*  (all 
text) 
250 
3 bibliotherapy or  imagery and psychotherap*  or counsel* or "milieu 
therap*" or psychosoc* or psycholog* or  support* NEAR/6 group*  or  
guide* NEAR/6 image*  or "gestalt therap*" or "nondirective therap*" 
or "play therap*" or  psychoanaly* NEAR/6 therap*  or "psychotherap* 
process*"  (all text)  
 
1758 
4 OR 1-3   1924 
5 explode Depression/ 161 
6 depressi* NEAR/3 disorder*  or  depressi* NEAR/3 symptom*  
depression  or depressive* or depressed or dysthymia*  (all text) 
384 
7 explode  Depressive Disorder/ 306 
8 OR 5-7 5372 
9 4 AND 8 196 
10 meta-analy* or metaanal* (all text) or meta-analysis.pt,ab,ti. 757 
11 explode Meta-Analysis as Topic explode all trees 33 
12 systematic* NEAR/4  review* or  systematic* NEAR/4  overview* (all 
text) 
1943 
13 extraction.ab. 0 
14 letter or comment or editorial .pt.  0 
15 10 or 11 or 12 or 13  2343 
16 15AND NOT 14 2343 
17 9 and 16 25 
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Cochrane Database of Systematic Reviews    Searched 10/03/2009 
 
 
Search   Filter Results 
1 explode Psychotherapy/ 147 
2 psychotherap* or "behavior* NEAR/6 therap*" or  behaviour* 
NEAR/6 therap*  or  biofeedback and psycho*  or  cognitive NEAR/6 
therap*  or  desensiti* and psychol*  or "implosive therap*" or  relax* 
NEAR/6 therap*  or  relax* NEAR/6 techniq*  or  therap* NEAR/6 
touch*  (all text) 
611 
3 bibliotherapy or  imagery and psychotherap*  or counsel* or "milieu 
therap*" or psychosoc* or psycholog* or  support* NEAR/6 group*  
or  guide* NEAR/6 image*  or "gestalt therap*" or "nondirective 
therap*" or "play therap*" or  psychoanaly* NEAR/6 therap*  or 
"psychotherap* process*"  (all text)  
 
2071 
4 OR 1-3   2162 
5 explode Depression/ 50 
6 depressi* NEAR/3 disorder*  or  depressi* NEAR/3 symptom*  
depression  or depressive* or depressed or dysthymia*  (all text) 
518 
7 explode  Depressive Disorder/ 25 
8 OR 5-7 526 
9 4 AND 8 390 
10 meta-analy* or metaanal* (all text) or meta-analysis.pt,ab,ti. 4191 
11 explode Meta-Analysis as Topic explode all trees 14 
12 systematic* NEAR/4  review* or  systematic* NEAR/4  overview* 
(all text) 
5676 
13 extraction.ab. 528 
14 letter or comment or editorial .pt.  0 
15 10 or 11 or 12 or 13  5676 
16 15AND NOT 14 5676 
17 9 and 16 390 
18 Restrict to reviews (not protocols) 290 
 
 
 
  
 177 
 
 
 
 
Cochrane Database of Technology Assessments  Searched 11/03/2009 
 
 
Search   Filter Results 
1 explode Psychotherapy/ 97 
2 psychotherap* or "behavior* NEAR/6 therap*" or  behaviour* 
NEAR/6 therap*  or  biofeedback and psycho*  or  cognitive NEAR/6 
therap*  or  desensiti* and psychol*  or "implosive therap*" or  relax* 
NEAR/6 therap*  or  relax* NEAR/6 techniq*  or  therap* NEAR/6 
touch*  (all text) 
 
119 
3 bibliotherapy or  imagery and psychotherap*  or counsel* or "milieu 
therap*" or psychosoc* or psycholog* or  support* NEAR/6 group*  
or  guide* NEAR/6 image*  or "gestalt therap*" or "nondirective 
therap*" or "play therap*" or  psychoanaly* NEAR/6 therap*  or 
"psychotherap* process*"  (all text)  
335 
4 OR 1-3   413 
5 explode Depression/ 42 
6 depressi* NEAR/3 disorder*  or  depressi* NEAR/3 symptom*  
depression  or depressive* or depressed or dysthymia*  (all text) 
80 
7 explode  Depressive Disorder/ 48 
8 OR 5-7 102 
9 4 AND 8 41 
10 meta-analy* or metaanal* (all text) or meta-analysis.pt,ab,ti. 242 
11 explode Meta-Analysis as Topic explode all trees 1 
12 systematic* NEAR/4  review* or  systematic* NEAR/4  overview* 
(all text) 
2061 
13 extraction.ab. 0 
14 letter or comment or editorial .pt.  0 
15 10 or 11 or 12 or 13  2101 
16 15AND NOT 14 2101 
17 9 and 16 19 
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PsycINFO      Search 1967 to March Week 2 2009 
 
 
Search   Filter Results 
1 exp Psychotherapy/ 131801  
2 (psychotherap$ or "behavior$ adj6 therap$" or (behaviour$ adj6 
therap$) or (biofeedback and psycho$) or (cognitive adj6 therap$) or 
(desensiti$ and psychol$) or "implosive therap$" or (relax$ adj6 
therap$) or (relax$ adj6 techniq$) or (therap$ adj6 touch$)).tw. 
86063  
3 (bibliotherapy or (imagery and psychotherap$) or counsel$ or "milieu 
therap$" or psychosoc$ or psycholog$ or (support$ adj6 group$) or 
(guide$ adj6 image$) or "gestalt therap$" or "nondirective therap$" or 
"play therap$" or (psychoanaly$ adj6 therap$) or "psychotherap$ 
process$").tw. 
403913  
4 exp Postpartum Depression/ or exp Recurrent Depression/ or exp 
Atypical Depression/ or exp Endogenous Depression/ or exp 
"Depression (Emotion)"/ or exp Reactive Depression/ or exp 
Treatment Resistant Depression/ or exp Major Depression/ 
81130  
5 (depressi$ adj3 disorder$).tw. 21335  
6 (depressi$ adj3 symptom$).tw. 23760  
7 (depression or depressive$ or depressed or dysthymia$).tw. 145304  
8 or/1-3 512793  
9 or/4-7 147147  
10 8 and 9 40511  
11 (meta-analy$ or metaanal$).tw. 9933  
12 meta-analysis.pt,ab,ti. 7042  
13 exp Meta Analysis/ 2865  
14 (systematic$ adj4 (review$ or overview$)).tw. 3996  
15 extraction.ab. 2129  
16 (letter or comment or editorial).pt. 0  
17 or/11-15 15238  
18 17 not 16 15238  
19 10 and 18 525  
20 limit 19 to English language 479  
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EMBASE       Search 1980 to 2009 Week 10 
 
 
Search   Filter Results 
1 exp Psychotherapy/ 78759  
2 (psychotherap$ or "behavior$ adj6 therap$" or (behaviour$ adj6 
therap$) or (biofeedback and psycho$) or (cognitive adj6 therap$) or 
(desensiti$ and psychol$) or "implosive therap$" or (relax$ adj6 
therap$) or (relax$ adj6 techniq$) or (therap$ adj6 touch$)).tw. 
34009  
3 (bibliotherapy or (imagery and psychotherap$) or counsel$ or "milieu 
therap$" or psychosoc$ or psycholog$ or (support$ adj6 group$) or 
(guide$ adj6 image$) or "gestalt therap$" or "nondirective therap$" or 
"play therap$" or (psychoanaly$ adj6 therap$) or "psychotherap$ 
process$").tw. 
168193  
4 (depressi$ adj3 disorder$).tw. 18770  
5 (depressi$ adj3 symptom$).tw. 19729  
6 (depression or depressive$ or depressed or dysthymia$).tw. 181469  
7 Reactive Depression/ or Bipolar Depression/ or Depression/ or 
Recurrent Brief Depression/ or Masked Depression/ or Long Term 
Depression/ or Atypical Depression/ or Agitated Depression/ or 
Puerperal Depression/ or Postoperative Depression/ or Major 
Depression/ or Endogenous Depression/ 
142332  
8 or/1-3 235329  
9 or/4-7 228187  
10 8 and 9 36871  
11 (meta-analy$ or metaanal$).tw. 22902  
12 meta-analysis.pt,ab,ti. 17783  
13 exp Meta Analysis/ 34829  
14 (systematic$ adj4 (review$ or overview$)).tw. 18115  
15 extraction.ab. 82426  
16 (letter or comment or editorial).pt. 666180  
17 or/11-15 137560  
18 17 not 16 133890  
19 10 and 18 1217  
20 limit 19 to English language 1060  
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MEDLINE In-Process & Other Non-Indexed Citations  Searched 6/03/2009 
 
 
Search   Filter Results 
1 psychotherapy.af. 947 
2 (psychotherap$ or "behavior$ adj6 therap$" or (behaviour$ adj6 
therap$) or (biofeedback and psycho$) or (cognitive adj6 therap$) or 
(desensiti$ and psychol$) or "implosive therap$" or (relax$ adj6 
therap$) or (relax$ adj6 techniq$) or (therap$ adj6 touch$)).tw. 
1375 
3 (bibliotherapy or (imagery and psychotherap$) or counsel$ or "milieu 
therap$" or psychosoc$ or psycholog$ or (support$ adj6 group$) or 
(guide$ adj6 image$) or "gestalt therap$" or "nondirective therap$" or 
"play therap$" or (psychoanaly$ adj6 therap$) or "psychotherap$ 
process$").tw.  
9235 
4 depression.af.  6561 
5 (depressi$ adj3 disorder$).af.  1076 
6 (depressi$ adj3 symptom$).af.  1401 
7 Depressive Disorder.af.  559 
8 (depression or depressive$ or depressed or dysthymia$).af. 8207 
9 1 or 3 or 2 10587 
10 8 or 6 or 4 or 7 or 5 8209 
11 10 and 9 1583 
12 (meta-analy$ or metaanal$).tw. 2131 
13 meta-analysis.ab,ti,pt. 1816 
14 Meta-Analysis.af. 1816 
15 (systematic$ adj4 (review$ or overview$)).tw. 2189 
16 extraction.ab.  7672 
17 (letter or comment or editorial).pt. 42128 
18 16 or 13 or 12 or 15 or 14 11268 
19 18 not 17 10981 
20 11 and 19 58 
21 limit 20 to English language 53 
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MEDLINE          Search 1950 to February Week 4 2009 
 
 
Search   Filter Results 
1 exp Psychotherapy/ 119668 
2 (psychotherap$ or "behavior$ adj6 therap$" or (behaviour$ adj6 
therap$) or (biofeedback and psycho$) or (cognitive adj6 therap$) or 
(desensiti$ and psychol$) or "implosive therap$" or (relax$ adj6 
therap$) or (relax$ adj6 techniq$) or (therap$ adj6 touch$)).tw.  
35200 
3 (bibliotherapy or (imagery and psychotherap$) or counsel$ or "milieu 
therap$" or psychosoc$ or psycholog$ or (support$ adj6 group$) or 
(guide$ adj6 image$) or "gestalt therap$" or "nondirective therap$" or 
"play therap$" or (psychoanaly$ adj6 therap$) or "psychotherap$ 
process$").tw.  
201805 
4 exp Depression/ 50959 
5 (depressi$ adj3 disorder$).tw. 17707 
6 (depressi$ adj3 symptom$).tw.  19872 
7 exp Depressive Disorder/ 59678 
8 (depression or depressive$ or depressed or dysthymia$).tw. 203764 
9 or/1-3  311659 
10 or/4-8 234895 
11 9 and 10 33833 
12 (meta-analy$ or metaanal$).tw.  23815 
13 meta-analysis.pt,ab,ti.  27840 
14 exp Meta-Analysis/ 20228 
15 (systematic$ adj4 (review$ or overview$)).tw. 19228 
16 extraction.ab.  91998 
17 (letter or comment or editorial).pt. 931461 
18 or/12-16 134304 
19 18 not 17 132489 
20 11 and 19 644 
21 limit 20 to English language 602 
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SCOPUS         Searched 12/03/2009 
 
 
 
Search   Filter Results 
1 KEY(Depressi* or depressive* or depressed or dysthymia*) 262504 
2 KEY(Psychotherapy)  76148 
3 KEY(“bibliotherapy or “self-help” or “self help” or (comput* and 
therap*) or (online and therap*))  
12978 
4 2 or 3 88255 
5 KEY((meta analysis) OR (metaanalysis) OR (systematic review) OR 
(systematic overview))  
63807 
6 1 and 4 and 5  562 
7 Limit to English language 505 
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Web of Knowledge              Searched 11/03/2009 
 
Science Citation Index Expanded (SCI-EXPANDED) 1945to search date 
Social Sciences Citation Index (SSCI)  1956 to search date  
 
 
Search   Filter Results 
1 Topic = ((behavior* or behaviour* or cognitive or meta?cognit* or 
implosive or psycho* or interpersonal or gestalt or person?cent* or 
activation* or bibliotherapy* or counsel* or supportive or 
non?directive or guided or image* or computer* or cbt) and therap*)  
 
Document Type=(ARTICLE OR REVIEW OR CORRECTION) 
88436 
2 Topic = ((behavior* or behaviour* or cognitive or meta?cognit* or 
implosive or psycho* or interpersonal or gestalt or person?cent* or 
activation* or bibliotherapy* or counsel* or supportive or 
non?directive or guided or image* or computer* or cbt) and 
psychotherap*)  
 
Document Type=(ARTICLE OR REVIEW OR CORRECTION/ 
ADDITION) 
26907 
3 1 OR 2 Restricted to English Language 91978 
4 Topic = Depress* Document Type=( ARTICLE OR CORRECTION 
OR REVIEW ) AND Languages=(ENGLISH) 
75773 
5 Topic=(dysthymi*) Document Type=( ARTICLE OR CORRECTION/ 
ADDITION OR REVIEW ) AND Languages = ( ENGLISH )  
1522 
6 4 OR 5  76816 
7 Topic=(met*analy*) 28241 
8 Title=("systematic review" or "systematic overview") 15610 
9 7 OR 8  42775 
10 Topic=(extraction) Document Type=( ARTICLE OR REVIEW OR 
CORRECTION ) AND Languages=( ENGLISH ) 
82658 
11 9 OR 10 92698 
12 3 AND 6 7894 
13 12 AND 11 505 
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Appendix B 
 
 
 
Screening Tool used to Assess the Eligibility of Reviews in Study One 
 
 
Article 
Reference 
Criterion Present? Y/N Include? Notes 
 Reviews RCTs - psychotherapy for 
Depression? 
   
Adults?  
Research Diagnosis of Depression?  
Individual Psychotherapy for 
Depression? 
 
Adequate Controls?  
Synthesis of Psychotherapy 
efficacy? 
 
Psychosis/PD/Medical/Substance 
Abuse? 
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Appendix C   
 
 
Composite Tool used to Extract Substantive & Quality Data* from Individual Reviews 
in Study One 
 
BIBLIOGRAPHIC DETAILS  
Descriptives*  (Adapted from CRDs DARE format) Quality*/ risk of bias  (Adapted 
from ScHARR format) 
Summary of Review (Our abstract):   
Authors Objectives:   Did the review address a 
clearly focused question? Y/N? 
Search Methods:   Was the search strategy 
adequate (i.e. did the 
reviewers identify all 
relevant studies?) 
Y/N? 
 
STUDY SELECTION 
What are the included designs in the 
review?  
 
Were the inclusion/exclusion criteria 
specified?  
Y/N? 
 
What types of therapy were included?  
 
What attempts were made to identify the ‘purity’ of therapy?  
Participants?  
 
Diagnostic  techniques?  
 
Severity?  
 
Duration?  
 
Did the review include the right kinds of 
studies? 
Y/N? 
 
 
STUDY OUTCOMES 
Assessment points in time/follow up?  
Comparison groups?  
Measures of severity?  
Outcomes used  in individual studies?  
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Continued from previous page.... 
VALIDITY ASSESSMENT 
How were individual studies determined suitable for inclusion?  
Did the reviewers assess the quality of 
the included studies? 
Y/N? 
 
Were appropriate outcome measures 
used? 
Y/N? 
 
 
SYNTHESIS 
Synthesis: Assessment of differences between included 
studies? 
 
Was the method of data extraction 
reported? 
Y/N? 
Heterogeneity found? Y/N? 
Heterogeneity accounted for Y/N? 
Are appropriate sub-group 
analyses presented? 
Y/N? 
If the results of the studies have been 
combined, was it appropriate to do so? Y/N? 
 
 
RESULTS OF THE REVIEW 
Authors’ Conclusions:  
Are the main results of the review 
presented (e.g. numerical results 
included with CIs) 
Y/N? 
Justified on included evidence? Y/N? 
Are issues of 
generalisability  
addressed?  
Y/N?  Justified on included evidence? Y/N? 
Authors statements concerning implications for 
practice/research?  
Justified on included evidence? Y/N? 
Our Comments on the review as a whole based on the qualitative/quantitative findings 
*  See main text for information about origins of table design. 
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Appendix D 
 
 
Synthesis Methods of  Reviews in Study One 
 
Review Method of Synthesis
†
 
Casacalenda et al. (2002) Post-treatment remission percentages for each study’s treatment condition 
were averaged across studies to give an average remission rate.  The 
average remission rates for each treatment condition were then assessed for 
significant differences using analysis of variance.  No weighting of 
individual study results by sample size, nor testing for between study 
heterogeneity were described.  The authors used SAS version 8.0 data 
analysis software. 
de Maat et al. (2006) The relative efficacy of treatments within studies were calculated using 
odds and relative risk ratios for remission at post treatment and relapse 
during follow up.  These effect sizes were then weighted according to study 
size and combined to produce an overall estimate of the odds or risk ratio 
for remission or relapse. The authors employed a fixed effects model, tested 
for heterogeneity between individual study results and used Review 
Manager 4.2 software of the Cochrane Collaboration. 
de Maat et al. (2007) As for de Maat et al. (2006) for post treatment outcomes only.   
Friedman et al. (2004) The relative efficacy of treatments within studies was calculated using 
Cohen’s d for both symptom reduction and recovery status.  Effect sizes 
were weighted according to study size and combined to produce a Cohen’s 
d for both symptom reduction and recovery. Between study heterogeneity 
was tested for using Chi-squared analyses.  Results were presented for both 
post treatment and follow up outcomes. The authors did not report the 
statistical significance of their results. 
Leichsenring (2001) Success rate differences between treatments were assessed in individual 
studies by testing for significant differences in correlation coefficients 
(Cramer’s Phi).  Correlation coefficients from studies were transformed and 
compared to test for significant heterogeneity. A weighted mean Phi value 
was subsequently derived for both post treatment and follow up outcomes.  
Parker et al. (2008) The relative efficacy of treatments within studies were calculated using 
Cohen’s d for symptom reduction on the BDI and odds and risk ratios for 
response. These effect sizes were then weighted according to study size and 
combined to produce an overall estimate of symptom reduction or response.  
The authors employed a random effects model, tested for heterogeneity 
between studies, and used the  META statistical package version 8.01.
 
  
Vittengl et al. (2007) The synthesis was based on the studywise logit transformed proportions of 
patients experiencing relapse or recurrence of depression by treatment type.  
These proportions were then weighted according to study size to provide an 
overall estimate of the numbers relapsing by treatment type.  The authors 
employed a random effects model and tested for heterogeneity between 
individual study results. 
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Appendix E 
 
 
Details of five Borderline Reviews Included in Study One 
 
Review Further Information 
Casacalenda et al. (2002) High levels of personality disorder (PD) comorbidity was reported 
for 3 of the 6 constituent studies which indicated the need for 
referral to a third reviewer (Elkin et al., 1989; Schulberg et al., 
1996; Scott and Freeman, 1992). The review was included as these 
studies did not treat depression specifically in the context of PD. 
The finding of high PD comorbidity was possibly due to a level of 
detail in reporting not seen in other reviews. For example, other 
eligible reviews included Elkin et al. (1989) but did not provide 
information concerning the proportion of patients with PD. 
Friedman et al. (2004) Presented pooled results for group and individual psychotherapy. 
Consequently, only the results of comparisons that met our 
eligibility criteria were included. 
Leichsenring (2001) High levels of reported personality comorbidity in some included 
studies were accepted for same reasons as for Casacalenda et al. 
(2002).   High levels of co-morbid Generalised Anxiety Disorder 
and/or Panic Disorder were identified in one study which used 
DSM III criteria (Shapiro et al., 1994).  The review was not 
excluded on the basis that  the primary diagnosis of patients in this 
study was depression.   
Parker et al. (2008) One of nine studies included patients with dysthymia (Hautzinger 
et al., 1996) whose BDI and HRSD scores were required to be 
greater than 20, indicating moderate depression (Gotlib and 
Hammen, 2002). These patients were considered as depressed 
according to their symptom severities. 
Vittengl et al. (2007) Results of comparisons that were based on studies not meeting our 
eligibility criteria were excluded. 
 
 
 
 
